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GENERAL INTRODUCTION  
AND SCOPE OF THIS THESIS
RESPIRATORY SYNCYTIAL VIRUS: 
DISCOVERY AND EMERGENCE
Respiratory syncytial virus (RSV) was identified for the first time in 1956 
as the cause of mild respiratory illness in chimpanzees [1]. Not long 
afterwards, it was recognized to cause human airway infections with 
severe disease occurring mainly in infants [2]. The name of the virus was 
changed from chimpanzee coryza agent to respiratory syncytial virus, due to 
the characteristic of the virus to generate syncytial cells, which have been 
found in autopsy samples from fatal RSV infections and in tissue culture 
[2,3]. These syncytia are the result of fusion of infected cells with adjacent 
cells, leading to formation of multi-nucleated enlarged cells.
RSV is an enveloped virus with a single-stranded, negative-sense RNA 
genome, belonging to the Pneumoviridae family [4]. The RSV genome 
contains 10 genes encoding for 11 known proteins as is illustrated in Figure 1. 
Three of these viral proteins are transmembrane glycoproteins: the fusion 
protein (F), the attachment protein (G), and the small hydrophobic protein 
(SH) [5]. Both the F and G protein are often used as targets for monoclonal 
antibodies and vaccines. The RSV F protein has two conformational states: a 
pre- and post-fusion conformation. Most of the neutralizing activity in serum 
is thought to originate from pre-F specific antibodies [6]. 
1
6
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FIGURE 1   Respiratory syncytial virus (RSV) genome and virion  ·
A. The single-stranded, non-segmented, negative sense RSV genome, which contains 10 
genes encoding 11 proteins. The M2 gene encodes for both M2-1 and M2-2 proteins. 
B. The spherical morphology of RSV is shown here. RSV virions are pleomorphic and can 
also have a filamentous or asymmetric shape. The fusion (F), attachment (G), and small 
hydrophobic (SH) proteins are surface proteins, which are linked to the viral membrane. The 
nucleoprotein (N) protects the RNA from degradation and binds the RNA together with the 
large polymerase (L) protein and the phosphoprotein (P), which play a role in replication and 
transcription. The nucleoprotein is also present on the virion surface [7]. Transcription factors 
M2-1 and M2-2 regulate the switch between replication and transcription. In addition, M2-1 
has a structural role and provides the link between the nucleoprotein and the matrix (M) 
protein, which lies underneath the viral membrane and provides the shape of the virion [8]. Not 
depicted in B are transcription factor M2-2 and the NS1 and NS2 proteins, two non-structural 
proteins that are thought to interfere with the host immune response.
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Soon after its discovery, RSV was recognized as a leading global cause 
of respiratory disease in infants. RSV is a highly infectious virus, causing 
yearly epidemics during the winter months. In most individuals, RSV 
infection only leads to a common cold. However, in some cases, RSV can 
cause bronchiolitis and viral pneumonia, a result of excessive inflammation 
in the lower airways [9]. Hospitalization and mortality peak below six 
months of age, when most infants experience their primary RSV infection 
[10,11]. The estimated global incidence of RSV infections is 33.1 million 
cases per year, resulting in 2.3 million hospital admissions and as much as 
118,200 deaths in children below 5 years of age [12]. In addition to infants, 
other vulnerable populations for severe RSV disease are the elderly, the 
immunocompromised, and individuals with underlying heart or lung 
conditions. Due to this substantial burden of disease, numerous vaccines 
and monoclonal antibodies are in (pre-) clinical development. Currently, 
the only market-approved drug to prevent RSV disease is Palivizumab, 
a prophylactic F protein-specific monoclonal antibody, which has been 
shown to reduce hospitalization in high-risk infants by 55% [13]. However, 
due to its high costs, the use of Palivizumab is restricted to children at high 
risk of RSV disease and its cost-effectiveness is under debate [14]. 
THE FORMALIN-INACTIVATED RSV VACCINE: 
 IMPORTANT LESSONS FROM THE PAST
Development of new RSV vaccines has been hampered by the disastrous 
outcome of multiple trials with a formalin-inactivated (FI) vaccine in the 
1960s [15-17]. Naïve vaccinees that received the FI-RSV vaccine were 
predisposed to enhanced disease upon a subsequent natural infection, 
which even resulted in the death of two children [15]. Since then, many 
research groups have tried to unravel the mechanisms underlying severe 
RSV disease. Although the precise cause of this vaccine-enhanced disease 
remains uncertain, it is thought that the induction of complement-binding, 
non-neutralizing antibodies in combination with a deleterious CD4+ T cell 
response are the main contributors [18-23]. The failure of these vaccine 
trials teaches us two important lessons: first, the immune response during 
an RSV infection is an important determinant of disease outcome; second, 
not just antibody levels, but also the functionality of the antibody response 
is crucial in preventing RSV disease. 
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THE ROLE OF MATERNAL ANTIBODIES IN RSV DISEASE
RSV hospitalization peaks below six months of age [10,11], when infants 
mainly rely on their innate immune system and maternal antibodies for 
protection against infectious diseases. Maternal antibodies predominantly 
consist of immunoglobulin G (IgG), as this is the only isotype that is 
transferred across the placenta in significant quantities [24]. Directly after 
birth, maternal antibody levels are high, which can provide partial protection 
against RSV infection in very young infants [25]. However, maternal 
RSV-specific antibodies quickly wane with a half-life that seems to vary by 
geographic location [26]. In western countries the maternal antibody half-
life ranges from 21-26 days [27,28], in Bangladesh it was calculated to be 
38 days [26], and a study in Kenya indicated a half-life of 79 days [29]. 
A NEW STRATEGY IN PROTECTION AGAINST RSV DISEASE: 
MATERNAL VACCINATION
Vaccine efficacy is low in infants below six months due to a poor T and 
B cell response resulting in an inadequate memory response [30]. 
An alternative strategy to protect infants at an early age is to vaccinate 
pregnant women. The rationale behind maternal vaccination is to boost 
RSV-specific antibody levels in the mother during pregnancy. These 
maternal antibodies will be transferred transplacentally to the unborn child, 
leading to higher RSV-specific antibody levels at birth. Maternal vaccines 
against pertussis, influenza, and tetanus are already approved and in use to 
protect both mother and child. No evidence of serious adverse events due 
to maternal vaccination have been reported so far [31,32]. However, before 
this vaccination strategy can be implemented to reduce the burden of RSV 
disease, we need more knowledge on RSV-specific maternal antibodies. In 
addition, the establishment of potential correlates of protection is essential 
for the evaluation of vaccine efficacy. 
Many contradicting studies exist on the correlation between maternal 
antibody titers and protection against RSV infection or disease. Although 
high maternal antibody titers are associated with a reduced chance of 
acquiring (severe) RSV disease or infection in some studies [25,26,33,34], 
no clear correlate of protection is known. Multiple other studies could 
not detect a beneficial effect of high maternal antibody levels [35-38] or 
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   14 30-7-2019   11:41:00
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even found an increased risk of recurrent wheezing [39]. However, the 
aforementioned studies only measured RSV-specific antibody levels or 
antibody neutralization capacity. 
AIM AND SCOPE OF THIS THESIS
Considering that maternal vaccination is a potential strategy to prevent 
RSV disease in infants, it is of crucial importance to obtain a thorough 
understanding of the role of RSV-specific maternal antibodies in protection 
and disease. Previous studies have shown that the mere presence of a 
high virus-specific maternal antibody concentration does not ensure 
complete protection. In this thesis, we hypothesize that the functionality 
of RSV-specific antibodies plays an important role in RSV infection and 
disease. It is important to note that most conventional assays determine 
the antibody levels by in vitro binding or neutralization assays, while other 
antibody effector functions are not taken into account. In addition, maternal 
antibody levels wane quickly after birth. Therefore, the requirements to 
advance research into the role of RSV-specific maternal antibodies are 
two-fold: first, we need to develop assays to assess a broader variety of 
RSV-specific antibody features and effector functions; second, reliable 
models are required to investigate the effect of waning (local) antibody 
levels on RSV infection and disease severity. 
In the first part of this thesis, we focus on Fc-mediated antibody effector 
functions, which are often overlooked in the current field of RSV research. 
An elaborate overview of the potential role of antibody functionality in 
RSV infection and disease is given in Chapter 2. We have developed 
multiple assays to study Fc-mediated antibody effector functions including 
antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-
dependent enhancement (ADE) of infection, and ADE of disease. In 
Chapter 3, we investigate both antigen-specific antibody levels and the 
capacity to induce NK cell activity of maternal antibodies from hospitalized 
RSV patients. Next, in Chapter 4, we use Fc gamma receptor-carrying 
cell lines to explore whether the capacity of antibodies to induce ADE of 
infection in vitro explains disease severity in hospitalized RSV patients 
and in a cotton rat FI-RSV model. In Chapter 5, we show that RSV can 
infect neonatal and adult natural killer (NK) cells, which is enhanced in 
the presence of sub-neutralizing antibody concentrations. Subsequently, 
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we investigate the impact of this infection on the effector functions of NK 
cells. Infection of NK cells is a common mechanism for viruses to evade 
the antiviral immune response. Chapter 6 describes all the viruses that are 
currently known to infect NK cells and the impact of infection on NK cell 
phenotype and effector function. In the last part of this thesis, we describe 
an in vivo mouse model to investigate the role of antibodies in RSV 
infection and disease. In Chapter 7, we compare different RSV inoculation 
methods, and use this knowledge to develop a mouse model for ADE of 
RSV infection and disease in vivo in Chapter 8. Finally, we discuss all our 
findings in Chapter 9 and elaborate on future perspectives.
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PART I
ABSTRACT
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory 
tract infections and hospitalization in infants under 1 year of age and there 
is currently no market-approved vaccine available. For protection against 
infection, young children mainly depend on their innate immune system 
and maternal antibodies. Traditionally, antibody-mediated protection 
against viral infections is thought to be mediated by direct binding of 
antibodies to viral particles, resulting in virus neutralization. However, in the 
case of RSV, virus neutralization titers do not provide an adequate correlate 
of protection. The current lack of understanding of the mechanisms 
by which antibodies can protect against RSV infection and disease or, 
alternatively, contribute to disease severity, hampers the design of safe and 
effective vaccines against this virus. 
Importantly, neutralization is only one of many mechanisms by which 
antibodies can interfere with viral infection. Antibodies consist of two 
structural regions: a variable fragment (Fab) that mediates antigen 
binding and a constant fragment (Fc) that mediates downstream effector 
functions via its interaction with Fc-receptors on (innate) immune cells 
or with C1q, the recognition molecule of the complement system. The 
interaction with Fc-receptors can lead to killing of virus-infected cells 
through a variety of immune effector mechanisms, including antibody-
dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent 
cellular phagocytosis (ADCP). Antibody-mediated complement activation 
may lead to complement-dependent cytotoxicity (CDC). In addition, both 
Fc-receptor interactions and complement activation can exert a broad 
range of immunomodulatory functions. Recent studies have emphasized 
the importance of Fc-mediated antibody effector functions in both 
protection and pathogenesis for various infectious agents.
In this review article, we aim to provide a comprehensive overview of the 
current knowledge on Fc-mediated antibody effector functions in the context 
of RSV infection, discuss their potential role in establishing the balance 
between protection and pathogenesis, and point out important gaps in 
our understanding of these processes. Furthermore, we elaborate on the 
regulation of these effector functions. Finally, we discuss the implications of 
Fc-mediated antibody effector functions for the rational design of safe and 
effective vaccines and monoclonal antibody therapies against RSV. 
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INTRODUCTION
Respiratory syncytial virus (RSV) infection is a major cause of severe 
respiratory illness requiring hospitalization in young infants [1]. 
Hospitalization for severe RSV-mediated disease peaks between six weeks 
and six months of life [2,3], when infants mainly depend on their innate 
immune system and maternal antibodies for protection against infectious 
diseases. However, the exact role of RSV-specific maternal antibodies is 
unclear. Some studies show that high titers of maternal antibodies are 
associated with protection against RSV infection [4-6]; whereas others 
indicate that high maternal antibody titers do not have a beneficial effect 
or even associate with an increased risk of recurrent wheezing [7-11]. It is 
important to note that the antibody titers in these studies are determined by 
in vitro binding or neutralization assays, while additional antibody effector 
functions are not taken into account. 
For nearly all licensed vaccines, antibodies are the presumed correlate 
of protection, but the underlying mechanisms of protection often remain 
unknown [12]. Recent research suggests that, in addition to binding and 
neutralization, antibody effector functions are important contributors to 
protective immunity against several viruses, including influenza virus 
[13-15], HIV [16,17], and Ebola virus [18,19]. 
In contrast to their beneficial role in providing protection against infection 
and disease, antibodies have also been implicated in disease enhancement. 
For example, non-neutralizing dengue-specific antibodies have been 
shown to mediate antibody-dependent enhancement (ADE) of disease 
[20,21]. Interestingly, the 1960’s formalin-inactivated (FI) RSV vaccine 
induced poorly-neutralizing antibodies which have been suggested to 
be involved in vaccine-enhanced disease upon natural infection [22-24]. 
These examples illustrate the possibility that virus-specific antibodies 
contribute to pathogenesis when failing to protect. 
Currently, the RSV field lacks a comprehensive overview of antibody 
effector functions in the context of RSV infection and disease. Here, we 
review what is known about various antibody effector functions during 
RSV infection, discuss their potential role in establishing the balance 
between protection and pathogenesis, and point out important gaps in 
our understanding of these processes. Moreover, we elaborate on the 
regulation of these effector functions on both the cellular and humoral side. 
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Finally, we discuss the implications of antibody-mediated effector functions 
for the rational design of safe and effective vaccines and monoclonal 
antibody therapies against RSV. A thorough understanding of the role of 
antibodies in protection or disease during RSV infection is crucial for the 
development of new and improved vaccination strategies and may provide 
much-needed new insights into the precise mechanisms of antibody-
mediated protective immunity. 
FC-MEDIATED ANTIBODY EFFECTOR FUNCTIONS
Antibody effector functions are an important part of the humoral immune 
response and form an essential link between innate and adaptive 
immunity. Most of these effector functions are induced via the constant 
(Fc) region of the antibody, which can interact with complement proteins 
and specialized Fc-receptors. The latter can induce activating or inhibitory 
pathways, depending on the type of receptor, and are found on B cells 
and most innate immune cells in various combinations. The most 
well-known Fc-mediated antibody effector functions are antibody-
dependent cell-mediated cytotoxicity (ADCC), antibody-dependent 
cellular phagocytosis (ADCP), and complement-dependent cytotoxicity 
(CDC). In addition, antibodies have been found to mediate inflammation 
and immunomodulation through the induction of cellular differentiation 
and activation. Each of these functions is described in detail below and a 
schematic overview is depicted in Figure 1. 
Antibody-dependent cell-mediated cytotoxicity (ADCC)
ADCC is induced when Fc gamma receptors (FcγRs) on innate effector cells 
are engaged by the Fc domain of antibodies that are bound to viral proteins 
on the surface of virus-infected cells. This interaction induces the release 
of cytotoxic granules (containing perforins and granzymes) resulting in 
killing of infected cells [25]. Multiple innate effector cells, including natural 
killer (NK) cells, neutrophils, monocytes, and macrophages, are capable of 
ADCC in vitro. However, the most important contributors to ADCC in vivo 
are thought to be NK cells, which express only FcγRIIIA. Figure 2 shows a 
schematic representation of ADCC.
In the field of tumor immunology, ADCC has been recognized as an 
important mechanism of action for therapeutic monoclonal antibodies 
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(mAbs) that target tumor cells (as reviewed by [26]). For infectious diseases, 
ADCC only recently started to gain attention. ADCC has been shown to 
form a critical component of effective immunity against HIV and influenza 
virus. ADCC-inducing HIV-specific antibodies were identified as a key 
correlate of protection in the RV144 HIV vaccine trial [27-29]. Moreover, 
HIV-infected individuals who control the virus without antiretroviral 
therapy demonstrated a broader polyfunctional humoral immune 
response including ADCC activity compared to viremic individuals [30-33]. 
Complement-dependent
cytotoxicity (CDC) & signaling
Antibody-dependent
cell-mediated cytotoxicity
(ADCC)
Antibody-dependent 
cellular phagocytosis (ADCP)
DC maturation
& activation
Degranulation, release of 
chemokines & cytokines
Macrophage
Eosinophil
Mast cell
Direct virus
neutralization
T cell skewing
Antibody-dependent
enhancement (ADE)
of infection
NK cell
Phagocyte
FcγR-carrying
cell
C1q
C3a/C5a
MAC
NeutrophilNETosis
FIGURE 1 Fc-mediated antibody effector functions  ·
Antibodies elicit a wide range of effector functions during viral infections. These include but 
are not necessarily limited to the functions depicted in this figure. Abbreviations: DC, dendritic 
cell; FcγR, Fc gamma receptor; MAC, membrane attack complex; NK cell, natural killer cell.
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There has been much debate about the role of ADCC during influenza-
induced disease. Some studies point to the protective capacity of ADCC-
inducing antibodies [34,35], whereas others do not show any role for NK 
cells in antibody-mediated protection [36], or even suggest involvement of 
ADCC in exaggeration of the immune response [37-39]. For multiple other 
clinically important viral infections, including dengue virus and Ebola virus, 
research into the effect of ADCC is ongoing [40-42]. Taken together, ADCC 
seems to be involved in the immune response against multiple viruses 
and is therefore potentially of interest in the context of RSV infection. 
ADCC in RSV infection
NK cells are the most important contributors to ADCC in vivo and important 
effector cells during RSV infection. In mice, increased numbers of NK cells 
are present in the lungs early after RSV infection [43-45]. In RSV-infected 
infants, the proportion of NK cells has been reported both to be decreased 
[46-49] or increased [50,51] in comparison with healthy controls or infants 
FIGURE 2 Antibody-dependent cell-mediated cytotoxicity (ADCC)  ·
Fc gamma receptors present on for example natural killer (NK) cells engage antibody-
bound infected cells and induce target cell death through the release of cytotoxic granules. 
Abbreviations: FcγRIIIA, Fc gamma receptor IIIA; NK cell, natural killer cell; RSV, respiratory 
syncytial virus.
NK cell
RSV-infected cell
Apoptosis
Cytotoxic 
granules
Granzymes
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FcγRIIIA
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with mild symptoms. Since maternally-derived antibodies are virtually 
always present during primary RSV infection and antibody-coated virus-
infected cells are a trigger for ADCC, it can be assumed that ADCC occurs 
during primary RSV infection. 
Although NK cells are thought to be the most important mediators 
of ADCC against virus-infected cells, this has never been shown for 
RSV. All studies mentioned below are performed with peripheral blood 
mononuclear cells (PBMCs), without distinction between different cell 
types. RSV-specific immunoglobulin G (IgG) has been shown to induce 
ADCC towards RSV-infected epithelial cells in vitro [52,53]. The major 
surface antigens of RSV are the fusion (F) and the attachment (G) protein 
which are both required for infectivity in vivo. The RSV F protein has two 
conformational states: post-fusion (post-F) and pre-fusion (pre-F), of 
which the latter is a potent target for neutralization [54]. Multiple studies 
show that anti-RSV G antibodies are efficient inducers of ADCC in vitro 
[55,56], and the involvement of this process in virus clearance in vivo has 
been proposed [57,58]. In contrast, anti-RSV F antibodies do not efficiently 
induce ADCC in vitro [55], although it must be noted that no distinction 
between pre- and post-F antibodies was made and the ADCC potential 
could differ between the two functional states of the F protein. 
Antibodies from breast milk, cord blood, and nasopharyngeal secretions 
and serum from RSV-infected infants show ADCC activity in vitro [52,53,59]. 
This shows that the antibodies that are present in vivo are capable of 
eliciting ADCC activity in vitro. Two studies showed that the level of ADCC 
activity measured in vitro was independent of clinical symptoms and age, 
suggesting that ADCC is not a determining factor in the varying clinical 
manifestations of primary RSV infection [53,59]. Interestingly, the ADCC 
capacity of serum antibodies from RSV-infected infants rapidly declines 
over time, whereas the neutralization capacity remains more stable. If 
ADCC is important in protection against infection, this decline could partly 
explain the susceptibility to repeated infections throughout life. 
Limited evidence is present on the occurrence of ADCC during RSV 
infection in vivo. The most convincing data is provided by mouse studies 
performed with anti-RSV G protein-specific Fab- or F(ab’)2 fragments 
lacking the complete Fc domain, or aglycosylated antibodies lacking 
the glycosylation site that is required for efficient FcγR and complement 
interactions [58,60,61]. It was shown that Fab fragments of the 1812A2B 
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   27 30-7-2019   11:41:03
28
PART I
anti-RSV G antibody and F(ab’)2 fragments of the 131-2G anti-RSV G 
antibody do not reduce viral load, whereas the corresponding intact 
antibodies do confer protection [58,60]. The authors propose that virus 
clearance by the 131-2G antibody is mediated through ADCC, however, the 
involvement of other Fc-mediated effector functions in this study cannot 
be ruled out. In an attempt to ascertain the role of ADCC by NK cells in the 
protective mechanisms of the anti-RSV G antibody 18A2B2, SCID beige 
mice (which are deficient in NK cell activity) were passively immunized with 
the full antibody [60]. In this study, the absence of NK cells had no effect 
on the protective capacity of 18A2B2, pointing to the involvement of other 
Fc effector functions. Further research is needed to study the exact role 
of ADCC for other mAbs and RSV-immune serum. Passive immunization 
with aglycosylated 1C2 anti-RSV G antibodies reduced virus titers 
significantly but were not as effective as wildtype antibodies, indicating 
that protection by the 1C2 antibody is mediated by both Fc-dependent 
and Fc-independent mechanisms [61]. Although these studies highlight 
the importance of Fc-mediated antibody effector functions in protection 
against RSV infection in the case of these specific anti-RSV G mAbs, the 
role of ADCC in protection or pathogenesis during natural RSV infection 
remains to be determined.
Antibody-dependent cellular phagocytosis (ADCP)
ADCP or opsonophagocytosis is the uptake of virus-antibody complexes 
or antibody-coated virus-infected cells by phagocytic cells (for a schematic 
representation of this process see Figure 3). Phagocytic cells, including 
monocytes, macrophages, neutrophils, eosinophils and dendritic cells 
(DCs), express FcγRI, FcγRII, and FcαRI, which can all mediate immune 
complex uptake. The exact phagocytic capacity of effector leukocytes 
is dependent upon the cell type, differentiation stage, and level of FcγR 
expression. ADCP results in the clearance of immune complexes from the 
infected host, by trafficking of the complexes to lysosomes for degradation 
and antigen processing for presentation on Major Histocompatibility 
Complex (MHC)-molecules on the cell surface. Interestingly, some 
viruses have exploited this mechanism to infect phagocytes by escaping 
from lysosomal degradation (described below in “Antibody-dependent 
enhancement of infection”).
ADCP has been extensively described for its role in protection against 
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bacteria, but its importance during viral infections is unclear. Some studies 
have been performed for influenza virus, showing that phagocytosis by 
(alveolar) macrophages may contribute to protection from infection in mice 
[36,62] and potentially plays a role in the recovery from severe infections 
in humans [15,63]. Also for cytomegalovirus (CMV), it was shown that 
vaccine-induced antibodies play an important role in vaccine efficacy, 
independent of neutralization or ADCC capacity [64]. In accordance with 
these results, a study by Nelson et al. showed no role for neutralization 
or ADCC, while robust ADCP induction was observed [65]. Antibody-
mediated clearance by phagocytes in vivo has also been suggested for 
HIV [66,67], adenovirus [68], West Nile Virus (WNV) [69], and foot-and-
mouth disease virus [70,71].
ADCP in RSV infection
Phagocytosis of RSV-antibody complexes or RSV-infected cells has 
to our knowledge never been directly explored as a protective immune 
mechanism for RSV. In vitro studies show phagocytosis of RSV immune 
complexes by neutrophils [56,72,73] and eosinophils [74]. Varying levels 
FIGURE 3  Antibody-dependent cellular phagocytosis (ADCP)  ·
Phagocytes can clear virus-infected cells and immune complexes that are engaged by Fc 
gamma receptors through phagocytosis. Uptake of viral particles or proteins leads to antigen 
presentation, which induces the adaptive immune system. Abbreviations: FcγR, Fc gamma 
receptor; MHC, major histocompatibility complex; RSV, respiratory syncytial virus
Phagocyte
RSV-infected cell
Phagocytosis of 
virus-infected cell
Phagocytosis of 
virus-antibody complex
Antigen
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of phagocytic activity have been observed for different RSV-specific 
monoclonal antibodies, suggesting that ADCP activity depends on 
epitope and/or affinity [56,73]. An in vivo mouse study has shown that 
macrophages are essential in conferring antibody-mediated restriction of 
RSV replication, whereas neutrophil depletion did not significantly affect 
pulmonary viral replication [75]. This suggests that Fc-mediated effector 
functions executed by macrophages rather than neutrophils are important 
in protection against RSV infection in a mouse model. 
Besides the uptake of viral particles, phagocytosis initiates the activation 
of cells. This can result in the release of a broad range of effector molecules 
[72-74], which will be described in detail in “Antibody-dependent 
immunomodulation during RSV infection”. Although there is limited 
evidence on the role of ADCP during RSV infection, the importance of 
macrophages in antibody-mediated protection in mice provides a basis 
for further investigation.
Antibody-mediated complement activation
Besides ADCC and ADCP, antibodies can also induce complement 
activation. The complement cascade contributes to pathogen elimination 
either directly, by means of complement-dependent cytotoxicity (CDC), or 
indirectly, through phagocytic clearance of complement-coated targets 
and the induction of an inflammatory response. Activation of the classical 
complement pathway results from binding of the recognition molecule 
C1q to the Fc domain of antibodies bound to virus-infected cells [76,77], 
as depicted in Figure 4. Upon binding of C1q, the proteases of the classical 
pathway are activated, leading to cleavage of C2 and C4. Together, the 
resulting cleavage products form the C3 convertase (C4bC2a) that cleaves 
C3 into C3a and C3b. One of the mechanisms by which the complement 
cascade is regulated, is cleavage of active C4b, which serves as a marker 
for complement activation. The release of anaphylatoxins C3a and C5a 
stimulates a pro-inflammatory environment by inducing the recruitment 
of immune effector cells and the activation of leukocytes, endothelial 
cells, epithelial cells, and platelets [78,79]. The highly reactive C3b binds 
to pathogens and infected cells, leading to immune complex clearance 
and phagocytosis through complement receptors found on immune cells. 
The terminal complement components will assemble into the membrane 
attack complex (MAC), resulting in lysis of the infected cell. Besides direct 
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FIGURE 4   Antibody-mediated complement activation  ·
Binding of C1q to antibody-bound virus-infected cells leads to activation of the classical 
complement pathway. C3 convertase (C4bC2a) is formed and cleaves C3 into C3a and 
C3b. Active C4b can be cleaved into the enzymatically inactive form C4d, which serves as 
a marker for complement activation. Further downstream in the classical complement 
pathway, C5 is cleaved into C5a and C5b. C3a and C5a are anaphylatoxins that stimulate 
a pro-inflammatory environment, although they act in different ways: C3a induces C3aR 
signaling, whereas C5a inhibits C3aR expression. C3b binds to pathogens and infected cells, 
leading to phagocytosis through complement receptors found on immune cells. The terminal 
complement components will assemble into the membrane attack complex (MAC), resulting 
in direct lysis of the infected cell. Abbreviations: C3aR, C3a Receptor; MAC, membrane attack 
complex; RSV, respiratory syncytial virus.
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antiviral activity, the complement system can also regulate B cell responses. 
The binding of complement-coated immune complexes to complement 
receptor 2 on B cells is reported to lower the B cell activation threshold, 
thereby promoting long-lived adaptive immunity and higher antibody 
levels [80,81].  
Complement can have both a protective and pathogenic role during viral 
infections. The protective capacity of poorly neutralizing antibodies during 
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WNV infection is mediated by the complement system, as was shown 
using knockout mice [69]. The presence of complement even enhances 
the neutralization capacity of WNV-specific antibodies [82]. In addition, an 
important role for complement has been shown in the protective capacity 
of (monoclonal) antibodies against influenza virus [39,83], vaccinia virus 
[84], CMV [85], and HIV [66,67]. In contrast, complement activation has 
also been suggested to contribute to disease severity in dengue virus 
[86,87] and HIV infection [88,89].
Antibody-mediated complement activation in RSV infection
The complement system consists of multiple components and elicits 
its effector functions through different pathways. Early studies have 
shown antibody and complement deposition on nasopharyngeal cells of 
RSV-infected infants [90]. Whether this contributed to viral clearance or 
disease was not determined. Studies in complement-deficient mice have 
shown that complement is important in antibody-mediated protection 
against RSV infection [60,75]. A number of different mechanisms have 
been suggested for this complement-enhanced protection. Firstly, direct 
enhancement of the neutralization capacity of antibodies by fixation of 
complement components to virus-antibody complexes may increase the 
steric hindrance of bound antibodies [91]. Another mechanism that could 
be at play is complement-dependent opsonization of virus-infected cells, 
which leads to subsequent uptake by phagocytes. Finally, complement has 
also been shown to increase the CD4(+) T cell response in the presence of 
RSV immune serum in an in vivo mouse model [92]. 
Besides its potential role in the clearance and/or pathogenesis of natural 
RSV infection, complement activation has been suggested to contribute 
to disease enhancement induced by natural infection following FI-RSV 
vaccination. C3a receptor (C3aR)-deficient mice had decreased airway 
hyperresponsiveness (AHR) and less mucus production in an FI-RSV 
vaccination-challenge model [93]. In this study, C3aR expression was 
enhanced in C5-knockout mice, showing that the balance in activation of 
different complement factors (C3a versus C5a) is important in determining 
disease outcome. Moreover, Polack et al. demonstrated the co-localization 
of IgG and C3 in the lungs of mice with enhanced RSV disease, but not in 
control mice [22]. In addition, both C3- and B cell-knockout mice showed 
a decrease in bronchoconstriction compared to WT mice vaccinated 
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with FI-RSV. Therefore, in a mouse model of vaccine-enhanced disease, 
the presence of C5 seems protective, whereas C3a promotes enhanced 
disease. This is also supported by the limited data available on complement 
activation during vaccine-enhanced disease in infants. Lung sections of 
the two children who died of vaccine-enhanced disease had extensive 
deposition of complement cleavage product C4d, which serves as a stable 
marker for complement activation [22]. The presence of C4d provides 
evidence for complement activation during vaccine-enhanced disease in 
infants, but it remains to be determined whether there is a causal relation 
between complement activation and vaccine-enhanced disease. Finally, 
mouse studies point to the involvement of complement components in 
the development of AHR and asthma upon RSV infection [94,95]. Taken 
together, the complement system seems to be important in antibody-
dependent protection in vivo, but it also potentially contributes to (vaccine-
enhanced) disease and asthma, suggesting a dual role in RSV infection 
that requires further investigation.
FIGURE 5  Antibody-mediated immunomodulation  ·
Immune complexes can skew immune cell maturation and activation of granulocytes, 
dendritic cells, T cells, B cells, and phagocytes. This immunomodulation can lead to 
A. degranulation, B. skewing of T cell responses, C. regulation of B cell antibody responses, 
and D. phagocytosis-induced secretion of immunomodulatory mediators. Abbreviations: 
ROS, reactive oxygen species.
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Antibody-mediated immunomodulation
Besides the well-defined classical Fc-mediated effector functions 
(ADCC, ADCP, CDC), immune complexes can also promote immune cell 
maturation and activation, leading to a wide range of effector activities and 
production of pro-inflammatory and immunomodulatory mediators (a 
limited overview is depicted in Figure 5). Some of these pro-inflammatory 
cytokine responses correlate with protection as has been shown for 
influenza [62] and HIV [96]. The importance of FcγRs in this process has 
been shown by the use of FcγR-deficient mice (as extensively reviewed in 
[97]). In contrast to the pro-inflammatory responses caused by immune 
complexes, injection with intravenous immunoglobulin (IVIg) can induce 
an anti-inflammatory state. It is proposed that this anti-inflammatory effect 
is partly due to the presence of sialylated antibodies in IVIg, which induce 
expression of FcγRIIB (the only inhibitory FcγR) and thereby dampen the 
inflammatory response [98].
Immune complexes can also regulate cellular maturation and activation. 
The balance between inhibitory and activating FcγR interactions is crucial 
in regulating B cell IgG responses [99-101], and skewing APC maturation 
and antigen presentation [102-105], which can modulate T cell activation. 
Immune complexes have also been shown to bias the macrophage 
immune response towards a Th2-like phenotype [106]. 
Antibody-mediated immunomodulation in RSV infection
RSV-antibody complexes can lead to activation of phagocytes either 
directly or after phagocytosis, resulting in the production of reactive 
oxygen species (ROS), thromboxane, (pro-inflammatory) cytokines, and 
chemokines [72,73,107], which may contribute to viral clearance. However, 
these mediators can also have immunopathological effects, including 
tissue damage, platelet aggregation, and bronchoconstriction. Given that 
neutrophils are the predominant airway leukocytes present in RSV-infected 
infants, their activation is suggested to be involved in the induction of severe 
RSV disease [108]. Interestingly, in contrast to RSV immune complexes, it 
has been reported that RSV alone does not lead to ROS production by 
granulocytes [107] and can even inhibit this process [73,109]. It has been 
suggested that anti-RSV G mAbs are less potent inducers of ROS and 
cytokine production than anti-RSV F mAbs [73], but this was based on 
experiments with only two RSV-specific antibodies. Notably, differences 
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in the capacity to induce a response may not be due to antigen-specificity 
per se but rather due to epitope localization, as described in the paragraph 
“Important epitopes during RSV infection”. 
Excessive eosinophilic activation has been suggested to play a role in 
the immunopathology of FI-RSV-induced disease in mice [22]. Whether 
the non-neutralizing antibodies induced by the FI-RSV vaccine play 
a role in this activation remains unknown. In vitro studies have shown 
that eosinophils can phagocytose RSV-antibody complexes, leading to 
degranulation [74]. The use of heat-inactivated serum abolished this effect, 
indicating complement involvement. 
Besides an immunomodulatory effect on granulocytes, RSV-antibody 
complexes can also affect T cell responses. Kruijsen et al. show in an in 
vivo mouse model that IFN-γ secretion by CD4(+) T cells is increased in the 
presence of RSV immune serum [92]. This increase is dependent on both 
FcγRs and the complement system. Additional in vitro experiments indicate 
that both anti-RSV G, as well as anti-RSV F antibodies can induce this 
enhanced CD4(+) T cell response, whereas CD8(+) T cells are only activated 
by the presence of anti-RSV G antibodies. Another in vitro study found that 
DCs primed with complexes composed of RSV and F-specific antibodies 
displayed an impaired capacity to activate CD8(+) and CD4(+) T cells [110]. 
RSV-antibody complexes also contribute to antibody-mediated 
immunomodulation through the induction or inhibition of cytokine and 
chemokine production in PBMCs. In an in vitro study, RSV-antibody 
complexes inhibited IFN-α production in PBMCs, whereas these 
complexes enhanced IFN-α production of PBMCs in the absence of 
CD14(+) cells [111]. Another in vitro study showed that, compared to RSV 
alone, RSV immune complexes induce increased IFN-α, IFN-γ, CXCL10, 
and CXCL11 production in monocytes [112]. In infant PBMCs, only CXCL10 
production was significantly enhanced. CXCL10 can mediate a neutrophil-
dependent excessive pulmonary inflammation [113], which could 
contribute to RSV pathogenesis. This indicates that immune complexes 
can potentially also activate neutrophils indirectly, through the induction 
of chemokines and cytokines in PBMCs. Altogether, these studies show 
that immune complexes are able to skew the RSV-specific immune 
response in multiple ways, but more research is needed to clarify the exact 
contribution of antibody-mediated immunomodulation to protection and 
disease during RSV infection. 
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Antibody-dependent enhancement (ADE) of infection
ADE refers to a phenomenon in which virus-specific antibodies promote, 
rather than inhibit, infection and/or disease. In ADE of infection, also known 
as extrinsic ADE [114], the number of virus-infected cells is increased in the 
presence of (natural or monoclonal) antibodies that are non-neutralizing or 
present in sub-neutralizing concentrations. ADE of infection requires the 
presence of FcγRs on target cells and is an efficient in vitro tool to assess 
Fc-FcγR interactions. However, while ADE of infection has been observed 
for many viruses in vitro (as extensively reviewed in [115]), its significance in 
vivo remains uncertain. A schematic representation of ADE of infection is 
depicted in Figure 6.
ADE of RSV infection
ADE of RSV infection has been demonstrated in vitro for both mAbs and 
RSV-immune serum in monocytic cell lines, PBMCs, neonatal and adult 
NK cells, and primary mouse and cotton rat immune cells [110, 116-120]. 
FIGURE 6  Antibody-dependent enhancement (ADE) of infection  ·
ADE of infection has been shown in vitro for multiple viruses, including RSV. High antibody 
titers neutralize the virus completely. Sub-neutralizing antibody titers form immune complexes 
that can interact with both the virus receptor and Fc gamma receptors, leading to enhanced 
infection levels compared to infection in the absence of antibodies.
Antibody
neutralizing capacity
PROTECTION ENHANCED INFECTION INFECTION
Fc gamma receptor
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However, whether the ADE of infection observed in vitro is related to in 
vivo disease outcome is doubtful. No correlation has been found between 
disease severity in infants and the capacity of serum antibodies to induce 
ADE of RSV infection in vitro [119]. Furthermore, ADE of infection has never 
been demonstrated in vivo. However, it must be noted that this has never 
been assessed during FI-RSV vaccine-enhanced disease. 
Antibody-dependent enhancement (ADE) of disease
ADE of disease, or instrinsic ADE [114], refers to a process in which the 
presence of pathogen-specific antibodies contributes to disease severity. 
For example, immune complexes might bind to FcγR-expressing immune 
cells, modulating the immune response and subsequently leading to 
enhanced inflammation. ADE of disease has been a presumed cause of 
severe disease following various viral infections and vaccinations [37, 114, 
121-123]. However, the underlying mechanisms are largely unknown and 
in vivo data supporting these claims are often lacking. However, for dengue 
virus infection some first clues to unravel the mechanism underlying ADE 
of disease have recently been published. Wang et al. have been able to 
show a correlation between FcγRIIIA binding capacity of dengue virus 
antibodies and disease severity in vivo [20]. The dengue-specific antibodies 
are thought to cross-react with platelet antigens and induce thrombo-
cytopenia. Suggested underlying mechanisms are FcγR-mediated platelet 
activation, phagocytosis or ADCC, but further investigation is needed to 
confirm these hypotheses. In addition, Katzelnick et al. have shown that 
high dengue-specific antibody titers correlate with protection, whereas 
intermediate antibody titers correlate with severe dengue disease [124]. 
Although low or no antibody titers are not protective, they do not enhance 
disease. It is possible that RSV-specific antibodies show a similar pattern, 
as illustrated schematically in Figure 7. 
ADE of RSV disease
Although in vitro ADE of infection does not seem to be a determinant for 
severe RSV disease [119], other antibody-mediated mechanisms could be 
involved, as has recently been shown for dengue virus infection [20]. Many 
animal studies on RSV infection highlight the role of an excessive immune 
response in FI-RSV vaccine-enhanced disease. It is likely that poorly-
neutralizing vaccine-induced antibodies play a role in the development of 
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FI-RSV vaccine-enhanced disease [22-24], although it remains uncertain 
which Fc-mediated effector functions are involved.
Little is known on the involvement of (maternal) antibodies in the 
development of severe disease after natural RSV infection. Severe RSV 
infections are most frequently seen in the first 6 months of life when infants 
have circulating maternal RSV-specific antibodies [2]. This suggests that 
RSV-specific antibodies may contribute to the induction of severe RSV 
disease. Results from animal studies with Fab fragments and FcγR-
knockout mice indeed show the involvement of antibody-mediated 
effector functions both in protection against viral replication [58,60,61] and 
in promoting inflammation [92]. 
Some studies have reported enhanced RSV disease to occur in the 
FIGURE 7  Antibody-dependent enhancement (ADE) of disease   ·
ADE of disease refers to a process in which the presence of pathogen-specific antibodies 
contributes to disease severity. Highly neutralizing antibodies result in sterile immunity, 
preventing infection and disease (left panel). The presence of low levels of protective 
antibodies allows for viral replication and leads to an Fc-mediated immune response that 
can either contribute to protection (second panel) or potentially lead to severe disease 
(third panel) compared to infection in the absence of antibodies (right panel). It is currently 
unknown whether Fc-mediated effector functions can lead to severe disease and which 
immunological mechanisms determine the difference between protective or enhancing 
Fc-mediated responses.
Antibody
protective capacity
NO DISEASE MILD DISEASE SEVERE DISEASE MILD DISEASE
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presence of waning immunity. Murphy and colleagues reported enhanced 
pulmonary pathology 3 months after immunization with an RSV F 
glycoprotein vaccine [125], which was not seen 1 week after immunization 
[126]. In a follow-up study, enhanced lung pathology was observed upon 
immunization with low doses of recombinant F protein, mimicking waning 
immunity [127]. Interestingly, the enhanced disease was independent of 
the presence of a Th1- or Th2-biasing adjuvant.
Taken together, there are clear indications suggesting that Fc-mediated 
antibody effector functions may contribute to severe RSV disease. 
Complement activation has been linked to vaccine-enhanced disease and 
asthma, and may therefore also be involved in severe RSV disease upon 
natural infection. In addition, the immunomodulatory effects of immune 
complexes can lead to a pro-inflammatory environment, which is thought 
to be the underlying cause of RSV-mediated pathology. However, more 
research on the involvement of individual Fc-mediated effector functions 
in disease outcome following RSV infection is needed. 
REGULATION OF FC-MEDIATED EFFECTOR FUNCTIONS
Fc-mediated antibody effector functions play an important role in shaping 
the immune response and their active regulation is crucial to prevent 
excessive immune activation. A number of determinants have been 
found to influence Fc-mediated effector functions on both the cellular and 
antibody side of the Fc-Fc receptor (FcR) interaction. Important antibody 
characteristics are the isotype, subclass, glycosylation pattern, and antigen 
specificity, while important cellular determinants are the epitope position 
relative to the target cell membrane and FcR expression and polymorphisms 
on the effector cell, which together determine the capacity of the antibody 
to interact with specific FcRs. Most antibodies are not specifically eliciting 
a single effector function, and therefore the combination of all these 
characteristics determines the outcome of the various Fc-FcR interactions 
and the interaction with the complement system.
Antibody isotype and subclass
Antibodies consist of two functional domains: the variable antigen-binding 
fragment (Fab) and the constant fragment (Fc) that interacts with FcRs and 
C1q. The isotype of the Fc domain (IgA, IgD, IgE, IgG, and IgM) represents 
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the major determinant of Fc-mediated effector functions. Of these isotypes, 
IgG is the most important when it comes to Fc-mediated effector functions, 
as this is the only isotype known to interact with the widely expressed FcγRs. 
Whereas the majority of antibodies in serum are of the IgG subtype, IgA is 
the major isotype present in mucosal secretions. This isotype interacts with 
its specific receptor FcαRI, which is present on neutrophils, eosinophils, 
monocytes, and macrophages (extensively reviewed in [128]). Activation 
of FcαRI by IgA-opsonized pathogens can induce ADCC, phagocytosis, 
degranulation, and cytokine release. Other important isotypes to briefly 
mention are IgM, which is a potent complement activator [76], and IgE, 
which has been linked to various allergic diseases.
In humans, four different IgG subclasses (IgG1-IgG4) are known. These 
subclasses differ in amino acid sequence, which influences their capacity 
to interact with certain classes of FcγRs and complement components 
as depicted in Table 1. Production of different isotypes and subclasses 
is tightly regulated and dependent on differentiation of the B cell, which 
can be influenced by cytokines and interactions with pattern-recognition 
receptors. The response to protein antigens usually involves T cell help and 
induces class switching to IgG1 or IgG3, whereas polysaccharide antigens 
induce class switching to IgG2 in the absence of T cell help [129]. Viral 
TABLE 1    Functionality of IgG subclasses
Subclass Se
ru
m
ab
un
da
nc
e
Fc
γR
I
Fc
γR
IIa
Fc
γR
IIb
Fc
γR
III
a
Fc
γR
III
b
C
1q Effector 
functions
IgG1 60 % +++ +++ + ++ +++ ++ ADCC, 
ADCP, CDC
IgG2 32 % - ++ - - - +  
IgG3 4 % ++++ ++++ ++ ++++ ++++ +++ ADCC, 
ADCP, CDC
IgG4 4 % ++ ++ + - - -  
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-
dependent cellular phagocytosis; CDC, complement-dependent cytotoxicity; FcγR, Fc 
gamma receptor; IgG, immunoglobulin G [133-135].
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infections, including RSV infections, mostly induce IgG1 and IgG3 antibody 
responses [130-132].
IgG1 and IgG3 have the highest affinity for FcγRs and are potent activators 
of complement, ADCC and phagocytosis [133,136,137]. IgG3 is the subclass 
with the highest potential to activate both FcγRs and complement, but due 
to its short half-life the preferred subclass for therapeutic cytotoxic activity 
is IgG1 [138]. In contrast, receptor-blocking antibodies are often of the 
IgG2 or IgG4 subclass to avoid Fc-mediated cytotoxic side effects [139]. 
Induction of specific subclasses can have major effects on the outcome of 
vaccine trials as has been shown for the HIV RV144 and VAX003 vaccines. 
RV144 recipients produced highly functional IgG3 antibodies that provided 
31.2% efficacy, whereas VAX003 recipients elicited a monofunctional IgG4 
antibody response that was not protective at all [140]. 
Antibody isotype and subclass in RSV infection
Severe RSV-mediated disease is most prevalent in infants below 6 months 
of age. These children mainly rely on maternally-derived IgG for protection 
against infectious diseases, but the correlation between serum IgG levels 
and protection against RSV disease is poor [8-11]. A recent study by Habibi 
et al. found that mucosal IgA titers are a better predictor of susceptibility to 
RSV infection than serum IgG levels in an adult challenge model [141]. In 
addition, they showed a hampered IgA memory B cell response to RSV, 
which may explain the life-long susceptibility to repeated RSV infections. 
In accordance with these results, lower levels of nasal IgA were found in 
naturally RSV-infected adults compared to healthy controls [142]. These 
findings highlight the importance of mucosal IgA in protection against 
RSV infection. However, it is questionable whether IgA plays a role in 
protection or disease during primary infection. IgA antibodies to RSV 
are only found in secretions after 4 months of age, confirming they are 
synthesized as a result of (primary) infection [143]. RSV-specific IgA has 
been shown to induce antibody-mediated effector functions. Although 
palivizumab-IgA demonstrated slightly higher lysis of RSV-infected HEp2 
cells by neutrophils (but not monocytes) in vitro, there was a somewhat 
decreased efficacy in vivo compared to palivizumab-IgG [144]. Additional 
experiments with FcαRI transgenic mice suggest that IgA-mediated 
protection is Fc receptor-independent. No further research with RSV-IgA 
immune complexes has been published to date and therefore their role in 
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protection or disease remains to be investigated.
Another interesting isotype is IgE, as the results from multiple studies 
suggest the involvement of this isotype in the development of 
RSV-mediated bronchiolitis and wheezing [145-148]. In a mouse model, 
RSV-specific IgE has been shown to enhance airway hyperresponsiveness 
[149]. Since all infants produce IgE in response to RSV infection [150], it is 
thought that the height and duration of the IgE response are important for 
the induction of subsequent immunopathology [148, 151, 152]. Mast cells 
abundantly express the IgE-specific Fc receptor (FcεRI) and were shown 
to play an important role in IgE-induced airway hyperresponsiveness in 
an RSV reinfection mouse model [149].
In addition to studies on isotypes, extensive studies have been performed 
on the presence of IgG subclasses during RSV infection. Wagner et al. have 
performed some early studies into the antibody subclass response to the 
RSV F and G glycoproteins in both infants and adults [131, 153, 154]. Primary 
RSV infections predominantly gave rise to IgG1 and IgG3 antibodies, 
whereas subsequent infection only led to an increase in IgG1 and IgG2 titers 
[131]. RSV infection led to a poor IgG4 antibody response in all subjects. 
RSV F protein was the most immunogenic, leading to higher antibody 
titers compared to the RSV G protein [153]. The IgG1/IgG2 ratio of antibody 
titers to the RSV F protein was fourfold higher than to the RSV G protein 
after the first three RSV infections in infants. This difference was thought 
to be due to the extensive glycosylation of the G protein, resulting in IgG2 
antibodies. IgG1 and IgG3 are the most potent FcγR-binding subclasses. 
This suggests that the majority of anti-RSV F antibodies are effective 
inducers of Fc-mediated effector functions, in contrast to the IgG2 subset 
of anti-RSV G antibodies. Experimental RSV infection in adults showed 
similar subclass responses to RSV F and G protein [154]. A recent study 
confirms the findings of Wagner et al., showing a strong IgG3 response 
in infants younger than 4 months, despite the presence of high levels of 
maternal antibodies [155]. A rise in RSV-specific IgG1 and IgG2 was only 
observed in infants older than 7 months.
Besides human studies, several mouse studies have been performed 
to investigate the subclass antibody response. Although some homology 
between mouse and human IgG subclasses has been found, it is unclear 
whether they induce the same downstream immune responses. In mice, 
neonatal IgG responses to RSV infection are significantly skewed towards 
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mIgG1 (homologous to human IgG4), indicating a Th2 bias [156], whereas 
primary infection in adult mice leads to a balanced mIgG2a/mIgG1 
response (homologous to human IgG1/IgG4) [157]. Compared to wild-type 
RSV infection, immunization with inactivated or nonreplicative RSV led to 
a low mIgG2a/mIgG1 ratio [24, 158]. The largest proportion of antibodies 
directed at the RSV-F protein was mIgG2 (homologous to human IgG1), 
whereas the G protein response had a significantly lower proportion of 
mIgG2 [158]. These results indicate that both the age of the host and the 
antigens determine the subclass response. However, it is remarkable that 
RSV infection leads to a poor IgG4 antibody response in humans, but to 
a high mIgG1 (homologue of human IgG4) response in (neonatal) mice. 
Thus, caution is warranted in the translation between human and mouse 
antibody studies.
Although extensive studies have been performed on the presence of 
specific subclasses, evidence on the role of these different subclasses 
during RSV infection is limited. One study describes a direct comparison 
between the functionality of palivizumab-IgG1 and -IgG2 [159]. The 
neutralizing potential of both subclasses was comparable. However, the 
IgG2 antibody showed negligible binding to murine FcγRs and human 
C1q, resulting in less efficacy in vivo as measured by increased viral lung 
titers in challenged cotton rats [159]. This finding underscores the protective 
potential of IgG1-mediated effector functions during RSV infection.
Antibody glycosylation
Glycosylation of the antibody Fc domain is another important regulator 
of Fc-mediated effector functions. Each IgG molecule contains a highly 
conserved asparagine at position 297 (N297) that functions as a glycosylation 
site that can harbor a variety of glycans, consisting of varying combinations 
of mannose, (bisecting) N-acetylglycosamine (GlcNAc), fucose, galactose 
and sialic acid (Figure 8). The complete absence of this glycan leads to 
a conformational state that is non-permissive for FcγR or complement 
binding, thereby impairing Fc-mediated antibody effector functions. 
Afucosylation has the most straightforward influence on antibody effector 
functions. The absence of the core fucose on the Fc-glycan directly boosts 
ADCC activity by enhancing the interaction with FcγRIIIA (Figure 2) [160-
162]. Interestingly, afucosylated mAbs have shown to be more protective 
against various infectious agents [163,164] and more efficacious in cancer 
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therapy [165,166]. However, increased levels of afucosylation are also 
associated with severe disease during secondary dengue infection [20].
Another biologically important modification to the Fc glycan is sialylation. 
The presence of sialic acid inhibits FcγR binding and is reported to be partly 
responsible for the anti-inflammatory activity of IVIg [98,167]. Besides 
having anti-inflammatory properties, sialylated Fc glycans have also 
been shown to induce the production of high-affinity broadly neutralizing 
antibodies against influenza virus [101].
Besides its effect on Fc receptor interactions, Fc glycosylation also 
affects complement C1q binding to immune complexes. A recent study 
shows that elevated galactosylation and sialylation increase C1q-binding, 
downstream complement deposition, and complement dependent 
cytotoxicity [168]. In contrast, agalactosylated IgG has also been suggested 
to elicit enhanced complement activation, considering its role in several 
autoimmune diseases [169]. These findings suggest that activation of 
complement potentially contributes to pathogen clearance, but can also 
contribute to inflammation in autoimmune disease, highlighting the dual 
role of complement.
Fc glycosylation is subject to active regulatory mechanisms that control 
the composition of the glycan structure. Major changes in glycosylation 
FIGURE 8  Antibody glycosylation  ·
Each IgG molecule contains a glycosylation site that can harbor a variety of glycans, consisting of 
varying combinations of mannose, (bisecting) N-acetylglycosamine, fucose, galactose and sialic 
acid. Antibody effector activity is substantially impaired in absence of this glycan. Abbreviations: 
Fab, antigen-binding fragment; Fc, crystallizable fragment; GlcNAc, N-acetylglycosamine.
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Galactosylation
Bisection
Sialylation
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occur during pregnancy [170,171], upon vaccination [101,172], and during 
certain viral infections [101]. Therefore, insight in the glycosylation pattern 
during RSV infection and disease may provide valuable clues on the cause 
of severe RSV disease. 
Antibody glycosylation in RSV infection
To our knowledge, only one group has investigated the effect of 
glycosylation in the response towards RSV infection. Hiatt et al. compared 
the original Palivizumab mAb with an afucosylated and agalactosylated 
plant-produced glycovariant (G0) in different in vitro and in vivo assays 
[159]. The G0 glycovariant showed enhanced binding to murine FcγRs 
but less binding to human C1q compared to the parental Palivizumab, 
whereas neutralization capacity was comparable. The in vivo protective 
capacity of the G0 glycovariant was improved compared to the original, 
as evidenced by decreased pulmonary viral titers. In conclusion, this study 
suggests that the influence of Fc-glycosylation may be important in the 
protective capacity of RSV-specific antibodies but this needs to be studied 
in more detail for other mAbs and virus- and vaccine-induced antibodies.
Epitope position
Next to antibody structure and glycosylation, the location of the antibody-
bound epitope with respect to the membrane of the infected cell has 
been shown to be pivotal in determining Fc-mediated effector functions. 
Since the use of mAbs, it has been noticed that different mAbs binding 
the same target protein can elicit different effector mechanisms [173]. 
Antibodies binding to epitopes closer to the membrane (membrane 
proximal epitopes) mediate ADCC and CDC activity more efficiently, 
whereas antibodies that target membrane distal epitopes are often highly 
neutralizing and efficient ADCP-inducers [13,174,175]. More specifically, 
recent research suggests that ADCP is most efficiently triggered when 
antibodies bind within 10 nm from the cell surface [176], indicating that 
the optimal ADCP-inducing epitope is located neither too close, nor too 
far away from the cell membrane. These studies suggest that besides the 
common need for particular Fc-FcγR interactions, there are fundamental 
differences in the activation requirements of specific Fc-mediated effector 
functions. For CDC activity, stabilization of complement components 
on the cell surface is essential. This would require a short distance from 
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epitope to cell membrane. During ADCC, the formation of an immune 
synapse is essential. This small synapse can only be formed when the NK 
cells engage antibodies bound in close proximity to the cell membrane, 
explaining the need for membrane proximal epitopes [175].
Important epitopes in RSV infection
Neutralization of RSV is mainly established by antibodies against the RSV F 
and RSV G protein [177]. Antibodies against the SH and N protein have also 
been described [178,179] and although these antibodies are not involved 
in neutralization, they may have other important (Fc-mediated) functions 
[180]. Capella et al. recently showed that antibodies against the pre-F 
protein were the most prevalent RSV-specific serum antibodies in infants 
below 2 years of age [181]. Both serum IgG levels against anti-RSV pre-F 
and G correlated with disease severity in this study. 
Various antigenic sites (named Ø and I-VIII) have been described for the 
two conformational states of the RSV F protein [182,183]. Pre-F-specific 
antibodies are better neutralizers than post-F-specific antibodies [184]. 
However, not all pre-fusion F antibodies have similar neutralizing activity 
[182]. The most potent neutralizing antibodies bind to distal epitopes, 
suggesting that the neutralizing potential of anti-RSV F antibodies not only 
relies on the conformation of F on which the epitope is present (e.g. pre- 
versus post-F), but may also depend on the location of the epitope relative 
to the viral or cellular membrane. As described above, the proximity to the 
membrane determines the efficiency of Fc-mediated effector functions 
[13,174,175]. This suggests that potently-neutralizing antibodies, binding to 
distal epitopes, may also be efficient inducers of ADCP. Antibodies binding 
to proximal epitopes are generally less neutralizing, but may be more 
potent in inducing ADCC and CDC. 
The most important antigenic site for the RSV G protein is the central 
conserved domain (CCD). Despite the high variability of RSV G, antibodies 
against the CCD are broadly neutralizing against both RSV A and B strains 
[185]. The G protein CCD binds to the CX3CR1 receptor, leading to attach-
ment of RSV to its target cells [186]. Antibodies against this receptor-binding 
domain efficiently neutralize RSV infection and decrease pathogenesis 
by binding soluble G protein, an immune evasion protein secreted by 
RSV-infected cells [56,57,187]. Soluble G protein has been found to inhibit 
Fc-mediated antiviral effects of macrophages and complement [75], and 
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to modulate trafficking of CX3CR1(+) cells [188]. Next to the important roles 
mentioned above, antibodies against the CCD domain are also able to 
induce Fc-mediated effector functions like ADCP and ADCC [56]. 
Taken together, not only the antigen but also the epitope determines 
the efficacy of antibodies. Interestingly, evidence suggests that targeted 
epitopes may differ between infants and adults [189], but the effect of these 
changes on the efficacy of the antibody response is unknown. Further 
research may uncover the relation between antigenic site and effector 
functions against RSV infection, and thereby reveal preferred antibody-
binding sites for protection against RSV disease. 
FcγR expression and polymorphisms
Another regulator of Fc-mediated effector functions is the expression 
pattern and polymorphisms of FcγRs. The majority of leukocytes express 
more than one FcγR type with varying downstream signaling activities. The 
level and variety of FcγR expression is tightly regulated during leukocyte 
development and can be modulated by certain mediators present during 
infection, inflammation, or even vaccination [103,190]. As stated before, 
the balance between inhibitory and activating FcγR interactions is crucial 
in regulating B cell IgG responses [99-101] and skewing APC maturation 
and antigen presentation [102-105]. Additionally, co-engagement and 
signaling through other receptors such as TLRs may influence the 
activation threshold [191]. Altogether, this points out the importance of 
receptor expression patterns on effector cells. 
Besides variation in FcγR expression patterns, single nucleotide 
polymorphisms (SNPs) in FcγRs occur. Although many SNPs have been 
identified, only few have been shown to impact receptor function [192]. 
One of the functional SNPs has been identified in FcγRIIa. Only the R131H 
allelic variant of this receptor is capable of interacting with IgG2, enabling 
efficient phagocytosis [193,194]. Another SNP affecting binding affinity has 
been characterized for FcγRIII, which has two co-dominantly expressed 
allotypes: V158 and F158. The presence of a valine residue at position 158 
increases the affinity for IgG1 and IgG3, augmenting for example NK cell 
activity [195,196]. 
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FcγR expression and polymorphisms in RSV infection
Different FcγRs can have opposing effects on the immune reponse, 
as has also been shown for RSV. In FcγR-/- mouse models, Gomez et 
al. demonstrate that murine FcγRIII (homologue of human FcγRIIA) 
contributes to viral replication and airway inflammation, whereas murine 
FcγRIIb (homologue of human FcγRIIb) has a protective effect as was 
shown by a decrease in viral titers [110]. In vitro, RSV infection has been 
found to increase mFcγRII and mFcγRIII expression in murine macrophage 
cultures which subsequently showed enhanced phagocytosis [197]. 
Although the clinical relevance of FcγR SNPs has been studied intensively 
for auto-immune diseases [198], cancer treatment [199] and various viral 
infections [200-203], there is no data on the role of these polymorphisms 
in RSV infection or disease. In a genetic association study, performed to 
identify genes that are involved in RSV susceptibility, a SNP in FCER1A 
was found [204]. This polymorphism had previously been found to be 
associated with altered FcεRI expression levels and allergic disease, 
supporting the involvement of IgE in RSV-mediated disease.
IMPLICATIONS FOR VACCINE AND MAB DEVELOPMENT
Currently there are no market-approved vaccines or antivirals available 
against RSV. The only available treatment is the administration of a 
prophylactic F protein-specific mAb (Palivizumab) to reduce hospitalization 
in high-risk infants [205]. However, the use of Palivizumab is restricted 
and its cost-effectiveness is often discussed [206]. Improved mAbs with 
higher efficacy rates are thus highly needed and many research efforts 
are ongoing to develop these mAbs. A recent clinical trial with a pre-F-
specific mAb (Suptavamab) failed to demonstrate efficacy in pre-term 
infants although the mAb was superior to Palivizumab in neutralization 
tests in vitro and in reducing viral load in the cotton rat model [207] (press 
release Regeneron, August 14, 2017). The failure of this highly neutralizing 
mAb indicates that protection against RSV-mediated disease, which is 
known to be immunopathological in nature, depends on more than just 
neutralization of the virus.
In addition to efforts made to develop improved therapeutic mAbs, 
there is an extensive pipeline of vaccines that are currently being tested in 
different phases of clinical development (https://www.path.org/resources/
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rsv-vaccine-and-mab-snapshot/). The development of vaccines is of 
great importance, especially for developing countries where RSV-related 
mortality is high and mAb therapy is inaccessible due to high costs. The 
majority of vaccine candidates currently in clinical trials are designed to 
induce systemic IgG, mostly against the RSV F protein. The results of 
the pre-F-specific Suptuvamab and the recent failures of two F-specific 
vaccine candidates tested in elderly, imply that a broader and more 
polyfunctional immune response may be needed to confer protection 
against RSV-mediated disease [208,209] (press release Novavax, 
September 15, 2016).
To this date, no accurate correlate of protection has been defined for 
RSV infection as virus-specific antibody levels or neutralization titers do 
not seem of use in this respect. The lack of a well-defined correlate of 
protection complicates the development of new vaccines, as efficacy now 
has to be demonstrated in expensive large-scale clinical trials. Mounting 
evidence suggests that antibody effector functions beyond neutralization 
can contribute to both protection and disease [110,159,180,210]. A 
balanced activation of different Fc-mediated effector functions is key to 
prevent excessive inflammation and tissue damage (Figure 9). It will be 
of importance to implement assays that identify Fc-mediated effector 
functions of mAbs and vaccine-induced antibodies. Studies in FcγR-
knockout mice have indicated the importance of Fc-FcγR interactions 
for protection against RSV infection [110,180], but the testing of mAbs 
and vaccines demands high-throughput approaches. Systems serology 
captures a wide array of antibody characteristics and effector functions. 
It has proven effective in identifying antibody features that contribute to 
protection for various (viral) pathogens [19,211,212]. Such an approach will 
provide detailed information on the characteristics that are required for a 
protective RSV antibody response. 
The ability to generate an antibody profile that selectively binds particular 
epitopes and FcγRs is important to enable the induction of only the desired 
antibody effector functions. Recent developments now allow targeted 
modifications to mAbs that can lead to enhancement or inhibition of specific 
Fc-mediated antibody effector functions through glyco-engineering or 
the induction of specific antibody subclasses or isotypes [159]. In the future, 
this might also be possible for vaccines. 
One can conclude from the studies presented above that Fc-FcR 
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interactions are an integral component of the immune response against 
RSV and should be considered in the rational design of next generation 
RSV-specific mAbs and vaccines. Only limited data is available on the 
effect of specific Fc-mediated antibody effector functions during RSV 
infection, but it is clear that these can be both beneficial and detrimental 
for protection against RSV infection and disease outcome. In the future, 
Fc-mediated effector functions might be harnessed to optimize the 
efficacy of RSV-specific mAbs and vaccine-induced antibodies. However, 
our current knowledge on the precise role of individual effector functions in 
RSV disease is too limited to rationally design such antibodies and vaccines. 
Therefore, until the individual contributions of Fc-mediated effector 
functions to protection and disease are unraveled, aiming to induce highly 
neutralizing antibodies seems the safest approach. These antibodies will 
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FIGURE 9  The balance between Fc-mediated protection and enhanced disease  ·
Antibody effector functions, regulated by differences in antibody characteristics, are suspected 
to play a role in disease outcome upon RSV infection. Immune activation by Fc-mediated 
effector functions is likely needed for efficient viral clearance. However, excessive activation 
may lead to inflammation and tissue damage. A balanced and contained immune response is 
most likely the key to protection upon infection. Abbreviations: Ab, antibody; ADCC, antibody-
dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; 
ADE, antibody-dependent enhancement.
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need to halt the infection at the site of entry and thereby prevent excessive 
(antibody-mediated) immune activation. It remains to be seen whether 
complete neutralization can be achieved via the induction of serum IgG 
alone, or whether the induction of mucosal IgA is necessary for reliable 
neutralization activity. The many clinical trials that are currently ongoing 
with maternal and neonatal vaccine candidates will show whether these 
approaches indeed result in protection during the first, most vulnerable, 
months of life. 
CONCLUDING REMARKS
Neutralizing antibody titers do not adequately correlate with protection 
against RSV disease. Interestingly, antibodies have additional Fc-mediated 
effector functions besides neutralization, but this area of research is 
currently underappreciated in the RSV field. With this review, we aim to 
encourage a paradigm shift from neutralization-based studies towards 
functional studies examining the precise role of Fc-mediated antibody 
effector functions in vaccine efficacy and RSV disease. We have evaluated 
the current literature on the effect of RSV-specific antibodies on NK cells, 
phagocytes, the complement system, cytokine production and B- and T 
cell skewing. Multiple in vivo studies using FcγR-knockout mice or modified 
RSV-specific antibodies indicate the importance of Fc-mediated effector 
functions in protection from RSV infection and disease [110,159,180,210]. In 
addition, Fc-mediated effector functions might have a role in ADE of RSV 
disease [22,23]. However, most studies into vaccine and mAb efficacy still 
only report antibody (neutralization) titers and disregard any Fc-mediated 
effector functions. The importance of these antibody effector functions has 
already been shown for multiple clinically important viral pathogens and is 
only starting to be explored for RSV. In our view, a better understanding of 
the broad range of effector mechanisms that are induced by RSV-specific 
antibodies will greatly contribute to the much-needed development and 
testing of next generation mAbs and vaccines against this virus.
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ABSTRACT
Background
Respiratory syncytial virus (RSV) is a major cause of severe acute lower 
respiratory tract infections in infants. Despite extensive research efforts, 
there is no vaccine available against RSV. In early life, the most important 
contributors to protection are the innate immune system and maternal 
antibodies. However, the mechanisms by which these antibodies can 
protect against severe RSV disease are incompletely understood, as both 
levels of antibodies as well as neutralization capacity correlate poorly with 
protection.
Methods
We performed a case-control study including infants hospitalized for 
RSV infection (n = 43), hernia surgery (n = 16), or RSV-negative viral 
respiratory tract infections (n = 18). We determined RSV antigen-specific 
maternal antibody levels in infant plasma using a multiplex immunoassay. 
Subsequently, we measured the capacity of RSV-specific maternal 
antibodies to induce natural killer (NK) cell activation, including CD107a 
surface expression as a measure for antibody-dependent cell-mediated 
cytotoxicity (ADCC), and interferon gamma (IFN-γ) production. 
Results
We found that the concentrations of antigen-specific maternal antibodies 
did not differ between cases and controls. Interestingly, RSV-specific 
maternal antibodies, and in particular G-specific antibodies, were able 
to induce potent NK cell activity in vitro. Finally, RSV-specific maternal 
antibodies from hospitalized infants with severe lower respiratory tract 
infections had a significantly lower capacity to induce NK cell IFN-γ 
production in vitro than antibodies from uninfected controls.
Conclusions
Our results suggest that Fc-mediated antibody functionality contributes 
to protection against severe RSV disease and warrant further studies to 
evaluate the potential of harnessing this knowledge to develop an effective 
vaccine. 
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INTRODUCTION
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory 
tract disease in young children, with an estimated 118,200 deaths 
worldwide in children below 5 years of age annually [1]. Despite decades 
of research, there are currently no market-approved vaccines available 
against this virus and their development is hampered by the absence of a 
well-defined correlate of protection. Severe RSV disease is most prevalent 
in the first six months of life [2, 3], when infants mainly rely on their innate 
immune system and maternal antibodies for protection against infectious 
diseases. Considering that maternal vaccination is a potential strategy 
to prevent RSV disease in infants, it is of pivotal importance to obtain a 
thorough understanding of the mechanisms by which maternal antibodies 
might protect against disease, both directly and through their interaction 
with innate immune cells. 
The role of maternal antibodies in RSV infection and disease is unclear. 
Some studies show that high RSV-specific maternal antibody titers 
are associated with protection against RSV infection or (severe) disease 
[4-7]. In contrast, other studies do not show a protective effect [8-11] or 
even indicate an association between high maternal antibody titers and 
an increased risk of recurrent wheezing [12]. Strikingly, the vast majority 
of studies investigating the role of (maternal) antibodies in RSV infection 
merely look at in vitro binding or neutralization capacity, while additional 
antibody effector functions are not taken into account. 
Natural killer (NK) cells are important innate immune cells in the early 
response to viral infection and their activity is tightly regulated via their 
interaction with antigen-specific antibodies [13]. Engagement of the main 
NK cell Fc gamma receptor (FcγRIIIA) by antibodies bound to virus-
infected cells leads to the release of cytotoxic granules containing perforins 
and granzymes, a process known as antibody-dependent cell-mediated 
cytotoxicity (ADCC) [14]. In addition, antibody-dependent activation of NK 
cells is known to result in the secretion of pro-inflammatory cytokines, 
including interferon gamma (IFN-γ) [15]. 
Several groups have shown clearance of RSV-infected cells by peripheral 
blood mononuclear cells (PBMCs) in the presence of monoclonal 
antibodies, or antibodies from different sources, including breast milk, cord 
blood, nasopharyngeal secretions, and serum [16-20]. However, none of 
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these studies shows whether killing was specifically NK cell-mediated. In 
addition, maternal antibodies from hospitalized RSV patients and controls 
have never been compared regarding functional properties other than 
neutralization and antibody-dependent enhancement of infection [21].
Here, we used samples from an observational case-control study of 
84 infants (<7 months of age) that were hospitalized for RSV (cases), an 
inguinal hernia surgery (uninfected controls), or viral respiratory infections 
other than RSV (RSV-negative infected controls). We first measured 
plasma levels of antigen-specific maternal IgG against the RSV attachment 
(G) protein, pre- and post-fusion (F) protein, and nucleoprotein (N) in 
cases and controls. We then assessed the capacity of plasma containing 
RSV-specific maternal antibodies to induce NK cell activity in vitro as 
measured by CD107a surface expression, a marker for degranulation, and 
IFN-γ production. Finally, we used these assays to investigate differences 
in the capacity to induce NK cell activity between antibodies from cases 
and controls. We propose that maternal antibody functionality may be of 
importance in determining disease outcome. 
METHODS
Study design
Plasma samples from hospitalized infants were collected in an 
observational case-control study in 2010-2014 and have been described 
before [21]. For the current study, hospitalized infants below 7 months of 
age with PCR-confirmed RSV infections were included as RSV cases. 
Age-matched infants admitted for inguinal hernia repair surgery were 
included as uninfected controls, whereas infants admitted to the hospital 
for viral respiratory tract infections other than RSV were included as 
RSV-negative infected controls. The ePlex System (Genmark Dx) was 
used for identification of respiratory viral pathogens and RSV subtype. No 
RSV was detected by PCR in nasopharyngeal aspirates from all uninfected 
controls or RSV-negative infected controls. Blood samples were taken 
within 24 h after admission. Patients with congenital heart or lung 
disease, immunodeficiency, or glucocorticoid use were excluded. The 
study protocols were approved by the Regional Committee on Research 
Involving Human Subjects Arnhem- Nijmegen (serving as the IRB) and 
were conducted in accordance with the principles of the Declaration of 
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Helsinki. Written informed consent was obtained from the parents of all 
infants.
Cells and viruses
Peripheral blood mononuclear cells (PBMCs) were obtained from 
healthy adult volunteers at the National Institute for Public Health and the 
Environment (RIVM, the Netherlands). Blood was collected in heparin 
tubes and the mononuclear fraction was isolated by density gradient 
centrifugation (Lymphoprep, Nycomed). Isolated cells were cultured in 
Roswell Park Memorial Institute medium (RPMI, Gibco) supplemented 
with 10% heat-inactivated fetal calf serum (FCS), 1% penicillin/streptomycin/
glutamine (PSG, Gibco), and 5 ng/mL recombinant human IL-15 
(Biolegend). Before use, PBMCs were rested overnight at a density of 
1x106 PBMCs/mL at 37°C and 5% CO2. 
For each of the PBMC donors, the presence of the V158F polymorphism 
in FcγRIIIA was determined by Sanger sequencing. Genomic DNA was 
isolated from 1x106 PBMCs using DNeasy Blood & Tissue kit (Qiagen) 
following manufacturer’s protocol. A polymerase chain reaction (PCR) was 
performed and the PCR product was subsequently sequenced. Primer 
sequences are detailed in Table 1.
Recombinant RSV-X and RSV-X-ΔG, in which the G gene is replaced by 
GFP, were propagated in Vero cells as described before [22]. Virus stocks 
were purified between layers of 10% and 50% sucrose by ultracentrifugation. 
The 50% tissue culture infectious dose (TCID50) per mL was determined 
on Vero cells using the Spearman and Karber method [23]. 
TABLE 1    Primer sequences 
Transcript Sequence
FcγRIIIA PCR Forward: 5’-TGGCCACCGTCACCTTATTC-3’
Reverse: 5’-GACACCTCCTAGCTACCCCA-3’
FcγRIIIA sequencing Forward: 5′-ATGGCAAAGGCAGGAAGTAT-3′
Reverse: 5′-CAACTTCCCATGTGATTGC-3′
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Control sera
The International Standard for Antiserum to Respiratory Syncytial Virus 
(16/284, National Institute for Biological Standards and Control) was used 
as control in the NK cell activation assay. An in-house reference serum 
pool (RIVM) known to have high RSV titers was used as standard in the 
multiplex immunoassay. Additionally, cord blood (CB) plasma pooled 
from >10 individual donors was used as a standard. RSV-infected 
Vero cells were used to deplete all RSV-specific antibodies from the 
CB pool, whereas RSV-ΔG-infected Vero cells were used to deplete all 
RSV-specific antibodies except those specific for RSV G. Mock-depleted 
CB control was made by incubation with uninfected Vero cells. Depletion 
of RSV-specific antibodies was confirmed by multiplex immunoassay as 
described below. Cord blood samples were collected from umbilical cords 
of healthy neonates born by cesarean delivery at Radboudumc Nijmegen 
(the Netherlands). All mothers provided written informed consent.
RSV-specific multiplex immunoassay (MIA)
To quantify the concentration of RSV-specific IgG and IgA, a multiplex 
immunoassay was performed as described before for IgG [24]. Briefly, 
plasma samples were diluted 200 and 4000 times and incubated with 
RSV antigen-coupled beads, including GA, GB, pre-F (DS-CAV1 form), 
post-F, and N. Except for N, which was produced in Escherichia coli, all 
antigens were produced in eukaryotic cells. The bound antibodies were 
detected with secondary R-phycoerthrin labeled goat anti-human IgA 
F(ab’)2 (Southern Biotech) or goat anti-human IgG F(ab’)2 (Jackson 
Immunoresearch Laboratories). Samples were measured on a Bio-Plex 
200 (Luminex Corporation) in combination with Bio-Plex Manager software 
version 6.1 (Bio-Rad). Later in the study the Bio-Plex 200 was replaced by 
a Flexmap 3D (Luminex Corporation) in combination with Xponent version 
4.2 (Luminex Corporation) and Bio-Plex Manager Software version 6.1. 
For each analyte, median fluorescence intensity (MFI) was converted to 
arbitrary units/ml (AU/ml) by interpolation from a 5-parameter logistic 
standard curve from an in-house reference serum pool known to have 
high RSV antibody concentrations [24]. Although all plasma samples were 
tested in the NK cell activation assay, not enough volume was left for some 
of the samples to be tested in the IgG (n = 8) and/or IgA (n = 11) MIA. These 
samples were divided over the 3 different groups.
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NK cell activation assay
Sterile Immulon ELISA plates (ThermoScientific) were coated with intact 
RSV particles at a concentration of 1.7x105 TCID50/well. After overnight 
coating at 4°C, wells were washed with PBS and blocked with 10% FCS in 
PBS for 30 min at RT. After washing with PBS, coated plates were incubated 
for 2 hours at 37°C with 10-fold diluted plasma, to allow for antigen-specific 
immune complex formation. Subsequently, unbound antibodies and other 
plasma constituents were washed away and 1x106 PBMCs were added per 
well, together with Brefeldin A (BD Bioscience), and anti-human CD107a-
PerCP/Cy5.5 (clone H4A3; BioLegend). PBMCs were incubated with the 
opsonized virions for 4 hours at 37°C, after which the cells were stained 
for flow cytometric analysis as described below. Incubation of PBMCs in 
RSV-coated plates in the absence of antibodies was used to determine 
the background signal. The PBMC supernatants were stored at -80°C and 
used for detection of perforin secretion as described below. 
Due to the limited amount of fresh PBMCs per donor, we were unable to 
test all samples using cells of all 6 donors. For this reason, we could test 63 
of the 84 plasma samples on cells from all 6 PBMC donors. For 18 samples, 
we were able to test with PBMCs from 2-5 different donors. Three samples 
were only tested on a single donor; these were all RSV-negative infected 
controls. Excluding these 3 samples had no effect on the subsequent 
statistical analysis. The mock-depleted CB pool was used for normalization 
between the different PBMC donors.
Flow cytometric analysis
PBMCs that were incubated with opsonized virions as described above 
were stained for flow cytometric analysis. Extracellular staining was 
performed with anti-human CD3-FITC (clone UCHT1, Biolegend), 
anti-human CD56-PE (clone HCD56, Biolegend), and Fixable Viability 
Staining-eFluor780 (eBioscience). After fixation and permeabilization, 
cells were intracellularly stained with anti-human IFN-γ-PECy7 (clone 
B27, Biolegend). Flow cytometric analysis was performed using the FACS 
LSR Fortessa X20 (BD Bioscience). In all experiments, NK cells were 
gated as the CD3–, CD56+ population. The gating strategy is depicted in 
Supplementary Figure 1. FlowJo software V10 (FlowJo, LLC) was used for 
data analysis. 
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Perforin ELISA
The supernatants collected after the NK cell activation assay were used to 
determine the total perforin secretion by ELISA (Mabtech). The ELISA was 
performed following the manufacturer’s protocol and optical density was 
measured at 450 nm using an ELISA reader (BioTek).
Statistical analysis
Comparison of two groups or data points was performed by using a 
nonparametric Mann-Whitney test. Multiple comparisons were analyzed 
by using a nonparametric Kruskal-Wallis test, followed by Dunn’s multiple 
comparisons test. Multiple comparisons of categorical values were tested 
by Chi-square test. P values <0.05 were considered statistically significant. 
Statistical analyses were performed with Prism 8 software (GraphPad).
RESULTS
Clinical characteristics of study subjects
Plasma samples were obtained from a total number of 84 infants below 
7 months of age that were hospitalized for RSV infection (cases), hernia 
surgery (uninfected controls), or viral respiratory infections other than 
RSV (RSV-negative infected controls). To ensure that our analyses were 
restricted to maternal antibodies, all plasma samples were screened 
for the presence of RSV-specific IgA. Since this antibody isotype is not 
transplacentally transferred and breastmilk IgA does not reach the blood, 
its presence in plasma is indicative of a humoral response by the child itself 
due to previous exposure. Based on the results, we excluded those children 
(n = 5) that tested positive for IgA (AU/mL > 0.2) against a minimum of 3 RSV 
antigens (Figure 1A). Excluded samples are indicated with white squares. 
Asterisks indicate the concentrations found in the in-house reference 
serum pool from adults, known to contain RSV-specific IgA. In addition, 
we excluded 2 children that had presumably received Palivizumab, based 
on the fact that they displayed unusually high IgG levels for both pre-F and 
post-F, while levels for N and G were low or even below detection level 
(data not shown).
The clinical and demographic characteristics of the children included in 
further analyses are depicted in Table 2. There was no significant difference 
in age, gestational age or breastfeeding between the three groups. However, 
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FIGURE 1   Characterization of the infant (maternal) RSV-specific antibody repertoire  ·
An RSV-specific multiplex immunoassay was performed to quantify the concentration of IgA 
and IgG specific for G, pre-F, post-F, and N in plasma. A. Relative concentration of plasma 
IgA depicted for each of the RSV antigens. Children that tested positive for IgA against a 
minimum of 3 RSV antigens (n = 5) are excluded for subsequent analyses and indicated with 
white squares. Pink asterisks indicate the IgA levels of the in-house RSV reference serum pool. 
B. Relative concentration of plasma IgG depicted for each of the RSV antigens. Graphs 
depict geometric mean and SD. C. Relative concentration of RSV-specific plasma IgG plotted 
against age. D. Correlation analysis of RSV N- and RSV pre-F-specific maternal antibody 
levels. Nonparametric Spearman correlation analysis was used to assess correlations. 
Abbreviations: AU, arbitrary units; IgA, immunoglobulin A; IgG, immunoglobulin G; RSV, 
respiratory syncytial virus.
there was a significant difference in division of sex between the three groups 
(P = 0.0459). A higher percentage of infants was infected with RSV-A (70%) 
compared to RSV-B (30%). The group of RSV patients contained both RSV 
mono-infections (n = 28) and co-infections (n = 15) with other respiratory 
viral pathogens, with rhinovirus being the most prevalent. 
A
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TABLE 2    Demographic and clinical characteristics of study subjects
RSV 
cases
(n = 43)
Uninfected 
controls
(n = 16)
RSV-negative 
controls
(n = 18)
P Value
Age in days 
(range)
70 (11-185) 79 (28-175)a 89 (16-202) 0.3260b
Gestational age 
in weeks (range)c
38 (34-41) NA 38 (35-41) 0.9749 d
Sex (M/F) 22/21 12/4 5/11e 0.0459f
Breastfeeding (%)g 21 (50%) NA 7 (39%) 0.8246f
RSV types
A 30 (70%) NA NA
B 13 (30%) NA NA
Co-infections (%) 15 (35%) NA NA
a Age of one infant was not recorded, b Comparisons between RSV patients, uninfected 
controls, and RSV-negative controls; Kruskal-Wallis test followed by Dunn’s test to adjust 
for multiple comparisons, c Gestational age of 1 RSV patient, all uninfected controls, and 3 
RSV-negative controls was not recorded, d Comparisons between RSV patients, uninfected 
controls, and RSV-negative controls; Mann-Whitney test, e Sex of two infants was not recorded
f Comparisons between RSV patients, uninfected controls (only for sex), and RSV-negative 
controls; Chi-square test, g Breastfeeding was not recorded for 1 RSV patient, all the uninfected 
controls, and 3 RSV-negative controls
The concentration of RSV-specific maternal IgG does not differ between 
RSV cases and controls  
We used a multiplex immunoassay (MIA) to quantify the concentration 
of maternal IgG specific for the RSV attachment (G) protein, fusion (F) 
protein, and nucleoprotein (N). G protein from both an A- and a B-strain 
was included, as these sequences are highly variable between the two 
RSV subtypes [25]. Both the pre- and post-fusion conformations of the F 
protein were included, as these harbor partly overlapping but also distinct 
epitopes [26].
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As has been published by others [7,24], the concentration of RSV 
G-specific antibodies was low compared to antibodies against the RSV F 
protein (Figure 1B). In addition, the concentration of N-specific antibodies 
was high. Although the N protein is generally regarded as a viral core 
protein, it has also been described to be present on the surface of viral 
particles and RSV-infected cells [27], which could explain the high levels 
of N-specific antibodies. Despite the cross-sectional design of the study, 
we could observe a gradual waning of maternal antibody concentrations 
with increasing age (Figure 1C). As would be expected, there was a strong 
correlation between the concentrations of antibodies targeting different 
RSV antigens, as exemplified for pre-F and N (Figure 1D). To assess a 
possible relation with RSV disease, we compared the concentrations of 
RSV antigen-specific antibodies between RSV-infected cases, uninfected 
controls, and RSV-negative infected controls. The concentrations of 
antigen-specific antibodies did not significantly differ between the three 
groups (Figure 2A-E), confirming previous findings in a subset of this 
cohort [11]. Taken together, these findings indicate that all children possess 
RSV-specific maternal antibodies, but their concentration does not explain 
susceptibility to severe RSV disease. 
RSV-specific maternal antibodies induce NK cell activity in vitro
We then set out to explore possible differences in NK cell activation by 
maternal RSV-specific antibodies, as NK cells play an important role in 
the control of viral lung infections. We first assessed whether maternal 
RSV-specific antibodies are capable of inducing NK cell activity in vitro. 
Incubation of primary PBMCs with RSV-antibody complexes formed with 
a dilution series of a mock-depleted cord blood plasma pool, naturally 
containing RSV-specific maternal antibodies, showed a concentration-
dependent activation of NK cells as measured by CD107a surface 
expression (Figure 3A). Surface expression of CD107a is an established 
marker for NK cell degranulation [28]. A pool of cord blood plasma largely 
lacking RSV-specific antibodies (RSV-depleted) showed strongly reduced 
NK cell activation, whereas cord blood plasma containing almost exclusively 
RSV G-specific antibodies (RSV-ΔG-depleted) induced similar activation 
as mock-depleted plasma. In addition to the release of cytotoxic granules, 
NK cells are potent producers of IFN-γ. We therefore also performed 
intracellular staining for this cytokine, which gave comparable results to 
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FIGURE 2 The RSV-specific antibody composition does not differ between uninfected 
controls, RSV patients, and RSV-negative infected controls  ·
An RSV-specific multiplex immunoassay was performed to quantify the amount of IgG 
specific for G, pre-F, post-F, and N in plasma. A-E. Comparison of the amount of antibodies 
against RSV-A attachment protein G (A), RSV-B attachment protein G (B), pre-fusion F 
protein (C), post-fusion F protein (D), and nucleoprotein N (E) between uninfected controls, 
hospitalized RSV patients, and hospitalized RSV-negative infected controls. All graphs 
depict geometric mean and SD. Kruskal-Wallis test with Dunn’s multiple comparisons test 
was used for comparison between multiple groups. Abbreviations: AU, arbitrary units; IgG, 
immunoglobulin G; RSV, respiratory syncytial virus.
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FIGURE 3  RSV-specific maternal antibodies induce NK cell activity   ·
A-B. NK cell-specific CD107a surface expression (A) and IFN-γ production (B) of three different 
PBMC donors after 4 hour incubation with viral particles opsonized with mock-depleted 
cord blood, RSV-depleted cord blood, or RSV-ΔG-depleted cord blood. Graphs depict 
geometric mean and SD. Kruskal-Wallis test with Dunn’s multiple comparisons test was 
used for comparison between the differently depleted cord blood pools of the same dilution 
(*p < 0.05, **p < 0.01). C-D. RSV-specific multiplex immunoassay of mock-depleted cord blood 
(complete bar) compared to RSV-depleted cord blood (filled bar, C), or RSV-ΔG-depleted 
cord blood (filled bar, D). Abbreviations: AU, arbitrary units; CB, cord blood; IFN-γ, interferon 
gamma; NK cells, natural killer cells; RSV, respiratory syncytial virus.
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CD107a surface expression (Figure 3B). 
To confirm the depletion of RSV-specific antibodies, we assessed their 
concentration in the various cord blood plasma pools using the RSV-MIA. 
Upon RSV-depletion, we observed a strong decrease in all measured 
specificities compared to the mock-depleted cord blood pool (Figure 
3C). The RSV-ΔG-depleted cord blood plasma pool showed comparable 
G-specific antibody levels as the mock-depleted pool, while the 
concentrations of the other measured specificities were even lower than 
upon RSV-depletion (Figure 3D). Interestingly, the relatively high level of NK 
cell activation by  RSV-ΔG-depleted cord blood plasma, containing similar 
amounts of G-specific antibodies as mock-depleted cord blood plasma 
but lower amounts of F- and N-specific antibodies than RSV-depleted 
cord blood,  suggests that the majority of antibody-mediated NK cell 
activation is induced by RSV G-specific antibodies (Figure 3A-B). Taken 
together, these results show that RSV-specific maternal antibodies can 
induce NK cell activity. As described before, RSV G-specific antibodies 
seem to be the most potent inducers of this activity [19]. 
Effect of FcγRIIIA polymorphism on NK cell activation
Notably, we observed considerable variation in CD107a surface expression 
and IFN-γ production between PBMC donors, prompting us to explore 
the underlying cause and assess the possibility for normalization. The 
presence of a common single nucleotide polymorphism (SNP) in FcγRIIIA, 
replacing the phenylalanine at position 158 with a valine residue (V158F), 
has been described to influence NK cell ADCC activity [29,30]. We therefore 
genotyped 6 PBMC donors: 4 were heterozygous (F/V), 1 was homozygous 
for valine (V/V), and 1 was homozygous for phenylalanine (F/F). 
Using a dilution series of the WHO RSV reference serum, we assessed 
RSV-specific antibody-mediated NK cell activation in the genotyped 
donors. CD107a surface expression was significantly enhanced on NK cells 
from heterozygous donors compared to the homozygous donors (Figure 
4A). Looking at IFN-γ production, a low response was not only confined to 
homozygous donors, as one heterozygous donor also showed low IFN-γ 
production (Figure 4B). To correct for these donor differences in subsequent 
assays, a mock-depleted cord blood plasma sample was included and used 
for normalization. After normalization, there was no difference in antibody-
mediated NK cell activation between donors (Figure 4C-D).
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FIGURE 4  Influence of FcγRIIIA polymorphism on NK cell activation  ·
A-B. NK cell-specific CD107a surface expression (A) and IFN-γ production (B) of six different 
PBMC donors after 4 hour incubation with viral particles opsonized with the indicated 
concentrations WHO RSV reference serum. C-D. CD107a surface expression (C) and IFN-γ 
production (D) after normalization to the mock-depleted cord blood pool. All graphs depict 
geometric mean and SD. Mann-Whitney test was used for comparison between the average 
of heterozygous donors and the average of homozygous donors at a concentration of 500 
IU/mL (**p < 0.01). Abbreviations: AU, arbitrary units; FcγRIIIA, Fc gamma receptor IIIA; IFN-γ, 
interferon gamma; NK cells, natural killer cells; RSV, respiratory syncytial virus.
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Maternal RSV-specific antibodies from patients with severe respiratory 
tract infections induce less potent NK cell activity compared to 
uninfected controls
To evaluate whether RSV-specific maternal antibody functionality, other 
than neutralization, relates to disease severity, we finally assessed the 
capacity of these antibodies from RSV patients and controls to induce 
activation of primary NK cells from healthy donors. We found considerable 
variation in the capacity of plasma containing maternal RSV-specific 
antibodies to induce CD107a surface expression (Figure 5A). Furthermore, 
RSV-specific antibodies from both RSV patients and RSV-negative 
infected controls induced slightly less CD107a surface expression than 
those from uninfected controls, but this difference was not statistically 
significant. Interestingly, we found that RSV-specific antibodies from both 
RSV patients and RSV-negative infected controls did show a significantly 
decreased potential to induce IFN-γ production compared to antibodies 
from uninfected controls (Figure 5B). 
CD107a surface expression is used as a proxy for NK cell degranulation. 
To assess the correlation between CD107a surface expression and 
degranulation, we measured perforin secretion in the supernatant of 
the NK cell activation assay for one PBMC donor. We observed a strong 
positive correlation between NK cell CD107a surface expression and 
perforin concentration (Figure 5C).
Finally, since the capacity of antibodies to induce NK cell activity could be 
directly related to antibody levels, we assessed the correlation between RSV 
antigen-specific antibody levels and IFN-γ production. As exemplified by 
the correlation between pre-F-specific antibody concentrations and IFN-γ 
production (Figure 5D), there was only a moderate correlation between the 
antibody levels and NK cell activation, suggesting that other factors besides 
concentration contribute to the functional capacity of these antibodies. In 
summary, these findings indicate that, in contrast to RSV-specific maternal 
antibody concentrations, the capacity of these antibodies to induce IFN-γ 
production by NK cells is significantly decreased in hospitalized infants 
with severe respiratory tract infections compared to uninfected controls. 
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FIGURE 5  NK cell activation in RSV patients compared to controls  ·
A-B. Normalized CD107a expression (A) and IFN-γ production (B) after 4 hour incubation of 
PBMCs with viral particles opsonized with 10-fold diluted plasma samples from uninfected 
controls, RSV patients, or RSV-negative infected controls. Graphs depict geometric mean 
and SD. Kruskal-Wallis test with Dunn’s multiple comparisons test was used for comparison 
between multiple groups (*p < 0.05, **p < 0.01). C. Correlation analysis between perforin 
secretion in the supernatant and CD107a surface expression of one donor. D. Correlation 
analysis between RSV pre-F-specific antibody levels and IFN-γ production. Uninfected 
controls are indicated in black, RSV patients in grey, and RSV-negative infected controls 
in white. Nonparametric Spearman correlation analysis was used to assess correlations. 
Abbreviations: IFN-γ, interferon gamma; NK cells, natural killer cells; RSV, respiratory syncytial 
virus.
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DISCUSSION
Studies investigating the role of (maternal) antibodies in RSV infection 
mostly focus on neutralization and binding titers. Whereas antibody-
mediated protection against RSV disease in vivo may depend at least in 
part on direct neutralization, additional antibody functionalities are likely 
to be important contributors. Interestingly, there is increasing evidence 
that Fc-mediated antibody functionality plays an important role during 
RSV infections (reviewed in [31,32]). In two independent in vivo studies, 
modification of the Fc domain of RSV-specific antibodies has shown 
major effects on lung viral titer [33,34]. These results strongly support 
the idea that Fc-dependent mechanisms may significantly enhance the 
efficacy of RSV-specific antibodies. In the present study, we measured 
RSV antigen-specific antibody levels, but these concentrations did not 
explain susceptibility to severe RSV disease. In addition, we analyzed the 
capacity of RSV-specific maternal antibodies to induce NK cell activity. We 
demonstrated that these antibodies, and in particular those targeting the 
G protein, can induce CD107a surface expression and IFN-γ production 
in primary NK cells. Importantly, we found that RSV-specific maternal 
antibodies from RSV patients and RSV-negative infected controls less 
potently induce IFN-γ production compared to uninfected age-matched 
controls. 
Antibody-mediated NK cell activation has gained increasing attention 
for its role in multiple other infectious diseases. The capacity of antibodies 
to induce NK cell ADCC correlated with the control of mycobacterium 
tuberculosis [35] and the killing of chlamydia trachomatis [36]. For HIV, 
ADCC-inducing antibodies have been identified as a key correlate of 
protection in the RV144 HIV vaccine trial [37-39]. For influenza, the role 
of ADCC was shown to be protective in some studies [40,41], but others 
point to the involvement of ADCC in exaggeration of the immune response 
[42-44]. Taken together, these examples show that the capacity of 
antibodies to induce ADCC can significantly contribute to protection.
In our study, the difference in antibody functionality between patients 
with severe lower respiratory tract infections and uninfected controls did 
not seem to be explained by antibody concentrations alone, thus, other 
factors are likely to play a role. It remains to be determined which factors are 
the most important regulators of the functionality of RSV-specific maternal 
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antibodies. One factor that affects antibody functionality is antigen-
specificity. Despite the difference in experimental set-up, we were able 
to corroborate previous findings from Gupta et al., who showed that RSV 
G-specific antibodies have an increased capacity to mediate clearance of 
RSV-infected cells compared to total intravenous immunoglobulin or a 
monoclonal antibody against RSV F [19]. In addition to antigen-specificity, 
several other antibody characteristics are known to influence antibody 
functionality. First, the epitope specificity of antibodies determines which 
effector functions are induced, as antibodies that bind membrane-
proximal epitopes mediate ADCC more efficiently than distal binders [45]. 
Second, glycosylation of the Fc domain was shown to be an important 
regulator of antibody functionality. Specifically the absence of the core 
fucose on the Fc glycan enhances the interaction with FcγRIIIA, thereby 
increasing ADCC activity [46]. Finally, different IgG subclasses have varying 
capacities to induce Fc-mediated effector functions [47].
Besides antibody characteristics, FcγR polymorphisms and expression 
patterns on effector cells can affect Fc-mediated antibody functions. We 
observed decreased CD107a surface expression of both homozygous (V/V 
and F/F) donors compared to the heterozygous (V/F) donors. It has been 
described that the presence of a valine residue at position 158 in FcγRIIIA 
results in increased binding affinity for IgG1 and IgG3 [29,30]. However, 
in the presence of two valine residues, resulting in the high affinity V/V 
phenotype, NK cells are pre-loaded with a high amount of FcγRIIIA-bound 
IgG [30], which could potentially interfere with the binding of RSV-specific 
antibodies in our assay. We did not assess the expression of FcγRIIB or 
FcγRIIC on the primary NK cells used in our experiments. Expression of 
FcγRIIB is seen in some individuals and effectively inhibits ADCC activity 
[48], whereas expression of FcγRIIC can both inhibit or stimulate ADCC 
activity, depending on the isoform that is expressed [49]. Although the 
effect of NK cell FcγR polymorphisms on IFN-γ production has never 
been assessed, our results suggest that other factors besides the V158F 
polymorphism play a role.
The main limitation of our study is the fact that children were not sampled 
at a time point before infection, but upon admission to the hospital. Due 
to the lack of this pre-infection sample, we were unable to investigate 
whether the low antibody functionality was a cause or consequence of 
severe respiratory tract disease. It has been shown that both inflammation 
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and infection can affect antibody functionality [50]. This could explain 
the significantly lower induction of IFN-γ production in both groups with 
severe lower respiratory tract infections, independent of the etiologic agent. 
Alternatively, antibodies with lower functionality could have already been 
present before infection, leading to disease susceptibility due to a reduced 
capacity to activate NK cells. Future research, preferably using samples 
obtained before infection, is needed to address this question. Another 
limitation is the lack of information on whether the uninfected controls 
will develop severe disease after encountering their first RSV infection. 
However, considering that virtually every child is infected by the age of two 
and only 2-3% of RSV-infected infants is admitted to the hospital [2,4], we 
believe the uninfected control group can be considered representative for 
infants that will experience a mild RSV infection.
To date, no correlate of protection has been defined for RSV infection. The 
lack of a well-defined correlate of protection complicates the development 
of new vaccines, as efficacy has to be demonstrated in large-scale clinical 
trials. In the current study, NK cell activation was highly variable within the 
groups. This indicates that the capacity of maternal antibodies to activate 
NK cells may partly explain RSV hospitalization but it is highly unlikely to 
be the only determinant, indicating that additional antibody characteristics 
and functionalities should be investigated. The use of a systems 
serology approach in the RSV research field may offer an unbiased and 
comprehensive way to systematically investigate antibody characteristics 
and effector functions. It has already proven effective in identifying antibody 
features that contribute to protection against various (viral) pathogens 
[35,51,52]. Also for RSV, such a systems serology approach may provide 
a useful framework to evaluate new vaccines and monoclonal antibodies.
In conclusion, our results highlight the need for further investigations 
into the role of Fc-mediated antibody effector functions in protection 
against RSV disease. In addition, our findings provide additional incentive 
for evaluating the RSV G protein as a vaccine target, where most efforts 
are currently focused on the RSV F protein. A thorough understanding 
of the protective capacity, in its broadest sense, of maternal RSV-specific 
antibodies will be invaluable for the development of a safe and effective 
vaccine against this devastating pathogen.  
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ABSTRACT
Respiratory syncytial virus (RSV) is the leading cause of severe respiratory 
illness in infants. At this young age, infants typically depend on maternally 
transferred antibodies (matAbs) and their innate immune system for 
protection against infections. RSV-specific matAbs are thought to protect 
from severe illness, yet severe RSV disease occurs mainly below 6 months 
of age, when neutralizing matAb levels are present. To investigate this 
discrepancy, we asked if disease severity is related to antibody properties 
other than neutralization. Some antibody effector functions are mediated via 
their Fc binding region. However, it has been shown that this binding may 
lead to antibody-dependent enhancement (ADE) of infection or reduction 
of neutralization, both possibly leading to more disease. In this study, we 
first showed that high levels of ADE of RSV infection occur in monocytic 
THP-1 cells in the presence of RSV antibodies and that neutralization by 
these antibodies was reduced in Vero cells when they were transduced with 
Fc gamma receptors. We then demonstrated that antibodies from cotton 
rats with formalin-inactivated- (FI-) RSV-induced pulmonary pathology 
were capable of causing ADE. Human matAbs also caused ADE and were 
less neutralizing in vitro in cells that carry Fc receptors. However, these 
effects were unrelated to disease severity because they were seen both in 
uninfected controls and in infants hospitalized with different levels of RSV 
disease severity. We conclude that ADE and reduction of neutralization are 
unlikely to be involved in RSV disease in infants with neutralizing matAbs.
Importance
It is unclear why severity of RSV disease peaks at the age when infants have neutralizing levels 
of maternal antibodies. Additionally, the exact reason for FI-RSV-induced enhanced disease, 
as seen in the 1960’s vaccine trials, is still unclear. We hypothesized that antibodies present 
in either of these conditions could contribute to disease severity. Antibodies can have effects 
that may lead to more disease instead of protection. We investigated two of those effects: 
antibody-dependent enhancement of infection (ADE) and neutralization reduction. We show 
that ADE occurs in vitro with antibodies from FI-RSV-immunized RSV-infected cotton rats. 
Moreover, passively acquired maternal antibodies from infants had the capacity to induce ADE 
and reduction of neutralization. However, no clear association with disease severity was seen, 
ruling out that these properties explain disease in the presence of maternal antibodies. Our 
data contribute to a better understanding of the impact of antibodies on RSV disease in infants.
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INTRODUCTION
Human respiratory syncytial virus (RSV) is the leading cause of lower 
respiratory tract disease in young children [1]. Hospitalization for severe 
RSV-mediated disease is most frequent between six weeks and six 
months of life [2,3]. It seems widely accepted that RSV-neutralizing, 
transplacentally transferred maternal antibodies (matAbs) can lower the 
risk for RSV infections [1,4,5]; however, many studies fail to reproduce these 
results [6-8]. There is no consensus on how much antibodies are sufficient 
for protection, but an average concentration of maternal antibodies seems 
insufficient. 
Maternal antibody levels are high during the first six months after birth. 
Strikingly, severe RSV disease most frequently occurs in this period of life 
[2,3], indicating RSV can infect infants even though matAbs are present. 
For these children who become infected with RSV, the role of matAbs in 
RSV disease is unclear. Associations between the severity of symptoms 
and classical serological parameters such as RSV neutralization titer or 
RSV-specific antibody levels have not been observed so far [4,6]. Yet, 
antibodies have additional effector functions, generally mediated via their 
Fc binding region, that contribute to immune defense. In this study, we 
investigate whether consequences of antibody-Fc receptor interactions 
could be related to the severity of symptoms during RSV infection.
Antibody-dependent enhancement (ADE) of RSV infection has 
been demonstrated in vitro [9] in monocytic cell lines. ADE means 
that RSV-specific antibodies in human serum, as well as monoclonal 
antibodies, increase the number of RSV-infected cells, when those cells 
carry Fc gamma receptors (FCGR) [10,11].  FCGR-carrying leukocytes, 
which are present in the lungs or recruited during infection, might be more 
readily infected and activated by RSV-antibody complexes compared 
to RSV alone. In addition to causing ADE, Fc receptors lower the RSV 
neutralization capacity of most monoclonal antibodies [12], allowing RSV 
to infect even in the presence of otherwise neutralizing antibody titers. 
Whether FCGR binding influences RSV (immuno-) pathology and severity 
of RSV disease has not been studied so far, but the ongoing pursuit of RSV 
vaccines demands more knowledge about the role of antibodies in RSV 
disease. Therefore, we investigated whether reduced neutralization and 
enhanced RSV infection of FCGR-bearing cells by maternal antibodies 
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that should provide passively acquired immunity relates to clinical disease 
severity in infants. Moreover, antibodies generated as part of active 
immunity induced by formalin-inactivated- (FI-) RSV vaccination have 
been shown to contribute to enhanced pathology [13]. Therefore, we also 
investigated whether reduced neutralization and enhanced RSV infection 
of FCGR-bearing cells relates to pathology in the FI-RSV cotton rat model.
We assessed two FCGR-mediated effects of RSV-specific antibodies: 
antibody-dependent enhancement of infection in monocytic THP-1 cells, 
and reduction of neutralization capacity in cells transduced with Fc gamma 
receptors. Both were investigated for passively transferred matAbs by 
titration series of plasma from human cord blood and for actively acquired 
antibodies from immunized cotton rats, a small animal model that is highly 
susceptible to RSV and shows vaccine-enhanced pulmonary pathology 
[14,15]. To assess possible associations with disease severity, plasma 
samples from infants with acute primary RSV infection were tested as 
well as sera from cotton rats showing FI-RSV-induced enhancement of 
pathology.
MATERIALS AND METHODS
Study design
Plasma samples from healthy controls and hospitalized infants with RSV 
infections used in this study, have been described before [6]. Hospitalized 
children below 1 year of age with PCR-confirmed RSV infections were 
included during 2011-2013. In the previous study only samples below 3 
months of age were included [6]. In this study we included all 51 children, 
of which 20% was > 3 months of age. Blood samples were taken within 
24 h after admission. Patients with congenital heart or lung disease, 
immunodeficiency or glucocorticoid use and infants born at a gestational 
age below 35 weeks were excluded. For analysis, patients were classified 
with severe symptoms when they required mechanical ventilation and 
admission to the intensive care unit. Infants with moderate disease were 
only monitored or received oxygen therapy. Infants below 1 year of age 
requiring surgery for an inguinal hernia repair were included as healthy 
controls. Nasopharyngeal aspirates from all uninfected individuals were 
RSV negative. Gender, gestational age, presence of breastfeeding and 
presence of parental smoking were comparable between all groups. The 
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study protocols were approved by the Regional Committee on Research 
involving Human Subjects Arnhem-Nijmegen (serving as the IRB) and 
were conducted in accordance with the principles of the Declaration of 
Helsinki. Written informed consent was obtained from the parents of all 
infants. A potential limitation of our study is the difficulty to separate the 
presence of matAbs from endogenous RSV-induced antibodies of the 
infant. However, with a median onset of disease of three days and the short 
time between symptoms and hospitalization, production of endogenous 
RSV-IgG is unlikely to have reached significant levels at the time of 
sampling. About 80% of patients were below 3 months of age. As Dutch 
infants in general suffer their first respiratory infection after 3 to 7 months 
of age, infants in our study most likely experienced a primary RSV infection 
[16]. Therefore, it is plausible that we detect mainly matAbs [17].
Cells 
Monkey kidney epithelial Vero-CCL81 cells were propagated in 
DMEM supplemented with 5% fetal calf serum (FCS) and 1% penicillin/
streptomycin/glutamax (PSG). The Vero cell-derived cell line expressing 
FCGR2a (Vero2a) was described earlier [12] and FCGR2a-expression was 
confirmed by flow cytometry (data not shown). Monocytic THP-1 cells were 
cultured in RPMI supplemented with 10% FCS and PSG [18]. Peripheral 
blood mononuclear cells (PBMC) were obtained from healthy volunteers. 
Blood was collected in heparin tubes and the PBMC fraction was isolated 
by density gradient centrifugation using Lymphoprep (Nycomed).
Virus and vaccine preparation
Live-attenuated recombinant RSV-X (rRSV) [19], recombinant RSV-X 
containing a GFP gene (designated RSV [19]) and RSV-A2, were 
propagated in Vero cells as described before [19] (Dutch GMO license 
IG-99-210). Virus stocks were purified in between layers of 10% and 50% 
sucrose by ultracentrifugation. FI-RSV and formalin-inactivated cell culture 
supernatant was prepared from RSV-A2 as described previously [20].
Cotton rats
Cotton rats (Sigmodon hispidus) were held at the animal facilities of 
Intravacc (Netherlands) and experiments were approved by the Animal 
Ethical Committee of RIVM. Animals were immunized intranasally with 
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105 infectious units rRSV or uninfected Vero cell supernatant (mock) or 
intramuscularly with a high or low dose FI-RSV (1:5 and 1:125 diluted in 
PBS, respectively) on day 0 and 21. Animals were challenged intranasally 
with 105 infectious units RSV-A2 on day 49. Animals were sacrificed, blood 
plasma was collected, and lungs fixed on day 53. Histopathologic analysis 
of lung sections using haematoxilin and eosin staining was done by Paul 
Roholl (Microscope Consultancy, Netherlands) as described previously 
[21]. To prepare single cell suspensions, lung tissue of untreated animals 
was separated after DNase/collagenase digestion. Isolated lung cells 
were phenotyped by staining with antibodies to an epithelial marker, 
pan-cytokeratin [22], and T cell marker CD3ε [23].
RSV infection and serology 
THP-1 cells, human PBMCs or cotton rat lung cells were used to measure 
ADE. Immune complexes were formed by pre-incubation of RSV with 
antibodies for 1 h at 37°C. Cells were inoculated by spinoculation for 1 h 
at 700 × g at 20°C in duplicates. Next, cells were washed with PBS and 
replenished with culture medium. Overnight incubation at 37°C was 
followed by flow cytometric analysis of GFP fluorescence using a FACS 
Canto II (BD Biosciences). RSV neutralization assays were carried out on 
Vero and Vero2a cells. Assays were performed in triplicate as described 
earlier [19]. 50% plaque reduction neutralization titers (PRNT50) were 
calculated from non-linear regression using Prism 7 (GraphPad) after 
normalization to antibody-untreated, RSV-infected samples. Spinoculation 
had no effect on ADE or change of PRNT50s in any of the infection assays 
(data not shown). Antibody-binding sites of FCGRs were blocked by 
adding 3 µg/mL staphylococcal FLIPr-like protein (kind gift from Kok van 
Kessel, University Medical Center Utrecht) [24] to THP-1 cells during RSV 
neutralization assays. Cells were pretreated for 1 h and supplemented 
during infection and initial incubation steps. FLIPr-like protein was removed 
with the inoculum.  
RSV-specific IgG concentrations in plasma samples were determined 
by ELISA against RSV particles as described previously [6]. 1 mg/ml IVIg 
(KIOVIG, Baxter) was referred to as 1 arbitrary unit.
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RESULTS
Antibody-dependent enhancement (ADE) of RSV infection and 
reduction of RSV neutralization (ΔPRNT50)
Infants that encounter RSV in the first months of life have maternal 
antibodies. Despite the presence of maternal antibodies, a subset of infants 
that encounters RSV becomes severely ill. The antibodies of severely 
diseased infants are not neutralizing enough to prevent infection, but they 
can induce multiple other effector functions through FCGR interactions. 
In this paper, we investigate the impact of these Fc receptor-mediated 
functions of maternal antibodies on the severity of disease symptoms 
during RSV infection. We assessed two antibody-Fc receptor mediated 
effects in vitro: antibody-dependent enhancement (ADE) and reduction of 
RSV neutralization.  
ADE of RSV infection in the presence of human serum has previously 
been demonstrated in monocytic cell lines, which carry Fc receptors [10,11]. 
ADE of RSV infection can be induced by sub-neutralizing concentrations 
of antibodies. At low concentrations, antibodies are not able to neutralize 
infection, but bind RSV and mediate binding to Fc receptors. This 
attachment and subsequent internalization facilitates higher infection 
rates than in the absence of antibodies, and is schematically illustrated for 
monocytic THP-1 cells in Figure 1A.
The second effect we investigated is the ability of the FCGR to reduce 
the neutralization capacity (PRNT50) of antibodies. Antibodies have higher 
neutralization potential on cells lacking FCGR compared to the same cell 
type expressing FCGR as is shown for wildtype Vero cells compared to 
Vero cells expressing FCGR [12]. This change in neutralization mediated 
by FCGR, we called ΔPRNT50 throughout the manuscript and is illustrated 
in Figure 1B. ΔPRNT50 represents the factor of reduction of neutralization 
and is calculated by dividing the PRNT50 in Vero cells by the PRNT50 in 
Vero cells expressing FCGR2a (Vero2a).  
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   97 30-7-2019   11:41:11
98
PART II
FIGURE 1 ADE and reduction of neutralization (ΔPRNT50) of RSV infection  ·
Schematic figure depicting the calculation of ADE in THP-1 cells (A) and ΔPRNT50 between 
WT and FCGR-transduced Vero cells (B).
ADE in primary cells and monocytic cell line THP-1
ADE of RSV infection in the presence of human serum has previously 
been demonstrated [10]. To investigate the effect of serum antibodies 
only and exclude the effect of other serum components, we use purified 
human immunoglobulin (IVIg). Serial dilutions of IVIg neutralized RSV (0% 
normalized infection) at high antibody concentrations and then facilitated 
up to 300% infection compared to the condition without antibodies (100% 
normalized infection) in monocytic, FCGR-carrying THP-1 cells (Figure 
2A, arrow points to maximum infection enhancement). Commercially 
available pooled human AB serum and a pool of cord blood plasma, both 
containing non-immunoglobulin components, showed similar titration 
curves. Maximum ADE was similar for the three antibody solutions (Figure 
2B). To confirm that ADE is mediated by antibody-FCGR interactions in 
THP-1 cells, FLIPr-like protein was supplemented, which blocks FCGR-
mediated Fc-binding. FLIPr-like protein reduced ADE from 340% to 125% 
infection for IVIg (Figure 2C). To assess whether ADE can occur in primary 
cells, we performed an ADE assay using human PBMCs. Also in primary 
immune cells, RSV infection was enhanced up to 230% (Figure 2D).
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FIGURE 2  ADE in monocytic cell line THP-1 and primary cells  ·
A. RSV neutralization assay using FCGR-carrying THP-1 cells in the presence of serially 
diluted IVIg, human serum, or cord blood. B. ADE is reported for the dilution at which infection 
is maximal (depicted by the arrow in A). C. Fc-binding sites of FCGRs were blocked by adding 
3 µg/mL staphylococcal FLIPr-like protein to THP-1 cells during RSV neutralization assay. 
D. RSV neutralization assay using cells that were isolated from human blood (human PBMCs). 
One representative graph of three PBMC donors is depicted. For other graphs, the means and 
SD of ≥ 3 individual experiments.
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FIGURE 3 Reduction of neutralization of RSV in FCGR2a-transduced Vero cells  ·
RSV neutralization assays using parental and FCGR2a-transduced Vero cells (Vero2a) in 
the presence of serially diluted IVIg, human serum or cord blood (A-C). The ΔPRNT50 is a 
measure for the reduction of neutralization titer in Vero2a cells (D) calculated by dividing 
the PRNT50[Vero] by PRNT50[Vero2a] (depicted by the arrow  in A-C). Means and SD of ≥ 3 
individual experiments.
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FIGURE 4   ADE and ΔPRNT50 by maternal antibodies  · 
ADE (A) and ΔPRNT50 (B) were determined for 15 individual cord blood samples. Statistical 
dependence between ADE and ΔPRNT50 was tested by Spearman’s correlation (C).
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ΔPRNT50 on FCGR2a-expressing Vero cells as measure for FCGR-
mediated reduction of neutralization 
Eliciting RSV-neutralizing antibodies is the primary goal of RSV vaccination 
efforts. Intriguingly, the presence of FCGRs in target cells mostly reduces 
the RSV neutralization capacity of monoclonal antibodies [12]. Preventing 
Fc receptor-interactions restored RSV neutralization by IVIg in THP-1 cells 
(Figure 2C). We previously demonstrated that the impact of FCGRs on RSV 
neutralization can be measured in Vero cells that stably express FCGR2a 
(Vero2a) [12]. In this study, titration series of IVIg, pooled human AB serum, 
and pooled cord blood plasma revealed a 4-fold reduced neutralization on 
Vero2a compared to parental Vero cells (Figure 3A-D). Although reduction 
in neutralization can be measured, FCGR-expressing Vero cells show no 
ADE, which is in line with observations for dengue virus [25]. 
Inter-individual variation in ADE and ΔPRNT50 
To further analyze ADE or ΔPRNT50 and any link to disease symptoms, 
we first assessed whether it would be feasible to distinguish between 
individuals with different capacities of ADE and ΔPRNT50. We tested the 
two Fc-mediated effects in cord blood from 15 individual donors. Most 
samples showed about 400% ADE compared to infection in the absence 
of antibodies (Figure 4A). The ΔPRNT50 showed a larger individual 
variation with up to 10-fold reduction of RSV neutralization in Vero2a cells 
(Figure 4B). Interestingly, the ΔPRNT50 was unrelated to ADE (Figure 4C), 
indicating that they are independent effects. 
ADE and ΔPRNT50 do not correlate with RSV neutralization or 
anti-RSV IgG levels.
To investigate a possible contribution of classical antibody characteristics 
to ADE or ΔPRNT50, both phenotypes were compared to two classical 
serological parameters: RSV neutralization in Vero cells (Figure 5A, B) 
and amount of RSV-specific IgG (Figure 5C, D). Slightly more reduction 
of neutralization was detected when RSV neutralization titers were highest 
(Figure 5B), but this was not significant. No associations between any of 
the other parameters were detected.
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FIGURE 5 ADE and ΔPRNT50 are independent of classical serological parameters  ·
ADE and ΔPRNT50 of 15 individual cord blood samples were compared to the RSV 
neutralization titer in Vero cells (A, B) or the relative amount of RSV-specific IgG (C, D). 
Associations were tested with Spearman’s correlation.
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ADE in primary cells from cotton rat lungs
ADE of RSV infection has not been demonstrated in vivo, but the inoculation 
of mice with RSV in complex with antibodies has been shown to reshape 
the immune response compared to RSV alone [26]. Natural RSV infections 
target pulmonary tissue, therefore we tested cells derived from lungs of 
naive cotton rats. To determine the type of cells in these lung cell isolates, 
we stained the cells for epithelial marker pan-cytokeratin [22] and T cell 
marker CD3ε [23]. Only 3% of cells were of epithelial origin, whereas 35% 
of cells were CD3ε positive (data not shown). This indicated that a large 
proportion of isolated cells were immune cells. Pools of plasma from 
RSV-challenged animals enhanced RSV infection in these cells by 330% 
(Figure 6A). No ADE was induced when serum from naive cotton rats was 
used, indicating the requirement of RSV-specific antibodies for ADE.
Characterization of FI-RSV-induced antibodies in immunized cotton rats
As cotton rat antibodies could enhance RSV infection in primary cells, 
we wanted to understand their effect on RSV disease. It has been shown 
that antibodies generated as part of active immunity induced in infants 
by FI-RSV vaccination contribute to enhanced pathology [13]. The cotton 
rat provides a model for FI-RSV-induced RSV pulmonary pathology [15]. 
Therefore, we investigated whether reduced neutralization and enhanced 
RSV infection of FCGR-bearing cells relates to pathology in the FI-RSV 
cotton rat model.
Animals were immunized with FI-RSV for non-protective antibodies 
or recombinant live-attenuated RSV (rRSV) for protective immunity. 
First, RSV-specific antibodies in cotton rats were characterized. RSV 
neutralization in Vero cells demonstrated low, dose-dependent titers 
of neutralizing antibodies in all FI-RSV-immunized animals, whereas 
neutralization capacity of plasma from animals immunized with rRSV was 
high (Figure 6B). Correspondingly, RSV-specific antibody levels were low 
after FI-RSV and high after rRSV immunization (Figure 6C).
Next, the ability of cotton rat antibodies to cause ADE in the human THP-1 
cell model was assessed. Plasma of all immunized animals caused ADE 
in THP-1 cells (Figure 6D). Infection was increased by 580% for plasma 
from rRSV-immunized animals and 380% after FI-RSV immunization. 
The dilution at which maximum ADE was measured, was low for the 
low-dose FI-RSV-, intermediate for high-dose FI-RSV- and highest for 
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FIGURE 6  ADE by RSV-specific cotton rat antibodies  ·
A. RSV neutralization assay using cells that were isolated from cotton rat lungs. Plasma 
pools were from naive (-) or wild-type RSV-infected (+) cotton rats. B-D. Four animals per 
group were immunized with live RSV (rRSV) or medium (mock), or with a low or high dose 
formalin-inactivated RSV (FI-RSV) or formalin-treated medium (FI-mock) and subsequently 
challenged with RSV. RSV neutralization titer (B) and RSV-specific IgG (C) of cotton rat plasma 
on day 4 after challenge. (D) RSV neutralization assay using THP-1 cells to determine the 
maximum ADE of cotton rat plasma.
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rRSV-immunized animals. This corresponds to RSV neutralization titers 
and RSV-specific antibody levels. ΔPRNT50 could not be determined 
for the cotton rat sera, due to a lack of neutralizing capacity making it 
impossible to calculate a PRNT50. 
Serum of cotton rats with lung pathology causes ADE in the absence of 
neutralization 
To assess the relationship between ADE of RSV infection and severity 
of pulmonary pathology in cotton rats, pathology after RSV challenge of 
FI-RSV- or rRSV-immunized cotton rats was studied. Affirming previous 
studies, immunization with rRSV protected the animals and resulted in little 
pathology after challenge (Figure 7A). Both FI-RSV-immunized groups 
showed elevated lung pathology compared to the group treated with rRSV 
or the mock vaccine. Moreover, the level of subepithelial, peri-arterial, and 
bronchiolar infiltrate was higher in FI-RSV-immunized cotton rats than in 
the control groups in our study. This is in accordance with the increased 
lymphocyte infiltration in FI-RSV-vaccinated children and animals in 
previous studies [27, 28].
Next, the ADE and RSV neutralization titer of cotton rat sera were 
compared to the sum of pathology scores (cumulative pathology score). 
Sera from mock-immunized animals were excluded. The capacity to 
induce ADE was present in all sera that contained RSV-specific antibodies, 
independent of the pathology score. More ADE appears to be linked to 
less pathology, although the difference in ADE over the range of pathology 
was small (Figure 7B). Lower pathology score might concur with efficient 
RSV neutralization and high anti-RSV antibody levels (Figure 6B, C). The 
latter was confirmed, as pathologic consequences of RSV challenge were 
high, when RSV neutralization titers were low (Figure 7C). Thus, antibodies 
from cotton rats with FI-RSV-induced pulmonary pathology were weak 
neutralizers and capable of causing ADE in vitro.
ADE and ΔPRNT50 do not correlate with RSV disease outcome in 
hospitalized infants
As ADE measured in vitro might relate to severe disease in vivo in absence 
of neutralization, a possible association between severity of symptoms in 
infants and ADE or ΔPRNT50 was investigated. Plasma from hospitalized 
patients with an acute primary RSV infection was analyzed. As this is not 
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FIGURE 7  Lung pathology in cotton rats that show antibody-dependent enhancement 
(ADE) in vitro in the absence of neutralization  ·
Four animals per group were immunized with live RSV (rRSV) or medium (mock), or 
with a low or high dose formalin-inactivated RSV (FI-RSV) or formalin-treated medium 
(FI-mock) and subsequently challenged with RSV. A. Histopathologic lung pathology scores. 
B, C.  Cumulative pathology scores, calculated by the sum of individual pathology scores, were 
compared with ADE and PRNT50 by Spearman’s correlation. 
10 1550 5020
0
200
400
600
800
1000
ADE
Cumulative pathology score
AD
E 
(%
 n
or
m
al
iz
ed
 in
fe
ct
io
n)
r  -0.84
P 0.001
10 15 20
0
100
200
300
400
RSV neutralization titer
Cumulative pathology score
RS
V 
ne
ut
ra
liz
at
io
n 
tit
er
r  -0.89
P <0.001
Intra-epithelial
eosinophils
Hypertrophy
epithelium
Subepithelial
infiltrate
Bronchioles
peribronch. infiltrate
. Peri-arterial 
infiltrate
Alveolitis
0
2
4
6
P
at
ho
lo
gy
 s
co
re
Low FI-RSV
High FI-RSV
Mock
rRSV
FI-mock
A
B C
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   107 30-7-2019   11:41:12
108
PART II
FIGURE 8  ADE and ΔPRNT50 by plasma from patients with different severities of 
RSV-mediated disease symptoms  ·
RSV neutralization assays using plasma samples from patients with moderate or severe 
RSV-mediated disease and healthy control patients (uninfected). Maximum ADE (A) and 
plasma titer at which ADE was maximal (B) were compared to disease severity. (C) ΔPRNT50 
was compared to disease severity. Statistical analyses employed one-way ANOVA for 
comparison between the three disease groups (**p < 0.01).
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a prospective study, the ideal control group of RSV-infected children with 
mild symptoms was not available, as blood of these children is not routinely 
sampled. A common practice in RSV research is to use age-matched 
uninfected infants as control. One assumes that this group is not protected 
and if healthy infants become RSV infected, a vast majority of 98-99% 
would develop only mild symptoms [29]. Analysis of the plasma samples 
showed that RSV neutralization and epitope specificity did not correlate 
with severity of symptoms [6]. The lack of this correlation indicates there is 
no bias for antibody concentration or neutralization in each disease group. 
Therefore, this is an ideal sample set to assess ADE and ΔPRNT50 on 
FCGR-expressing cells. 
First, maximum ADE of RSV infection by plasma from uninfected, 
moderate, and severe groups was examined on THP-1 cells. ADE ranged 
from 400 to 1000% of infection, showing a greater variation than in cord 
blood samples. However, disease severity and average ADE were not 
related (Figure 8A). Next, the plasma titer at which ADE was maximal 
was calculated for all samples. The infants with moderate RSV disease 
had a significantly higher ADE titer than the uninfected controls, but no 
correlation with severe disease could be found (Figure 8B). On Vero2a 
cells, the ΔPRNT50 ranged from 1- to 4-fold reduced neutralization 
(Figure 8C), but the average ΔPRNT50 was similar in all groups. We also 
checked correlation between ADE, ΔPRNT50 and age, but no relation was 
found (data not shown). 
DISCUSSION
The serum concentration and neutralization capacity are of primary 
concern when assessing the antiviral activity of antibodies. However, 
antibodies have many other functions, mediated by the Fc region, that 
play a role in the immune response. On FCGR-bearing cells, the antibody-
FCGR interaction may lead to antibody-dependent enhancement (ADE) 
of infection or to reduction of neutralization (ΔPRNT50).  We performed 
this study, because we were intrigued by the fact that most severe RSV 
cases occur in RSV patients under the age of six months, when relatively 
high levels of RSV-neutralizing matAbs can be found. Moreover, infants 
that experienced vaccine-enhanced disease after the 1960’s FI-RSV trials 
had an RSV-specific antibody response, albeit non-protective. Both these 
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maternal antibodies and FI-RSV-induced antibodies could therefore have 
a detrimental role in RSV-mediated disease when not neutralizing enough 
to protect infants from infection.
Generally, Fc-mediated effector functions of RSV-specific antibodies 
are not considered when studying acute RSV disease, even though some 
studies demonstrated ADE of RSV infection in vitro including an increase 
of ADE after RSV infection [9-11, 30]. RSV-specific matAbs may cause ADE 
and reshape the immune response against RSV [26, 30, 31]. Interestingly, 
matAbs against dengue virus (DenV) have been suggested to worsen 
DenV disease in infants [32, 33].
We investigated whether FCGR interactions of RSV-specific serum 
antibodies relate to the severity of RSV disease symptoms in different 
settings. ADE of RSV infection and ΔPRNT50 were studied in FCGR-
bearing cells using plasma from naive children with severe RSV disease, 
cord blood plasma, and plasma from FI-RSV-immunized cotton rats 
showing pathology. There are clear differences between severe RSV 
disease in naive infants that fully depend on maternal antibodies for 
RSV-specific immunity and FI-RSV vaccine induced pathology that is 
mediated by pathogenic vaccine-induced antibodies in the presence 
of an unbalanced cellular response [34]. For example, FI-RSV vaccine-
enhanced pulmonary pathology is associated with inadequate cellular 
immune responses [35-37]. Another well-established difference is the 
low RSV neutralization capacity of serum antibodies induced by FI-RSV 
vaccination [13, 38, 39]. The use of sera from two different types of RSV 
disease, allowed us to assess the ADE and neutralization-reducing 
characteristics for both passively acquired matAbs and actively acquired 
antibodies in a vaccination setting.
ADE was seen for plasma of both healthy and severely ill infants in different 
degrees, but we did not find a correlation between ADE and RSV disease. 
There are several considerations to be made. First, it is well described that 
ADE is related to more disease severity in DenV [40-42]. However, there are 
fundamental differences between DenV and RSV infection. Only a single 
serotype exists for RSV, whereas heterotypic, non-neutralizing antibodies 
exacerbate DenV disease. In addition, the primary target cells for RSV are 
lung epithelial cells, in contrast to immune cells for DenV. Interestingly, 
there is a growing body of evidence that RSV also infects immune cells. 
Recently, infection of several subsets of immune cells has been found in 
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infants with severe RSV disease [43, 44]. Infection of these FCGR-carrying 
immune cells may well be aided by ADE, which could affect the immune 
response and subsequent pathology, as in DENV infections.  
Second, our study demonstrates that ADE of RSV in vitro occurs only 
at non-neutralizing concentrations of antibodies. Even minute amounts 
of antibodies that fail to neutralize can mediate ADE. Possibly, such 
conditions existed in some of the infants in our study: bronchial antibody 
concentrations can be about 100-times lower than in circulation, where 
we measured them [45-47] and RSV-specific matAbs can decline rapidly 
with a half-life of approximately one month [3]. Such the age-dependent 
decline of matAbs has been described in DenV infections and has been 
suggested to increase the risk for severe disease [48, 49]. Interestingly, in 
contrast to most RSV-specific monoclonal antibodies, neutralization by 
palivizumab improves in cells expressing FCGR [12]. This unique feature 
of the therapeutic monoclonal antibody might explain its clinical efficacy.
Third, our findings on maternal antibodies from children with varying 
levels of RSV disease were different from findings on antibodies from 
cotton rats that show vaccine-enhanced pulmonary pathology mediated 
by FI-RSV-induced immune responses. In children, neither ADE nor 
reduced neutralization did correlate with disease severity, but in FI-RSV-
immunized cotton rats high ADE capacity in vitro coincides with pathology 
in the absence, but not in the presence of neutralization, as seen for 
rRSV-immunized animals. This suggests that ADE cannot induce severe 
pathology in presence of neutralization, but should be considered in 
non-neutralizing conditions.
Although various reports do emphasize the importance of antibodies in 
vaccine-enhanced RSV disease [13, 38, 39, 50], it is generally accepted 
that FI-RSV vaccine enhanced pathology results from an unbalanced 
immune response and a combination of aberrant humoral and cellular 
responses. In animal models, especially CD4+ T cells seem to be important 
mediators of pathology [35, 37]. Interestingly, such a requirement for the 
FCGR-carrying cellular arm of the immune system might explain why 
RSV-specific antibodies have a low probability of influencing disease 
through ADE, in the absence of a cellular response, such as is the case with 
maternally derived antibodies. It would also be in accordance with data 
from a previous study, in which it was shown that passive transfer of serum 
from FI-RSV-immunized cotton rats to naive animals was not sufficient to 
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induce vaccine-enhanced disease [51]. This does not exclude that such 
antibodies, in their original setting, thus acquired through immunization, in 
combination with immune cells, could play a role in disease, but only when 
they are non-neutralizing, as is the case in FI-RSV-immunized animals.
Our data show that severe pulmonary pathology in the cotton rat 
FI-RSV vaccination model occurs in the presence of antibodies that are 
non-neutralizing and cause ADE in vitro. This relation may also exist in 
humans: since the initial demonstration that the formalin-inactivated vaccine 
enhanced disease severity in children, ADE has been considered as an 
explanation [52]. FI-RSV-immunized infants developed non-neutralizing 
antibody titers, a prerequisite for ADE, possibly because formalin treatment 
of RSV modified the viral surface epitopes [11, 53]. Correspondingly, 
vaccine-enhanced pathology was partially attributed to increased levels of 
non-neutralizing antibodies and immune complex deposition in previous 
reports [13, 38, 39, 50]. This could lead to augmented RSV infection of 
immune cells that carry FCGR and/or reshaping of the immune response 
by FCGR signaling. 
Recently, it has been shown that binding of immune complexes to FCGR 
is not enough to induce ADE for Ebola virus [54]. Downstream signaling 
pathways were required to observe enhancement of infection. This may 
explain why we were unable to detect ADE on the FCGR-transduced Vero 
cells. Most likely, the FCGRs expressed on Vero cells are non-functional in 
signaling; they only mediate the binding of immune complexes and cannot 
internalize the RSV-antibody immune complexes.
We show that there is ADE capacity in vitro when RSV-mediated 
pathology and RSV-specific antibodies are present. However, additional 
research is needed to elucidate the involvement of ADE in infection of 
immune cells in vivo during natural RSV infection or after vaccination. We 
did not see a correlation between ADE in vitro and disease severity for the 
infants in our cohort with the assays described in this paper. However, 
multiple additional antibody functions that may have immunomodulatory 
effects have not been tested yet (reviewed in [55]). In addition, using THP-1 
cells as a model system only demonstrates the effect on monocytes, 
whereas other immune cells express different combinations of FCGRs and 
could react differently. It could well be that ADE is part of a set of conditions, 
including the status of the infant’s immune system or airway size that 
determine the outcome of RSV infection. 
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In summary, antibodies can favor ADE and have reduced neutralization 
capacity in Fc-receptor carrying cells. Antibodies from FI-RSV-immunized 
cotton rats showed no neutralization and were able to induce ADE in vitro. 
In infants, ADE and reduced neutralization by matAbs in vitro did not relate 
to severity of RSV disease symptoms, although all tested human plasma 
did have the capacity to cause ADE. There may be different effects from 
passively transferred matAbs compared to antibodies induced by direct 
vaccination, particularly when they are non-neutralizing as we show for 
those induced by formalin-inactivated vaccines. This could lead to different 
outcomes of ADE.
This report shows that ADE should not be ignored as a possible player 
in RSV infection. Most importantly, the induction of non-neutralizing 
antibodies or sub-neutralizing antibody titers should be avoided. It 
remains a challenge to find out whether immune cells are infected through 
ADE of RSV infection in vivo. It should also be noted that RSV infection of 
immune cells may have multiple effects, in a range from (hyper)activation 
to shutting down cellular effector functions. Any of these effects could 
lead to the known contribution of immune cells to immunopathology in 
severe RSV-mediated disease. Determining whether ADE of RSV infection 
is possible in these cells in vivo and how these cells react may provide 
clues to why severe RSV disease occurs in certain cases and how we can 
prevent the burden of disease in these young infants.
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ABSTRACT
Background
Respiratory syncytial virus (RSV) is a major cause of severe acute lower 
respiratory tract infections in infants. Natural killer (NK) cells are important 
anti-viral effector cells that likely encounter RSV in the presence of virus-
specific (maternal) antibodies. Since NK cells potentially contribute to 
immunopathology, we investigated whether RSV affects their anti-viral 
effector functions.
Methods
We assessed the phenotype and functionality of primary neonatal and 
adult NK cells by flow cytometry after stimulation with RSV or RSV-antibody 
complexes. 
Results
We demonstrate for the first time that RSV infects neonatal and adult NK 
cells in vitro. Pre-incubation of virus with sub-neutralizing concentrations 
of RSV-specific antibodies significantly increased the percentage of 
infected NK cells. Upon infection, NK cells were significantly more prone 
to produce IFN-γ, while secretion of the cytotoxicity molecule perforin was 
not enhanced. 
Conclusions
Our findings suggest that (antibody-enhanced) RSV infection of NK cells 
induces a pro-inflammatory rather than a cytotoxic response, which may 
contribute to immunopathology. Considering that most RSV vaccines 
currently being developed aim at inducing (maternal) antibodies, these 
results highlight the importance of understanding the interactions between 
innate effector cells and virus-specific antibodies.
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INTRODUCTION
Human respiratory syncytial virus (RSV) is a major cause of severe lower 
respiratory tract disease in infants [1]. There are currently no market-
approved vaccines or antivirals available against this virus. The estimated 
global burden of RSV-associated severe acute lower respiratory infection 
was 33.1 million in 2015, with an estimated 118,200 deaths in children 
below 5 years of age [2]. Hospitalization for severe RSV-mediated disease 
peaks between six weeks and six months of life [3], when infants mainly 
depend on maternal antibodies and their innate immune system for 
protection against infectious diseases. Despite extensive research efforts, 
the immunological determinants of severe RSV-mediated disease 
remain elusive.
Natural killer (NK) cells are innate lymphocytes that play an important 
role in the control of viral lung infections. Within days after infection, large 
numbers of NK cells are recruited to the lung and become activated [4,5]. 
NK cells have multiple mechanisms to combat viral replication: 1) death 
receptor-mediated cytolysis to kill virus-infected target cells, 2) production 
of pro-inflammatory cytokines with antiviral activity (e.g. IFN-γ), and 3) 
antibody-dependent cell-mediated cytotoxicity (ADCC), in which NK 
cells bind antibody-coated virus-infected target cells via CD16/Fc gamma 
receptor III (FcγRIII) followed by target cell lysis. 
The role of NK cells during RSV-induced disease is still unclear. In 
mice, increased numbers of NK cells are present in the lungs early after 
RSV infection [4-6]. In this model, the presence of NK cells is sufficient to 
eliminate RSV infection [7] and depletion of NK cells significantly increases 
viral loads [8]. However, increasing evidence suggests that NK cells also 
contribute to inflammatory lung injury, for example via the production of 
IFN-γ [5,8,9]. 
 There are contradictory reports on NK cells in humans during severe 
RSV infection. In infants, the proportion of NK cells has been reported both 
to be decreased [10-13] or increased [14,15] in comparison with healthy 
controls or infants with mild symptoms. NK cell gene expression in whole 
blood was reported to be downregulated in infants with severe RSV 
disease compared to controls [16]. Therefore, definitive conclusions about 
the role of NK cells in RSV infection and disease cannot be drawn from the 
data currently available.
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In this study, we investigated whether interaction of RSV or RSV-antibody 
complexes with NK cells affects their function. Interestingly, we found that 
RSV infects NK cells and that infection influenced the effector function of 
both neonatal and adult NK cells. RSV-infected NK cells were more prone 
to produce IFN-γ than uninfected cells, while the percentage of perforin-
secreting cells was not increased. We show that pre-incubation of RSV 
with sub-neutralizing concentrations of virus-specific antibodies increases 
the number of infected and, hence, IFN-γ secreting NK cells. We propose 
that (antibody-enhanced) infection of NK cells with RSV may contribute to 
immunopathology, through induction of a pro-inflammatory rather than a 
cytotoxic response in these cells.
MATERIALS AND METHODS
Cells and viruses
Peripheral blood mononuclear cells (PBMC) were obtained from healthy 
volunteers at the National Institute for Public Health and the Environment 
(RIVM, the Netherlands). Cord blood mononuclear cells (CBMC) from 
umbilical cords of healthy neonates born by caesarian section were 
collected at Radboudumc Nijmegen (the Netherlands). Blood was collected 
in heparin tubes and the mononuclear fraction was isolated by density 
gradient centrifugation (Lymphoprep, Nycomed). NK cells were purified 
by negative selection using a CD56+ NK cell isolation kit (Miltenyi Biotec). 
In all experiments, NK cells were gated as the CD3(-), CD56(+) population. 
Isolated cells were cultured in IMDM (Gibco) supplemented with 10% heat-
inactivated fetal calf serum (hiFCS), 1% penicillin/streptomycin/glutamin 
(PSG, Gibco), and 5 ng/mL recombinant IL-15 (Biolegend). CBMCs were 
stored at -135°C and thawed before NK cell isolation. 
Vero cells (ATCC-CCL81) were propagated in DMEM supplemented with 
5% hiFCS and 1% PSG. Human chronic myelogenous leukemic K562 cells 
(kind gift from Jeannette Cany, Radboudumc Nijmegen, the Netherlands) 
were propagated in IMDM, supplemented with 10% hiFCS and 1% PSG.
Recombinant RSV-X and RSV-X-GFP7 (encoding green fluorescent 
protein) were propagated in Vero cells as described before [17,18]. 
Virus stocks were purified between layers of 10% and 50% sucrose by 
ultracentrifugation. 50% tissue culture infectious dose (TCID50)/mL was 
determined on Vero cells using the Spearman and Karber’s method [19].
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   122 30-7-2019   11:41:14
123
RSV INFECTS NK CELLS
5
Plaque reduction neutralization test (PRNT)
Using RSV-X-GFP7, a Vero-based PRNT was performed for intravenous 
immunoglobulin (IVIg, KIOVIG, Baxalta), Palivizumab (SYNAGIS, Abbvie), 
and the WHO International standard for antiserum to RSV (NIBSC), as 
described previously [18]. Based on the neutralization curves, the amount 
of international units (IU) of anti-RSV neutralizing antibodies per mL was 
calculated for IVIg and Palivizumab using the WHO standard as reference 
serum (containing 2000 IU/mL).
RSV infection
NK cells were infected with RSV-X-GFP7 or RSV-X by spinoculation for 1 
h at 700 × g at 20°C, followed by incubation for 1 h at 37°C. A multiplicity of 
infection (MOI) of 1 based on titration on Vero cells was used. Next, cells were 
washed with PBS and replenished with culture medium. For antibody-
dependent enhancement (ADE) assays, RSV was pre-incubated with the 
indicated concentrations of IVIg or Palivizumab for 10 minutes at 37°C, 
before spinoculation of NK cells. Incubation at 37°C was followed by flow 
cytometric analysis at the indicated time points using an LSR Fortessa X20 
(BD Biosciences). RSV infection was blocked by co-incubation with 100 
nM fusion inhibitor (TMC-353121, MCE) [20]. CD16/FcγRIII was blocked by 
pre-incubation of NK cells with 50 µg/mL anti-CD16 Fab fragments (3G8, 
Ancell). Infection was measured by GFP expression for RSV-X-GFP7 or 
with a FITC-conjugated RSV-G antibody (131-2G, Millipore). Productivity 
of NK cell infection was assessed by TCID50 of the cleared supernatants 
on Vero cells as described above. 
Flow cytometric phenotypic characterization
The following fluorochrome-conjugated monoclonal antibodies were used 
to phenotypically characterize (RSV-infected) NK cells: CD3-APCAF750 
(UCHT1, Beckman Coulter), CD16-PacificOrange (3G8, Thermofisher), 
CD56-ECD (N901, Beckman Coulter), CD85j-PerCP-Cy5.5 (ILT2, LILRB1; 
GHI/75, BioLegend), CD161-APC (191B8, Miltenyi), CD158a-AF700 
(KIR2DL1; 143211, R&D systems), CD158a/h-PC5.5 (KIR2DL1/S1; EB6B, 
Beckman Coulter), CD158b1/b2,j-PC7 (KIR2DL2/L3/S2; GL183, Beckman 
Coulter), CD158e1-BV421 (KIR3DL1; DX9, BioLegend), CD159a-APC 
(NKG2A; Z199, Beckman Coulter), CD159c-PE (NKG2C; 134591, R&D 
systems), CD244-AF700 (2B4; C1.7, BioLegend), CD314-APC (NKG2D; 
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ON72, Beckman Coulter), CD335-PC7 (NKp46; BAB281, Beckman Coulter), 
CD336-PE (NKp44; Z231, Beckman Coulter), CD337-PerCP-Cy5.5 
(NKp30; P30-15, BioLegend), RSV-G-FITC (131-2G, Millipore). Cells were 
measured using a Navios flow cytometer (Beckman Coulter). 
NK activation assay
At 20 hours post infection (hpi) with RSV or RSV-antibody complexes, 
the NK cells were incubated for 4 h in the absence or presence of K562 
target cells together with Brefeldin A (BD Bioscience) and CD107a-PE/Cy7 
antibody (H4A3, Biolegend). Subsequently, cells were stained using the 
following antibodies: CD56-PE (HCD56, Biolegend), CD3-PerCP (SK7, BD 
Biosciences), RSV-G-FITC (131-2G, Millipore), IFN-γ-APC antibody (B27, 
BD Bioscience), perforin-BV421 (B-D48, Biolegend), and fixable viability 
dye eFluor780 (eBioscience).
Statistical analysis
Comparison of two groups or data points was performed by using a 
non-parametric Wilcoxon signed rank test. Multiple comparisons were 
analyzed by using a non-parametric Friedman test, followed by Dunn’s 
multiple comparison test. P values <0.05 were considered statistically 
significant. All statistical analyses were performed with Prism 7 software 
(GraphPad).
Ethics statement
All blood donors (PBMC) and mothers (CBMC) provided written informed 
consent.
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RESULTS
RSV infects and replicates in primary adult NK cells
To assess the interaction of RSV with NK cells, primary adult NK cells (>95% 
CD3(-) cells) were spinoculated with RSV-X-GFP7 at a Vero-based MOI of 1. 
We observed steadily increasing expression of virus-encoded GFP, which 
is indicative of viral replication. In a time-course experiment, the maximum 
percentage of GFP-positive NK cells (CD3(-), CD56(+)) was observed at 
24 hpi (Figure 1A). The level of RSV infection showed considerable donor 
variability, and reached a maximum of up to 20% infected NK cells in some 
donors. The amount of intracellular GFP increased over time as shown by 
the MFI (Figure 1B). TCID50 assays of the NK cell supernatant showed a 
decrease in viral titer over time, suggesting that little or no infectious viral 
particles were released (Figure 1C). Inoculation of NK cells with RSV-X-GFP7 
in the presence of a fusion inhibitor (TMC) showed efficient inhibition of 
NK cell infection (Figure 1D), indicating that viral entry was required for 
GFP detection and depended on the fusion (F) protein. The TMC vehicle 
control (DMSO) showed no effect on infection (Supplementary Figure 1A). 
Moreover, increasing the titer of the inoculum resulted in considerably 
higher infection rates (Supplementary Figure 1B), suggesting that RSV 
does not exclusively infect a minor NK cell subpopulation. Altogether, 
these data show that RSV infects primary adult NK cells in vitro.
Non-neutralizing RSV-specific antibodies enhance NK cell infection
The vast majority of individuals infected with RSV possess RSV-specific 
antibodies, which vary in concentration and are either maternally-derived 
through transplacental transfer or induced by previous exposure. NK 
cells that are recruited to the lung most likely encounter viral particles 
in complex with these antibodies. Since IgG levels in the lung are lower 
than those found in serum [21], even neutralizing concentrations of serum 
antibodies may be accompanied by non-neutralizing antibody levels in 
the lung. Here we show that, while high antibody concentrations result in 
virus neutralization, incubation of NK cells with RSV-antibody complexes 
formed at sub-neutralizing concentrations results in antibody-dependent 
enhancement (ADE) of infection (Figure 2A). 
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FIGURE 1 RSV infects primary NK cells in vitro  ·
A-B. Flow cytometric analysis showing the percentage (A) or Median Fluorescence Intensity 
(MFI, B) of GFP-positive cells for adult primary NK cells after spinoculation with RSV-X-GFP7 
(MOI = 1). Graphs depict geometric mean and SD of n = 4 donors pooled from two independent 
experiments.  C. TCID50 of cleared RSV-infected NK cell supernatant on Vero cells. Graph 
depicts geometric mean and SD of n = 3 donors from one experiment. The dashed line depicts 
the retitration of the initial RSV inoculum. D. NK cells were spinoculated with RSV-X-GFP7 
in the absence or presence of a fusion inhibitor (TMC) and infection was measured by flow 
cytometry at 20 hpi. Data was pooled from six independent experiments and each set of 
paired data points represents an individual donor (n = 14). Wilcoxon signed rank test was used 
for comparison between conditions (***p < 0.001).
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FIGURE 2  Antibody-dependent enhancement of RSV infection in NK cells  ·
A. Infection of adult primary NK cells in the presence of RSV-X-GFP7-antibody complexes 
(with the indicated concentration of IVIg or Palivizumab). Graph depicts the geometric 
mean and SD of n = 3 donors from one experiment. Dashed line depicts the geometric 
mean percentage GFP-positive cells in absence of antibodies (no Abs). B. Infection of 
NK cells with RSV-X-GFP7 or (sub-) neutralizing RSV-antibody complexes (5 µg/mL 
or 500 µg/mL IVIg). Data was pooled from six independent experiments and each set 
of paired data points represents an individual donor (n = 14). C. Infection of NK cells with 
sub-neutralizing RSV-antibody complexes (5 µg/mL IVIg) in the absence or presence of a 
fusion inhibitor (TMC). Data was pooled from six independent experiments and each set of 
paired data points represents an individual donor (n = 14). D. Infection of NK cells in the >> 
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<<  absence or presence of sub-neutralizing RSV-antibody complexes (5 µg/mL IVIg) with 
50 µg/mL CD16-blocking Fab fragments. Graph depicts the geometric mean and SD of n 
= 3 donors from one experiment. All GFP measurements were performed by flow cytometry 
at 20 hpi. Non-parametric Friedman test with Dunn’s multiple comparison test was used for 
comparisons  between multiple conditions ( *p < 0.05, ****p < 0.0001). Wilcoxon signed rank 
test was used for comparison between two conditions (***p < 0.001).
This was shown for both IVIg, naturally containing RSV-specific antibodies, 
and Palivizumab, an RSV-specific monoclonal antibody targeting the 
F protein. IVIg showed maximum enhancement around 1 ug/mL, 
corresponding to 0.0027 IU/mL of anti-RSV neutralizing antibodies. 
For Palivizumab, maximum enhancement was observed at 0.03 ug/
mL, corresponding to 0.0013 IU/mL. The standardized concentration 
neutralizing antibodies of IVIg and Palivizumab were calculated using 
the WHO international standard for antiserum to RSV as a reference 
(Supplementary Figure 1C). 
Incubation of NK cells with RSV-antibody complexes formed at 
sub-neutralizing antibody concentrations (5 µg/mL or 0.014 IU/mL IVIg), 
resulted in up to 4-fold increased infection compared to the absence of 
antibodies (Figure 2B).  Neutralizing antibody concentrations (500 µg/
mL or 1.4 IU/mL IVIg) completely inhibited infection. ADE of infection was 
completely blocked in the presence of TMC, indicating that viral entry still 
depended on the F protein (Figure 2C). ADE of NK cell infection seems 
to involve CD16/FcγRIII, as incubation with CD16-blocking Fab fragments 
decreased infection in the presence but not in the absence of RSV-specific 
antibodies, although this difference was not statistically significant (Figure 
2D). Spinoculation was used to enhance infection in all experiments, but 
this had no effect on the fold increase of antibody-enhanced infection 
compared to regular infection (Supplementary Figure 1D).
Phenotypic characterization of RSV-infected NK cells
Next, we set out to determine the phenotypic characteristics of 
RSV-infected NK cells using an extensive NK cell receptor panel. Those 
receptors showing the most pronounced effect upon infection are shown 
in Figure 3; the remaining receptors are depicted in Supplementary Figure 
2. In the presence of sub-neutralizing RSV-antibody complexes, the 
activation markers NKG2D and NKp44 are downregulated (Figure 3A, B). 
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FIGURE 3  Phenotypic characterization of RSV-infected NK cells  ·
A-D. Adult primary NK cells were inoculated with RSV-X or sub-neutralizing RSV-X-antibody 
complexes (5 µg/mL IVIg) and stained with three different antibody panels for flow cytometric 
analysis at 20 hpi. RSV-infected and uninfected populations within one well are indicated 
with (+) and (-), respectively. Geometric mean of fluorescence intensity (MFI) is depicted for 
the markers with the most pronounced differences compared to mock-infected NK cells: 
activating receptors (A) NKG2D and (B) NKp44, and KIRs (C) KIR3DL1, which is inhibitory, and 
(D) KIR2DL2/L3/S2, which can be either activating or inhibiting. Graphs depict the geometric 
mean and SD of n = 6 donors pooled from two independent experiments. Non-parametric 
Friedman test with Dunn’s multiple comparison test was used for comparison between 
multiple conditions (*p < 0.05, **p < 0.01, ***p < 0.001).
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 The presence of RSV alone has a similar, but non-significant effect. In 
contrast, the HLA-C-specific killer cell immunoglobulin-like receptors 
KIR3DL1, which is inhibitory, and KIR2DL2/L3/S2, which can be activating 
or inhibiting, were more abundantly expressed on RSV-infected NK cells 
compared to mock-infected cells (Figure 3C, D). Taken together, although 
the effect on individual markers is not very dramatic, RSV-infected NK cells 
appear to be skewed towards an inhibitory phenotype.
Neonatal NK cells are susceptible to (antibody-enhanced) RSV 
infection 
RSV is known to cause the most severe symptoms in the first months of 
life [3]. Therefore, the cells that are present at the moment of severe RSV 
disease in infants may more closely resemble umbilical cord blood NK 
cells than adult cells. We found that also neonatal NK cells (>88% CD3(-) 
cells) could be infected by RSV in vitro, and that infection was blocked by 
the fusion inhibitor TMC (Figure 4A). Neonatal NK cells showed a 6-fold 
increase in infection upon incubation with RSV-antibody complexes 
formed at sub-neutralizing antibody concentrations (5 µg/mL IVIg) 
compared to the no-antibody control (Figure 4B). Neutralizing antibody 
concentrations (500 µg/mL IVIg) completely inhibited infection. Overall, 
these results show that neonatal NK cells are comparable to adult NK cells 
in their susceptibility to RSV infection.
RSV infection of NK cells induces IFN-γ production
Since RSV infection of immune cells can have a profound effect on their 
functionality [22-24], we set out to explore the effect of RSV infection on 
NK cell functionality. First, we assessed IFN-γ production in four different 
NK cell populations: mock-infected control cells (1), RSV-exposed 
infected (2) and uninfected (3) cells, and uninfected cells exposed to RSV 
in the presence of TMC (4). The gating strategy for the NK cell activation 
assays is depicted in Supplementary Figure 3. RSV-infected neonatal NK 
cells showed significantly more IFN-γ-expressing cells compared to all 
control conditions (Figure 5A). CD107a, a marker of NK cell activity, was 
also upregulated in RSV-infected NK cells (Supplementary Figure 4). In 
agreement with the results obtained for infection by RSV in the absence 
of antibodies, infection of neonatal NK cells by RSV-antibody complexes 
resulted in even more IFN-γ-expressing cells (Figure 5B). Similar results 
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5FIGURE 4   Neonatal NK cells are susceptible to RSV infection  ·Human neonatal NK cells were spinoculated with RSV-X-GFP7 (MOI = 1). A. Percentage 
infected cells in absence or presence of a fusion inhibitor (TMC) as measured by flow 
cytometry. Data was pooled from two independent experiments and each set of paired data 
points represents an individual donor (n = 8). B. Percentage infected cells after inoculation 
with RSV or RSV-antibody complexes (5 µg/mL or 500 µg/mL IVIg). Data was pooled from 
two independent experiments and each set of paired data points represents an individual 
donor (n = 6). Wilcoxon signed rank test was used for comparison between two conditions 
(***p < 0.001). Non-parametric Friedman test with Dunn’s multiple comparison test was used 
for comparison between multiple conditions (**p < 0.01).
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FIGURE 5  RSV infection of NK cells induces IFN-γ production  ·
Neonatal (A-B) or adult (C-D) NK cells were infected with RSV-X, inoculated with RSV-X and 
TMC, or mock-infected. RSV-infected and uninfected populations are indicated with (+) and 
(-), respectively. At 20 hpi, NK cells were incubated for 4 h with Brefeldin A and subsequently 
stained for intracellular IFN-γ. A&C. Percentage NK cells positive for intracellular IFN-γ 
depicted for control NK cells, RSV(+) and RSV(-) cells within one RSV-inoculated well and for 
NK cells inoculated with RSV and TMC. B&D. Same as (A/C) except for pre-incubation of the 
viral inoculum with 5 µg/mL IVIg, resulting in ADE. All graphs depict geometric mean and SD of 
n = 6 (neonatal) or n = 8 (adult) donors pooled from two (neonatal) or four (adult) independent 
experiments. Non-parametric Friedman test with Dunn’s multiple comparison test was used 
for comparison between conditions (*P<0.05, **P<0.01, ***P<0.001).
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were obtained using adult NK cells (Figure 5C-D). In summary, both 
neonatal and adult NK cells are prone to produce IFN-γ upon RSV infection, 
and ADE of infection increases the total number of IFN-γ-positive cells by 
increasing the number of infected cells. 
RSV infection of NK cells does not enhance perforin secretion
In addition to IFN-γ secretion, an important NK cell function is the secretion 
of granzymes and perforins to induce target cell death. Upon encountering 
a cytotoxicity trigger, e.g. virus-infected or tumor cells, NK cells rapidly 
release pre-existing granules containing both granzymes and perforins. 
Secretion of these granules results in a loss of intracellular perforin 
staining, which can be detected by flow cytometry [25]. This experimental 
approach allows for the discrimination between infected and uninfected 
cell responses in the same well, which would not be possible by measuring 
perforin released in the supernatant. We determined the percentage of 
perforin-negative cells as a measure for perforin secretion in five different 
NK cell populations: mock-infected control cells without K562 target cells 
(1), mock-infected control cells with target cells (2), RSV-exposed infected 
(3) and uninfected (4) cells with target cells, and uninfected cells exposed 
to RSV in the presence of TMC with target cells (5).
Perforin secretion was slightly increased in all conditions upon the addition 
of target cells to neonatal NK cells (Figure 6A). Although RSV-infected NK 
cells are considerably more prone to produce IFN-γ than control cells 
(Figure 5A), this was not the case for perforin secretion. When neonatal 
NK cells were incubated with sub-neutralizing antibody concentrations 
(5 µg/mL IVIg), only the RSV-negative cells were significantly more likely 
to secrete perforin than unstimulated cells, possibly due to activation by 
neighboring opsonized RSV-infected NK cells (Figure 6B).
Since neonatal NK cells are described to be intrinsically less cytotoxic 
than adult NK cells [26,27], we investigated whether the latter were 
more reactive in our cytotoxicity assay. Unlike neonatal cells, adult NK 
cells showed a significant increase in perforin secretion upon addition of 
target cells, supporting the reportedly low cytotoxic capability of neonatal 
NK cells (Figure 6C). Strikingly, only RSV-infected NK cells did not show 
significantly increased perforin secretion upon addition of target cells. ADE 
of NK cell infection enhanced this effect, resulting in a significant difference 
in perforin secretion between infected and uninfected NK cells in the same 
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FIGURE 6   RSV infection of NK cells does not enhance cytotoxicity  ·
Neonatal (A-B) or adult (C-D) NK cells were infected with RSV-X, inoculated with RSV-X 
and TMC, or mock-infected. RSV-infected and uninfected populations are indicated with 
(+) and (-), respectively. At 20 hpi, NK cells were incubated for 4 h with Brefeldin A in the 
absence or presence of K562 target cells and subsequently stained for intracellular perforin. 
A&C. Percentage NK cells negative for intracellular perforin staining depicted for control NK 
cells (with or without target cells), RSV(+) and RSV(-) cells within one RSV-inoculated well and 
for NK cells inoculated with RSV and TMC. B&D. Same as (A&C) except for pre-incubation 
of the viral inoculum with 5 µg/mL IVIg, resulting in ADE. All graphs depict geometric mean 
and SD of n = 6 (neonatal) or n = 8 (adult) donors pooled from two (neonatal) or four (adult) 
independent experiments. Non-parametric Friedman test with Dunn’s multiple comparison 
test was used for comparison between conditions ( *P<0.05, **P<0.01, ***P<0.01).
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well (Figure 6D). These data suggest that, unlike what was seen for IFN-γ, 
the secretion of perforin is not enhanced and possibly even reduced in 
RSV-infected adult NK cells. 
DISCUSSION
In the past, it was thought that epithelial cells were the only target of RSV 
[11,28]. However, there is increasing evidence that RSV is also able to 
infect immune cells in humans [22,23] and viral RNA has been detected 
in peripheral blood cells during acute infection [29]. In our experiments, 
infected NK cells did not release infectious viral particles, which is 
consistent with studies of RSV infection in other immune cells [24,30,31]. 
Infection of NK cells has been documented before for several unrelated 
viruses (including HIV, vaccinia, human herpesvirus 6, and influenza) and 
only some of these establish productive infections [32-35].
Considering that NK cells, recruited to the lungs during infection in 
infants, likely encounter RSV bound to (sub-neutralizing levels of) virus-
specific antibodies, it is probable that Fc gamma receptor (FcγR)-mediated 
antibody effector functions are activated. Recently, researchers found that 
antibodies with enhanced binding to CD16/FcγRIII determined disease 
severity in dengue infection [36]. Moreover, in vitro ADE of RSV infection 
has been shown before by several groups including our own [37-39]. In the 
current study, we show that in the presence of sub-neutralizing antibody 
concentrations, infection of NK cells can be enhanced up to 4-fold for adult 
NK cells and up to 6-fold for neonatal NK cells, resulting in a substantial 
proportion of infected NK cells in vitro. Further research is needed to 
determine the exact contribution of CD16/FcγRIII to ADE of RSV infection 
in NK cells.
We show that RSV infection of NK cells results in increased numbers of 
IFN-γ-producing cells. In mouse models of RSV infection, NK cells were 
shown to be the most important source of IFN-γ early after infection [4,5]. 
However, the role of IFN-γ in RSV disease has been much debated. On 
the one hand, it has been suggested that IFN-γ is involved in acute lung 
injury, allergic airway disease, and airway obstruction in animal models 
[5,40,41] and appears to be associated with virus-induced wheezing in 
humans [42].  On the other hand, decreased IFN-γ levels were found in 
the blood and in the nasopharyngeal aspirates of mechanically ventilated 
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   135 30-7-2019   11:41:15
136
PART III
infants compared to non-ventilated infants [43,44]. However, it is debatable 
whether measurements in the blood accurately reflect IFN-γ levels in the 
lungs during RSV infection. Also, in a more recent study, IFN-γ levels 
were found to be elevated during RSV bronchiolitis when measured by 
nasosorption, but not in nasopharyngeal aspirates, showing a clear effect 
of sampling technique [45]. Considering these findings, it seems that the 
detrimental effects of IFN-γ are an exacerbated outcome of an intrinsically 
beneficial role for this molecule in protection against RSV disease. We 
have shown that RSV infection of NK cells leads to more IFN-γ-producing 
cells, a potential way through which the virus disturbs the balanced NK cell 
response. In contrast to the increase in IFN-γ production in RSV-infected 
NK cells, we did not observe more perforin secretion upon RSV infection. 
Adult NK cells infected in the presence of RSV-antibody complexes even 
showed significantly lower perforin secretion than uninfected cells in the 
same well. This effect is likely only seen in adult NK cells because of the 
intrinsically lower capacity of neonatal NK cells to elicit a cytotoxic response. 
This is also evidenced by the almost 10-fold lower MFI for perforin in 
neonatal compared to adult NK cells (data not shown). Overall, we only 
observed minor differences between neonatal and adult NK cells. This 
was an unexpected finding, as earlier studies show more RSV infection 
in neonatal compared to adult monocytes [46] and severely decreased 
cytotoxic responses by neonatal NK cells [26,27]. Our experiments were 
performed with the addition of small amounts of IL-15 (5 ng/mL). This 
has been shown to increase the functionality of neonatal NK cells [27] and 
possibly explains the limited differences between adult and neonatal NK 
cells in our study. Moreover, high variability has been observed between 
cord blood donors in earlier studies [47] with some donors exhibiting 
similar or even higher cytotoxicity levels than adult donors. 
Of note, in our experiments, CD107a expression correlated with IFN-γ 
production but not with perforin secretion. This suggests that CD107a 
is not merely a secretion marker of perforin, but acts as a more general 
marker for NK cell activity.
Increased IFN-γ production together with a possible inhibition of 
perforin secretion suggests a shift towards a pro-inflammatory rather 
than a cytotoxic NK cell state. In addition, the phenotypic characteristics of 
RSV-infected NK cells suggest skewing towards a less cytotoxic and more 
inhibitory phenotype. This may impair the cytolytic function of these cells, 
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as has been shown for other viruses [35,48]. Based on previous reports 
and the data described in this paper, we propose that the pro-inflammatory 
response of RSV-infected NK cells may contribute to the development 
of RSV-mediated severe disease. Notably, the formalin-inactivated RSV 
vaccine that caused enhanced disease upon natural infection, induced 
primarily non-neutralizing antibodies [49]. Our data support the idea that 
these antibodies may have contributed to enhanced inflammation [50].
For future research, it would be interesting to investigate whether NK cell 
functionality differs between infants with severe RSV disease and healthy 
infants. Obtaining NK cells from the lung is however problematic due to 
ethical considerations and the limited time window for sampling. In addition, 
peripheral blood of RSV-infected hospitalized infants only contains low 
numbers of NK cells [10,11,13], which makes it difficult to study these cells. 
It would be very interesting to compare neonatal umbilical cord blood NK 
cells from infants who later develop severe RSV-mediated disease with 
cells from infants that did not suffer severe disease upon infection. 
To conclude, we have shown that RSV-infected NK cells are more prone 
to produce IFN-γ than uninfected cells, whereas the cytotoxic response is 
not increased. This combination may contribute to RSV immunopathology 
in vivo, but more research is needed to support this hypothesis. Moreover, 
we show that Fc-mediated effector functions like ADE of infection can 
have a profound effect on the immune response and a potential role in 
the development of disease. Our findings contribute to the understanding 
of the potential mechanisms responsible for the development of severe 
RSV disease and highlight the critical need to further characterize the role 
of NK cells and RSV-antibody complexes therein, as this will assist in the 
development of safe and effective RSV vaccines. 
Supplementary Materials are available online at: 
https://academic.oup.com/jid/article/219/5/723/5106664#supplementary-data
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ABSTRACT
Natural killer (NK) cells are essential in the early immune response against 
viral infections, in particular through clearance of virus-infected cells. 
In return, viruses have evolved multiple mechanisms to evade NK cell-
mediated viral clearance. Several unrelated viruses, including influenza 
virus, respiratory syncytial virus, and human immunodeficiency virus, can 
directly interfere with NK cell functioning through infection of these cells. 
Viral infection can lead to immune suppression, either by downregulation 
of the cytotoxic function or by triggering apoptosis, leading to depletion of 
NK cells. In contrast, some viruses induce proliferation or changes in the 
morphology of NK cells. In this review article, we provide a comprehensive 
overview of the viruses that have been reported to infect NK cells, we 
discuss their mechanisms of entry, and describe the interference with NK 
cell effector function and phenotype. Finally, we discuss the contribution 
of virus-infected NK cells to viral load. The development of specific 
therapeutics, such as viral entry inhibitors, could benefit from an enhanced 
understanding of viral infection of NK cells, opening up possibilities for the 
prevention of NK cell infection.
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INTRODUCTION
Natural killer (NK) cells are innate lymphocytes that represent the first line 
of defense against tumor cells and viral infections [1,2]. The importance of 
NK cells in the antiviral immune response is underscored by the increased 
susceptibility to viral diseases of patients with a congenital NK cell deficiency. 
Although NK cell deficiencies are rare, multiple cases have been described 
in which increased susceptibility to numerous herpesviruses is shown, 
which has been extensively reviewed elsewhere [3]. 
NK cells have multiple mechanisms to kill virus-infected cells, including 
the engagement of extracellular death receptors and exocytosis of 
cytolytic granules [4]. To mediate cytolysis through engagement of death 
receptors expressed on target cells, NK cells express multiple extracellular 
ligands, including Fas ligand (FasL) and the tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) [5]. Viral infection, for example by 
cytomegalovirus (CMV) and encephalomyocarditis virus (EMCV) [4], 
can induce the expression of death receptors on infected cells, which 
can subsequently interact with FasL and TRAIL on NK cells, resulting in 
apoptosis of the target cell. The other route to induce cytotoxicity is through 
the release of stored cytolytic granules that contain perforin and granzymes 
that enter the target cell and trigger apoptosis through caspase-mediated 
signaling pathways [4]. In addition to cytotoxicity, NK cells contribute to the 
antiviral response through the release of a wide range of proinflammatory 
cytokines with antiviral activity [6].
 Activation of NK cells is regulated by a balance in the engagement of 
its activating and inhibitory receptors in combination with the presence of 
certain cytokines. Together, these stimuli determine the type and strength 
of NK cell activity [7]. 
Healthy cells inhibit NK cell activation mainly through the expression 
of major histocompatibility complex class I (MHC-I) molecules, which 
interact with inhibitory receptors present on the NK cell surface. Inhibitory 
NK cell receptors that ligate to MHC-I include killer cell immunoglobulin-
like receptors (KIRs) and leukocyte immunoglobulin-like receptors (LILRs) 
[7]. This inhibitory receptor-mediated signaling is essential to counteract 
activating signaling in order to protect against NK cell over-activity. Some 
viruses are known to downregulate surface expression of MHC-I to interfere 
with the presentation of viral antigens, thereby escaping detection by the 
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adaptive immune system [8]. Although this immune evasion strategy is 
effective in preventing recognition by T cells, decreased MHC-I expression 
promotes the recognition and clearance of virus-infected target cells by NK 
cells [9]. The concept of target cell recognition via the absence of inhibitory 
MHC-I engagement is known as the “missing-self” hypothesis.
The activating receptors that are expressed by NK cells facilitate 
activation upon detection of viral or stress-induced ligands on target cells. 
For example, the natural cytotoxicity receptors (NCRs, including NKp46, 
NKp44, and NKp30 are known to bind viral glycoproteins [10,11], allowing 
for activation of NK cells upon detection of infected cells. In addition, NK 
cells are activated through binding to antibody-opsonized target cells with 
Fc-γ receptor IIIA (FcγRIIIA), which induces antibody-dependent cell-
mediated cytotoxicity (ADCC). 
Due to the important role of NK cells in the early antiviral immune 
response, viruses have evolved numerous strategies to evade NK cell 
effector functions. One of these evasion strategies is the manipulation of NK 
cells through direct infection. In this review, we provide a comprehensive 
overview of the viruses that have been reported to infect NK cells. We 
discuss their mechanisms of entry, describe how they affect NK cell 
function, and indicate which viruses deplete NK cells through the induction 
of apoptosis. Moreover, we address the contribution of infected NK cells to 
viral load. 
ENTRY MECHANISMS 
Viruses have evolved many mechanisms to enter host cells. The best-
known mechanism is entry through binding to specific receptors, which 
either leads to fusion directly at the plasma membrane, or to entry 
following clathrin- or caveolin-dependent endocytosis of the viral particle. 
Additionally, viruses may require direct cell-cell interactions for infection. 
Finally, viral entry may occur through macropinocytosis, which is the 
nonspecific uptake of extracellular material. Hence, non-specific binding of 
virus can lead to internalization, even in the absence of specific viral entry 
receptors on the target cell. Macropinocytosis has been described for 
multiple viruses [12], but to date this has not been identified as a strategy to 
enter NK cells. The different entry mechanisms that have been shown for 
viral infection of NK cells are described below and summarized in Table 1.  
Liz_Van_Erp_order_137353_binnenwerk_4x4fc_biotop100_2.indd   146 30-7-2019   11:41:16
147
VIRAL INFECTION OF NK CELLS
6
TABLE 1   Overview of viruses known to infect natural killer (NK) cells
Virus Family
Entry 
Mechanism
Modulation 
of NK cells P
ro
du
ct
iv
e 
in
fe
ct
io
n
Re
fe
re
nc
e
Torque teno 
virus (TTV)
Anelloviridae U U Y [13]
Human pegivirus 
(HPgV)
Flaviviridae U ↑ Survival
↓ IFN-γ production
U [14]
Cytomegalovirus 
(CMV)
Herpesviridae U U N [15]
Epstein Barr virus 
(EBV)
Herpesviridae Acquisition of receptor 
after cell-cell interaction
Receptor: CD21
Co-receptor: MHC-II
Morphological changes
Transformation
NK cell malignancies
N [16-21]
Herpes simplex 
virus (HSV)
Herpesviridae Cell-cell interaction with 
HSV-infected fibroblasts
U U [22]
Human herpes-
virus 6 (HHV-6)
Herpesviridae U ↑ CD4 expression U [23]
Varicella zoster 
virus (VZV)
Herpesviridae Cell-cell interaction with 
VZV-infected epithelial 
cells
↑ CD57 expression
↑ Chemokine receptors
↓ CD56 expression
↓ FcγRIII expression
Y [24]
Influenza 
A virus (IAV)
Ortho-
myxoviridae
Clathrin- and caveolin-
dependent endocytosis
Receptor: sialic acids
↑ Apoptosis
↓ Cytotoxicity
↓ Cytotoxicity receptors
↓ Cytokines and 
   chemokines
N [25-29]
Measles 
virus (MV)
Paramy-
xoviridae
U ↓ Cytotoxicity U [30]
Respiratory 
syncytial 
virus (RSV)
Pneumo-
viridae 
Possibly 
macropinocytosis
Receptor: FcγRIIIA 
(RSV-antibody 
complexes)
↑ IFN-γ production
↑ KIR expression
↓ Cytotoxicity
↓ Cytotoxicity  
   receptors
N [31,32]
Vaccinia 
virus (VV)
Poxviridae Cell-cell interaction ↑ KIR signaling
↓ Cytotoxicity
N [33,34]
Vesicular stoma-
titis virus (VSV)
Rhabdoviridae U U Y [35]
Human immuno-
deficiency virus 1 
(HIV-1)
Retroviridae Receptor-mediated entry
Receptor: CD4
Co-receptors: CXC4 /
CCR5
↑ Apoptosis Y [36-40]
Human T-lympho- 
tropic virus (HTLV)
Retroviridae Cell-cell interaction with 
T cells 
↑ Proliferation
↑ Survival
U [41-43]
Abbreviations: FcγR, Fc gamma receptor; IFN, interferon; KIR, killer cell immunoglobulin-like 
receptor; MHC, major histocompatibility complex; Y= yes N=No U=Unknown
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Receptor-mediated viral entry
One of the entry pathways for viruses is through binding of cellular receptors 
by viral proteins, which leads to receptor-mediated entry. NK cells express 
multiple receptors that are known to be used for virus entry. Additionally, 
it has been described that NK cells acquire entry receptors from infected 
cells, either through direct contact via the immunological synapse or by 
exosome transfer (extensively reviewed in [44]).
Human influenza A virus (IAV) is an enveloped virus that has been shown 
to directly infect both human and mouse NK cells in vitro [25,26]. In vivo 
infection of NK cells was demonstrated in several mouse studies [26,45]. 
Viral entry by IAV into NK cells from human peripheral blood mononuclear 
cells (PBMCs) was found to be mediated by clathrin- and caveolin-
dependent endocytosis [25]. IAV virions generally infect respiratory tract 
epithelial cells by binding of viral hemagglutinin (HA) protein to α-2,3 and/
or α-2,6 linked terminal sialic acids, which are found in abundance on the 
surface of respiratory tract epithelial cells [46]. It has been confirmed that 
both forms of sialic acids are also present on the surface of NK cells [26]. 
In addition, the α-2,6 terminal sialic acids are present on activating NK cell 
receptor NKp46 [11]. Indeed, free HA binding and internalization into NK 
cells was shown to be terminated by sialidase treatment, demonstrating 
dependence on the sialic acid interaction [27]. Interestingly, the interaction 
of NKp46 with HA on the surface of virus-infected cells is a known 
mechanism for NK cell recognition and killing of target cells [11], but it 
appears that the IAV virion itself is able to infect NK cells by internalization 
of the virion through the same interaction with NKp46 [27]. 
Human immunodeficiency virus 1 (HIV-1) has also been shown to infect 
human NK cells both in vitro [36] and in vivo [37]. HIV-1 is an enveloped virus 
that enters cells by binding with its viral envelope glycoprotein gp120 to the 
CD4 receptor, and to one of the co-receptors C-X-C chemokine receptor 
4 (CXCR4) or C-C chemokine receptor 5 (CCR5) [37]. Virus binding to CD4 
brings the virion within range of the co-receptors which then facilitate 
membrane fusion and subsequent release of the viral core into the host 
cell cytoplasm. Due to abundant expression of co-receptor CXCR4, NK 
cells are mostly susceptible to CXCR4-tropic strains of HIV-1 [40]. However, 
CCR5-tropic strains were also found to infect NK cells, after upregulation of 
CCR5 expression on NK cells [39,40]. CCR5 expression was either induced 
by stimulation of NK cells with feeder cells in presence of IL-2 [39], or by 
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depletion of CCL chemokines that inhibit CCR5 expression [40]. The CD4 
receptor is not commonly expressed within the NK lineage, but infection 
with human herpesvirus 6 (HHV-6, family Herpesviridae) can upregulate 
CD4 expression in NK cells [23]. It is thought that this HHV-6 infection 
primes NK cells for HIV infection [23]. Alternatively, a CD4-independent 
pathway may facilitate HIV-1 entry in absence of CD4 [36]. 
Epstein Barr virus (EBV, family Herpesviridae) is a lymphotropic virus 
that is present in a variety of lymphocyte neoplasms including NK cell 
lymphoma [16], indicating that EBV can infect NK cells in vivo. Moreover, 
latently infected non-neoplastic NK cells have been detected in patients 
with primary EBV infection [17]. The entry mechanism for NK cells is 
under debate as EBV usually infects oropharyngeal epithelial cells and 
B cells. The EBV envelope glycoprotein gp350/220 interacts with the 
CD21 receptor on the surface of B cells and subsequent interaction of the 
viral gp85-gp25-gp42 glycoprotein complex with MHC-II molecules 
triggers membrane fusion (reviewed in [47]). Whereas NK cells do express 
MHC-II molecules [48,49], they do not express CD21 on their cell surface. 
Interestingly, one study indicated the acquisition of the CD21 receptor by NK 
cells upon interaction with CD21-positive, EBV-infected cells [18]. Others 
show a CD21-independent mechanism of NK cell infection by EBV [19].
The receptor-mediated entry of IAV, HIV, and EBV into NK cells indicates 
that NK cells are permissive for infection due to expression or acquisition of 
virus entry receptors. However, for many other viruses known to infect NK 
cells, no receptor has been identified yet. Our group recently showed that 
RSV can also infect NK cells in vitro and that infection is enhanced in the 
presence of sub-neutralizing concentrations of RSV-specific antibodies 
[32]. This study proposes that FcγRIIIA, the IgG-receptor expressed on 
NK cells, mediates binding to NK cells in the presence of virus-specific 
antibodies [32]. Although to date it has not been described for other 
viruses, antibody-mediated entry could be exploited by many more 
viruses as a mechanism to enter NK cells in individuals that carry virus-
specific antibodies. 
Cell-cell interaction-mediated viral entry
NK cells closely interact with infected cells, for example through the 
interaction between death receptors and their ligands, in order to clear 
the viral infection. During this interaction, they may acquire membrane 
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fragments that contain entry receptors for viruses. This transfer of entry 
receptors between cells could take place via the immunological synapse, 
or via intercellular transfer of exosomes (reviewed in [44]). In addition, cell-
cell interaction may facilitate direct virus entry through the immunological 
synapse. 
The human T cell leukemia virus 1 (HTLV-1, family Retroviridae) is known 
to require cell-cell interactions for infection, as infected cells produce 
virtually no cell-free infectious viral particles [41]. In an extensive imaging 
study by Igakura and colleagues, the HTLV-1 core complexes and genome 
were shown to accumulate at cell-cell junctions and were subsequently 
transferred to uninfected cells [42]. This transfer mechanism was not only 
observed between T cells, the main target for HTLV, but also between 
CD4+ T cells and NK cells [42]. Earlier studies had also shown transfer of 
HTLV-1 from T cells to NK cells, but only after activation of the NK cells with 
an anti-FcγRIII antibody [43]. 
Vaccinia virus (VV, family Poxviridae) was also proposed to spread to NK 
cells through cell-cell contact [33,34]. This virus is able to enter various cell 
types through non-specific macropinocytosis [50]. VV has been shown 
to infect NK cells in vitro, but only after co-culturing with other, infected, 
cell types [33,34]. It was suggested that NK cells become infected by VV 
upon interaction with infected target cells [33]. These observations imply 
that there is a transfer of VV particles through the immunological synapse 
or via exosomes. It must be noted, however, that acquisition of virus entry 
receptors by NK cells through cell-cell interactions cannot be ruled out for 
VV. 
Two other cell-associated viruses are herpes simplex virus (HSV, family 
Herpesviridae) and varicella zoster virus (VZV, family Herpesviridae). HSV 
was shown to enter NK cells after co-culture with infected fibroblasts [22]. 
Incubation of NK cells with cell-free HSV only induced NK cell lysis at MOIs 
>100. VZV infection of NK cells in vitro was recently shown after co-culture 
with infected epithelial cells [24]. Also cell-free direct infection was 
observed in the case of VZV, indicating that multiple entry mechanisms 
may be involved. 
Although some of these viruses are known to produce virtually no cell-
free infectious viral particles, an indirect effect of other infected cell types 
cannot be ruled out. Infected cells may secrete multiple soluble mediators 
(e.g. cytokines and chemokines) that could prime NK cells and make them 
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more prone to infection. Significantly higher NK cell infection rates are 
seen after stimulation with IL-2 for VZV, and after stimulation with IL-15 for 
RSV, compared to unstimulated cells [24,32] [unpublished observations]. 
In conclusion, additional experiments are needed to establish whether 
infection through co-culture of infected cells with NK cells is a direct or 
indirect effect.
Unknown internalization mechanism
There are many more viruses found to infect NK cells, but research into 
their entry mechanisms is lacking. DNA of the asymptomatic Torque teno 
virus (TTV, family Anelloviridae), also known as the transfusion-transmitted 
virus, has been found in NK cells of viremic individuals [13]. RNA from 
human pegivirus (HPgV), a virus of the Flaviviridae family formerly known 
as hepatitis G virus, was detected in NK cells from infected individuals [14]. 
Furthermore, vesicular stomatitis virus (VSV, family Rhabdoviridae) [35], 
measles virus (MV, family Paramyxoviridae) [30], human cytomegalovirus 
(CMV, family Herpesviridae) [15], and HHV-6 [23] have been reported to 
infect NK cells in vitro, but their entry mechanisms are unknown. Entry in the 
absence of a virus entry receptor may be explained by macropinocytosis, 
as no specific entry receptor is required for this process [12]. Respiratory 
syncytial virus (RSV) has been shown to enter epithelial cells through 
macropinocytosis [31]. Whether entry of NK cells by RSV is mediated 
through macropinocytosis has not been investigated. In summary, these 
studies indicate that viral infection of NK cells is not a rare phenomenon 
but widespread across various virus families. 
MODULATION OF NK CELL FUNCTION AND PHENOTYPE
Because of the prominent role of NK cells in antiviral immunity, viruses have 
evolved multiple evasion strategies that affect NK cell effector functions and 
phenotype. Both these aspects are addressed below and are summarized 
in Table 1. 
Influence on effector function
Inhibition of cytotoxicity is the most prominent effect caused by viral 
infection of NK cells. In vitro infection by IAV results in decreased cytotoxic 
function and induction of apoptosis in both adult and cord blood NK cells 
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[25,26,28]. A follow-up study demonstrated that interaction with either 
the intact influenza virion or free HA protein inhibits NK cell cytotoxicity 
in a dose-dependent manner through downregulation of the NKp46 
and NKp30 signaling pathway [27]. Besides human IAV, avian IAV virions 
or free avian HA protein also inhibit human NK cell cytotoxicity [29]. 
Moreover, infection with avian IAV induces apoptosis of NK cells [29]. 
Thus, these studies demonstrate that binding of IAV is enough to inhibit 
cytotoxicity, whereas NK cell infection leads to depletion of NK cells 
through apoptosis. This cellular depletion is supported by evidence of 
decreased NK cell numbers in both the peripheral blood and lungs of 
IAV-infected patients [51,52]. 
Similar effects were demonstrated for VV infection, which also leads 
to decreased cytotoxicity [33]. However, incubation with UV-inactivated 
VV did not affect cytotoxicity, indicating that VV replication is required for 
inhibition [33]. This decreased cytotoxicity was a result of increased NK cell 
sensitivity to inhibitory killer immunoglobulin-like receptor (KIR) signaling, 
induced by active viral replication. In addition, decreased perforin secretion 
was shown for RSV-infected compared to uninfected adult NK cells [32]. 
The use of a fusion-inhibitor in this study indicated that the mere binding 
or presence of the virus was not enough to inhibit perforin secretion.
Decreased ability to lyse target cells has also been reported for HSV and 
MV-infected NK cells [22,30]. The authors did not investigate the effect of 
non-infectious viral particles, therefore it is unclear whether infection of 
NK cells was required to inhibit cytotoxicity. For HIV, only a limited effect 
on the cytotoxic response in vitro was observed in two independent 
studies [36,40]. The authors propose that the modest impact on killing 
capacity in vitro was due to the low infection levels that were established 
[36,40], as depressed NK cell cytotoxicity has been detected in patients 
with AIDS [53-56]. In addition, viruses can affect NK cell function indirectly 
by inducing either proliferation or apoptosis. HTLV and HPgV induce 
increased proliferation and prolonged survival [43,57], whereas in many 
other in vitro infections apoptosis is induced, as seen for HIV [36], HHV-6 
[23], and IAV [25]. Depletion of NK cells during viral infections has been 
shown in clinical studies for IAV [51,52] and RSV [51,58], but whether this is 
due to direct infection of NK cells is unknown. 
Besides their cytotoxic potential, NK cells are also prominent cytokine 
and chemokine secreters. Multiple viruses have been shown to affect 
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cytokine secretion. In the presence of IAV, a downregulation was observed 
for the production of multiple pro-inflammatory cytokines and chemokines 
including IFN-γ, GM-CSF, MIP-1α (CCL3), MIP-1β (CCL4), and RANTES 
(CCL5) [26]. On the contrary, another study showed an increase in IFN-γ 
and TNF-α in the cell supernatant after in vitro IAV infection, although this 
increase was mainly dependent on the presence of IL-15 [28]. In addition, 
it must be noted that no distinction was made between IAV-infected and 
IAV-exposed NK cells, and differences in infection levels and the influenza 
strain used could potentially explain the difference between these studies. 
 Besides IAV, there are more viruses that increase or suppress NK 
cell IFN-γ production. RSV-infected NK cells have an increased IFN-γ 
production, compared to RSV-exposed uninfected or mock-infected 
NK cells [32]. The combination with decreased perforin secretion of 
RSV-infected NK cells suggests that RSV infection of NK cells induces a 
proinflammatory rather than a cytotoxic response that could contribute to 
the immunopathology seen in vivo. Conversely, incubation of NK cells with 
HPgV seems to decrease IFN-γ production, but this effect is independent 
of infection [57]. 
Taken together, it seems that viruses have evolved multiple mechanisms 
to inhibit NK cell cytotoxicity or induce apoptosis, which could serve as 
an important immune evasion strategy. Additionally, the effect of viruses 
on effector cytokine production by NK cells can vary per virus, leading to 
variable polarization of the NK cells and (ultimately) in skewed steering of 
other immune cells. 
Influence on phenotype
Virus infection does not necessarily modulate NK cell effector functions 
directly, but often causes changes in receptor expression. As the balance 
in activating and inhibiting receptor signaling is crucial for NK cell activity, 
these phenotypical changes may indirectly influence effector functions. 
Additionally, the phenotype of infected NK cells can be altered by changes 
in morphology or even transformation into malignant cells.
Downregulation of the expression of activating NK cell receptors has been 
described for RSV [32]. Independent of infection, the presence of RSV or 
RSV-antibody complexes results in lower NKG2D and NKp44 expression 
levels. In addition, upon infection of NK cells, the expression of (inhibitory) 
KIRs (KIR3DL1 and KIR2DL2/L3/S2) is upregulated [32]. Functional data 
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in this study show upregulated IFN-γ production and decreased perforin 
secretion, but whether this is a direct consequence of the phenotypical 
changes has not been investigated [32]. Downregulation of activating NK 
cell receptor NKp46 has been described after IAV exposure of adult and 
cord blood NK cells [28]. This NKp46 downregulation was accompanied 
by increased IFN-γ secretion, decreased perforin expression and 
decreased cytotoxicity [28]. However, a direct link between phenotype and 
functionality was not investigated. In contrast to these findings, a study 
performed by Mao and colleagues did not show altered NKp46 expression 
on NK cells after exposure to IAV virions [27]. An additional study reported 
no differences in activating (NCR1, NKG2D, NKRP1c, CD244c and Ly49D) 
or inhibiting (NKG2A, Ly49A, Ly49C/I, and Ly49G2) receptor expression 
after IAV infection of NK cells, but NKp46 expression was not investigated 
[26]. Although no difference in receptor expression was found, the cytotoxic 
potential of NK cells was downregulated in both these studies [26,27]. 
Incubation of NK cells with VZV leads to decreased CD56 and FcγRIII 
expression, in combination with an increased expression of CD57, which is 
a hallmark of NK cell maturity [24]. In addition, VZV induces the expression 
of skin-homing chemokine receptors CCR4 and cutaneous lymphocyte 
antigen (CLA) on infected NK cells, thereby promoting a skin-homing 
phenotype [24]. Data supporting a functional effect of these phenotypical 
changes is lacking. Viral infection of NK cells has also been shown to cause 
de novo expression of receptors that are not intrinsically expressed within 
the NK lineage. HHV-6 induces CD4 expression in infected NK cells, 
enabling subsequent (CD4-dependent) HIV infection [23]. The effect of 
CD4 expression on functionality of the HHV-6-infected NK cells was not 
investigated. 
Changes to the morphology of NK cells have been reported following 
EBV infection in vitro, where infection of NK cells caused cell deformation 
and increased size [19]. Moreover, EBV infection in vivo has been linked 
to NK cell malignancies [20,21], suggesting the involvement of EBV in 
transformation of NK cells.
These studies indicate that each virus induces a different phenotype, 
often skewed towards an NK cell state that promotes the establishment of 
a successful infection. 
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CONTRIBUTION TO VIRAL LOAD 
Replication of the viral genome, transcription of viral proteins, and 
subsequent release of new infectious virions are necessary for virus spread. 
Since NK cells are infected, they may also contribute to the viral load. A 
significant role for production of virus particles within NK cells has not been 
described for the majority of viruses mentioned in this review. Nevertheless, 
in vitro studies have observed (limited) production of infectious viral 
particles by NK cells infected with HIV-1 [38, 40], VZV [24], and VSV [35]. 
HIV-1-infected NK cells produce infectious HIV in vitro and depletion of 
NK cells from PBMC results in significant reduction of HIV-1 propagation 
[38,40]. VZV-infected NK cells were able to transmit infectious virus to 
epithelial cells, suggesting productive infection by VZV [24]. Production of 
infectious VSV particles has only been investigated in NK cell lines, where 
VSV infection seemed to result in a persistent infection that continued to 
produce infectious VSV for over a year [35]. Taken together, it is currently 
unknown whether infected NK cells serve as a reservoir for certain viral 
infections and contribute significantly to the dissemination of the virus. 
Although HIV-1, VZV and VSV seem to establish productive infections, it 
remains to be investigated whether the amount of released infectious viral 
particles is enough to significantly contribute to the viral load in vivo.
CONCLUSION AND FUTURE PERSPECTIVES
Accumulating evidence demonstrates that NK cells can serve as target 
cells for viral infections. Viruses have evolved multiple mechanisms to enter 
NK cells, change the cellular effector function and affect the subsequent 
immune response. Literature discussed in this review shows that viruses 
from nine different families can infect NK cells, indicating this is not an 
uncommon phenomenon. An overview of the most thoroughly studied 
viruses that infect NK cells and their effect on NK cell function is shown in 
Figure 1. 
To date, almost all viruses that have been found to infect NK cells are 
enveloped viruses, with the exception of TTV. This suggests that there is a 
bigger (evolutionary) advantage for enveloped viruses compared to naked 
viruses to infect NK cells and modulate anti-viral NK cell immunity. 
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FIGURE 1 Schematic representation of the most-studied viruses that infect NK cells · 
Abbreviations: BV, Epstein Barr virus; HIV, human immunodeficiency virus; HSV, herpes 
simplex virus; HTLV, human T-lymphotropic virus; IAV, influenza A virus; RSV, respiratory 
syncytial virus; VV, vaccinia virus; VZV, varicella zoster virus.
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Cells infected with enveloped viruses display viral proteins on their 
membrane, making them prone to ADCC by NK cells [4]. Therefore, the 
inhibition of NK cell ADCC capacity may be specifically of importance as 
immune evasion strategy for enveloped viruses. 
It is apparent that viruses that cause systemic infections will encounter 
NK cells during an infection. However, infections with viruses like influenza 
and RSV are restricted to the lungs. Consistent with their important 
immunological role NK cells are distributed throughout the whole body, 
including the lungs [59]. Moreover, infection with influenza and RSV has 
been shown to lead to a pulmonary influx of NK cells in vivo [60-63]. 
This co-localization of NK cells and viruses during infection supports the 
potential benefit for viruses to evade the anti-viral NK cells response.
Generally, only a proportion of NK cells is infected in in vitro experiments. 
For viruses that enter NK cells through target cell interactions, the proximity 
of NK cells with infected cells seem to be the main determinant for infection. 
In the case of receptor-mediated entry, limited expression of specific entry 
receptors may result in non-homogeneous infection of NK cells, although 
other factors or phenotypic alterations may also be responsible. As NK cells 
are among the first cells to react to viral infections, inhibition or skewing of 
a small subset may already have a significant impact on the subsequent 
immune response. This is supported by increasing evidence showing that 
NK cells have an important role in shaping the adaptive immune response 
to viral infections (as reviewed in [64,65]). This also has implications for 
vaccine development, as attenuated viruses used for vaccination may 
not infect NK cells and therefore induce different skewing of the adaptive 
(memory) immune response compared to natural infection. With the 
limited data that is available, it is impossible to determine whether this 
altered NK cell response would be beneficial or detrimental for protection.
A caveat of multiple studies that investigate NK cell infection is the lack 
of a clear distinction between the effect of infection as opposed to mere 
interaction. Incubation of NK cells with viral particles can lead to modulation 
of NK cell function in absence of infection. The mere interaction between 
viral particle and NK cell can be enough to trigger or inhibit certain effects. 
Whether infection is a prerequisite for NK cell modulation, can be studied 
using UV-inactivated viruses, as has been done for VV [33], or in the 
presence of a fusion inhibitor, as has been done for RSV [32]. However, in 
most of the abovementioned studies these controls were absent.
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Several questions remain unresolved and need further investigation. 
The contribution of infected NK cells to disease severity and viral load 
remains unclear. Answering this question is challenging, as isolation of 
(local) cell subsets from patients is often impossible, making it difficult to 
demonstrate infected NK cells in vivo. The potential use of animal models 
is limited, as NK cell receptor repertoires differ between species. Moreover, 
many viruses are host-specific and infection in animals may not mimic the 
human situation. 
It is essential to expand our knowledge on possible cellular targets and 
reservoirs of viral infections. Intervention strategies to treat viral infections, 
such as viral entry inhibitors, may have different effects on particular cell 
types, as was demonstrated for influenza in murine NK cells [45]. Hence, 
the development of specific therapeutics could benefit from studies into 
viral infection of different cell types. In addition, viruses that are known to 
spread through cell-cell interactions may require alternative targets for 
drug development. The fact that viruses can infect NK cells, suggests that 
this feature contributes to establishing a successful infection. Therapeutic 
inhibition of NK cell infection may therefore counteract the evasion 
strategies of the virus, potentially leading to an enhanced antiviral immune 
response.
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ABSTRACT
Human respiratory syncytial virus (RSV) is a major cause of severe 
lower respiratory tract disease requiring hospitalization in infants. There 
are no market-approved vaccines or antiviral agents available, but a 
growing number of vaccines and therapeutics are in (pre)clinical stages 
of development. Reliable animal models are crucial to evaluate new 
vaccine concepts, but in vivo RSV research is hampered by the lack of 
well-characterized animal models that faithfully mimic the pathogenesis 
of RSV infection in humans. Mice are frequently used in RSV infection and 
vaccination studies. However, differences in the use of mouse strains, RSV 
subtypes, and methodology often lead to divergent study outcomes. To 
our knowledge, a comparison between different RSV inoculation methods 
in mice has not been described in the literature, even though multiple 
methods are being used across different studies. In this study, we evaluated 
various pathological and immunological parameters in BALB/c mice after 
intratracheal or intranasal inoculation with RSV-A2. Our study reveals that 
intranasal inoculation induces robust pathology and inflammation, whereas 
this is not the case for intratracheal inoculation. As immunopathology is an 
important characteristic of RSV disease in infants, these data suggest that 
in mice intranasal inoculation is a more appropriate method to study RSV 
infection than intratracheal inoculation. These findings will contribute to the 
rational experimental design of future in vivo RSV experiments. 
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INTRODUCTION
Respiratory syncytial virus (RSV) infection is a major cause of severe 
lower respiratory illness requiring hospitalization in young infants [1]. 
Currently, there are no market-approved vaccines available, although 
multiple vaccines are in (pre)clinical stages of development (https://
www.path.org/resources/rsv-vaccine-and-mab-snapshot/). Reliable 
animal models are crucial to evaluate new vaccine concepts. Several 
animal models have been developed to study RSV infection and disease, 
including mice, cotton rats, chimpanzees, cattle, and sheep [2,3]. However, 
none of these models fully replicates the pathogenesis of RSV infection in 
humans. In light of this, it is pivotal to obtain a thorough understanding of 
the implications of the use of different methodologies, in order to design 
experimental approaches that are most suitable for answering specific 
research questions.
Despite their limitations, mice are the most commonly used animal 
species for in vivo modeling of RSV disease. Most inbred mouse strains, 
including the widely used BALB/c and C57 Bl/6 mice, are semi-permissive 
for RSV infection. These mice need an inoculum with a high viral titer 
to detect any lower respiratory tract disease symptoms and general 
measures of illness such as weight loss [4,5]. In addition, the innate and 
adaptive immune responses after RSV infection differ between humans 
and mice. For example, mice show a limited recruitment of neutrophils 
to the lungs, whereas neutrophils are the most abundant cell type during 
human RSV infection [4,6]. However, the availability of a vast array of 
mouse-specific reagents and molecular tools makes mice indispensable 
for gaining mechanistic insights into RSV infection and disease. 
Not only is the translation from mouse to human difficult for RSV 
infection, the comparison between mouse studies is also challenging. 
This is due in part to differences arising from the use of varying mouse 
strains and RSV subtypes. The mouse strain is a major determinant 
of RSV susceptibility and subsequent pathogenesis [7,8]. In addition, 
responses vary greatly between different RSV subtypes and (clinical) 
isolates, even if the same mouse strain is used [9,10]. It has also been 
found that the cell line used for RSV propagation and the purity of the 
viral inoculum influence infectivity and pathology [11-13]. These reports 
highlight that appropriate selection of the study setup is crucial to allow 
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for proper interpretation of the results.
For multiple pathogens other than RSV, it has been suggested that 
different infection routes also play a role in the inconsistent outcomes 
between studies. For example, both the site of pathogenesis as well as 
mortality rates after influenza virus infection in ferrets differed between 
intranasal and intratracheal inoculation [14,15]. Moreover, different 
outcomes were observed for intranasal versus intratracheal infection of 
mice with Listeria monocytogenes [16] and Pseudomonas aeruginosa [17]. 
To our knowledge, comparison between these inoculation methods with 
regard to viral load, pathogenesis, and the immune response has never 
been undertaken for RSV infection in mice. Although intranasal inoculation 
methods are most common within the RSV field [18], intratracheal 
inoculation has also been described [19-21]. 
In this study, we evaluated virus-induced pathology and the antiviral 
immune response in BALB/c mice after intratracheal or intranasal 
inoculation with RSV-A2. Although mice in both groups received an equal 
dose of the same virus stock, striking differences in viral load, lung damage, 
and inflammatory mediators were apparent. Our study reveals that at three 
days post-infection, intranasal inoculation results in robust pathology and 
immune activation, whereas intratracheal inoculation barely induces either 
lung damage or inflammation. As immunopathology is an important 
characteristic of RSV disease in infants, these data suggest that intranasal 
inoculation in mice is a more appropriate method to mimic the effect of 
RSV infection in humans than intratracheal inoculation.  Together, these 
findings provide important insights that are essential for the rational design 
of future in vivo experiments with RSV.
MATERIALS AND METHODS 
Mice
Female, specific-pathogen-free BALB/c mice (7-9 weeks old) were 
obtained from Charles River Laboratories and kept at the animal facilities of 
Intravacc (Netherlands). The animals were allowed to acclimatize for at least 
one week. Different batches of mice were used for all five experiments. The 
study was approved by the Animal Ethical Committee of the Netherlands 
(CCD; 20185186; April 23, 2018). All experiments were performed in 
accordance with the guidelines of the institutional animal care committee.
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Cells and virus
HEp-2 cells (ATCC CCL-23) were cultured in minimum essential medium 
(MEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented 
with 10% heat-inactivated fetal calf serum, and 1% penicillin/streptomycin/
glutamine (Gibco). Human RSV-A2 (ATCC, VR1302) was propagated in 
HEp-2 cells. The virus stock was purified between layers of 10% and 50% 
sucrose by ultracentrifugation. Virus titer was determined by 50% tissue 
culture infective dose (TCID50) assay on HEp2 cells. TCID50/ml was 
calculated using the Spearman and Karber method [22] and converted to 
plaque-forming units (pfu) per mL by multiplying by 0.69. 
Inoculation of mice
Two types of experiments were performed, intratracheal inoculation 
and intranasal inoculation. The intratracheal inoculation experiment was 
performed three times, whereas the intranasal inoculation experiment was 
performed twice. All experiments were carried out on different days. Every 
experiment consisted of two groups, one RSV- and one mock-infected, 
of three animals each. The different experiments are indicated by distinct 
symbols (shape and color) in the graphs. 
On day 0, mice were intratracheally or intranasally infected with live, 
sucrose-purified RSV-A2. Preceding intratracheal inoculation, mice 
received an intraperitoneal injection of ketamine/xylazine (80 and 10 mg/
kg, respectively). Mice were subsequently infected via a cannula in the 
trachea with 2 x 106 pfu RSV-A2 diluted in phosphate buffered saline (PBS) 
in a total volume of 50 µL. Before intranasal inoculation, mice received 
anesthesia through inhalation of isoflurane (3.5% in O2). Mice were then 
infected with 2 x 106 pfu RSV-A2 diluted in PBS in a total volume of 50 µL, 
which was administered dropwise to the nose. A schematic representation 
of the inoculation techniques is shown in Figure 1A. Control animals were 
mock-inoculated either intratracheally or intranasally with 50 µL PBS 
containing 10% sucrose.
Sample collection
Three days post-infection (dpi), mice were euthanized by exsanguination 
under isoflurane anesthesia. Bronchoalveolar lavage (BAL) samples and 
lungs were collected and processed as described below. Weights were 
measured daily during the course of the experiment.
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BAL samples were obtained by infusing 0.8 mL or 0.9 mL (depending 
on weight of the animal) PBS into the lungs via the trachea, followed by 
aspiration into a syringe. The BAL sample was centrifuged at 500 × g 
for 5 min. Cell pellets were collected for flow cytometric analysis and the 
supernatant was snap-frozen and stored at -80°C for subsequent analysis 
of cytokine/chemokine and albumin concentrations. 
Single-cell suspensions were prepared from mouse lungs by digestion 
with collagenase and DNase (Sigma-Aldrich, Saint Louis, MO, USA). 
Cells were pushed through 70 µm cell strainers and erythrocytes were 
lysed with ammonium-chloride-potassium (ACK) lysis buffer (0.155 M 
NH4CL, 10 mM KHCO3, and 0.1 mM Na2EDTA). Lung cells were used for 
determination of the viral load.
Viral load
The amount of viral RNA was used as a proxy for viral load and was 
determined by quantitative reverse transcriptase PCR (RT-qPCR). Total RNA 
was extracted from lung single-cell suspensions using a Nucleospin RNA 
extraction kit (Machery Nagel, Düren, Germany), and quantified on a Qubit 
fluorimeter (Invitrogen, Thermo Fisher Scientific). Subsequently, cDNA 
was synthesized using an iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA, USA) on a thermal cycler (ABI GeneAmp 9700, Applied Biosystems, 
Thermo Fisher Scientific). Finally, qPCR was performed on a real-time PCR 
machine (Applied Biosystems StepOne Plus) using SYBR Green reagents 
(Bio-Rad) and RSV-specific primers. Resulting CT values were converted 
to arbitrary units (AU) using a standard curve. Amplification with primers 
corresponding to mouse actin mRNA was performed in parallel and used 
for normalization. Primer sequences are detailed in Table 1. 
TABLE 1     Primer sequences
Transcript Sequence
RSV N Forward: 5’-TGACAGCAGAAGAACTAGAGGC-3'
Reverse: 5'-TGGGTGATGTGAATTTGCCCT-3'
Mouse actin Forward: 5'-CGGTTCCGATGCCCTGAGGCTCTT-3'
Reverse: 5'-CGTCACACTTCATGATGGAATTGA-3'
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Flow cytometric analysis of immune cell subsets in the BAL
BAL cells were isolated as described above and incubated with anti-mouse 
CD16/CD32 Fc receptor block (BD Pharmingen, BD Biosciences, San Jose, 
CA, USA) at 1 µg per 2 x 106 cells for 10 min at 4°C. Cells were subsequently 
incubated with the following antibodies: CD3-Pacific Blue (17A2, Biolegend, 
San Diego, CA, USA), CD4-APC (RM4-5, BD Pharmingen), CD8a-PE 
(53-6.7, Biolegend), CD11b-BV711 (M1/70, Biolegend), CD19-BV510 (1D3, 
BD Horizon, BD Biosciences), CD41-PE-CY7 (MWReg30, Biolegend), 
CD45-BUV395 (30-F11, BD Horizon), NKp46-BV605 (29A1.4, Biolegend), 
Ly-6G-PE/Dazzle (1AB, Biolegend). Ultimately, cells were fixed in 3.7% 
paraformaldehyde in PBS for 10 min before flow cytometric analysis using 
an LSR Fortessa X20 (BD Biosciences). FlowJo software V10 (FlowJo, BD, 
Franklin Lakes, NJ, USA) was used for data analysis. The gating strategy 
for one representative BAL sample is depicted in Supplementary Figure 1. 
Albumin and cytokine/chemokine determination in BAL fluid
Albumin concentrations were determined using a mouse albumin ELISA 
(ICL, Portland, OR, USA), according to the manufacturer’s protocol. 
Cytokine/chemokine concentrations in BAL samples were analyzed using 
the mouse anti-virus response panel LEGENDplex (Biolegend), according 
to the manufacturer’s protocol. This assay contained the following 
cytokines/chemokines: CCL2 (MCP-1), CCL5 (RANTES), CXCL1, CXCL10 
(IP-10), IFN-α, IFN-β, IFN-γ, IL-1β, IL-6, IL-10, IL-12, GM-CSF, and TNF. 
Statistical methods
All statistical analyses were performed with Prism 7 software (GraphPad 
Software, San Diego, CA, USA). Viral load, albumin concentrations, cell 
counts and cytokine/chemokine concentrations were log transformed 
before statistical testing. Comparisons between two groups were performed 
using an unpaired Student’s t-test. Multiple comparisons were analyzed 
using a one-way analysis of variance (ANOVA), followed by Tukey’s multiple 
comparisons test. Differences in mouse body weight between mock- and 
RSV-inoculated animals were analyzed using a two-way ANOVA, using 
the day and group as variables, followed by Sidak’s multiple comparisons 
test. P values <0.05 were considered statistically significant. 
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RESULTS
Intranasal inoculation results in slightly higher viral load and more 
pronounced pathology compared to intratracheal inoculation
To compare the effect of the inoculation method on viral load and pathology, 
BALB/c mice were (mock-) infected with vehicle control or RSV-A2 
either intratracheally (n = 9 per group, divided over three experiments) or 
intranasally (n = 6 per group, divided over two experiments). We pooled 
all data per group for subsequent analysis. Separate experiments are 
indicated in the graphs by distinct shapes and colors of symbols. The 
technical differences between intratracheal and intranasal inoculation are 
illustrated in Figure 1A.
The viral load was determined at three dpi by assessing the amount of 
viral RNA in total lung cells using RT-qPCR. The results showed a higher 
FIGURE 1  Viral load and pathology following intratracheal or intranasal respiratory 
syncytial virus (RSV) infection  ·    >>
Mice were (mock-) inoculated either intratracheally or intranasally with 2 x 106 pfu of live 
RSV-A2 or vehicle control. A. Schematic figure of the intratracheal and intranasal inoculation 
methods. B-C. Viral load in mouse lung cells as determined by RT-qPCR. Two animals that 
tested negative for RSV after intratracheal inoculation (B) were excluded from further analysis 
and removed from panel (C). Geometric mean and SD are depicted. Viral load was log 
transformed before statistical comparison between the two groups was performed using an 
unpaired Student’s t-test (*p < 0.05). D. Albumin concentration in the bronchoalveolar lavage 
(BAL) fluid measured by ELISA. Albumin concentrations were log transformed before analysis 
by a one-way ANOVA, followed by Tukey’s multiple comparisons test. Geometric mean and 
SD are depicted. E. Mouse body weight with the weight at day 0 set to 100%. Each data-point 
represents the mean weight (+/- SD) of all mice from the indicated group: mock intratracheal 
(IT) (n = 9), RSV IT (n = 7), mock intranasal (IN) (n = 6), RSV IN (n = 6). Body weights between 
mock- and RSV-infected animals are compared using a two-way ANOVA, followed by Sidak’s 
multiple comparisons test. Only the IN inoculation groups showed a difference between mock- 
and RSV-inoculated animals (*p < 0.05). Mice from separate experiments are indicated with 
a distinct symbol (IT: white / light / black circles; IN: white / dark squares). Abbreviations: AU, 
arbitrary units; BAL, bronchoalveolar lavage; IN, intranasal; IT, intratracheal; KX, ketamine-
xylazine; LRT, lower respiratory tract; RSV, respiratory syncytial virus; SD, standard deviation; 
URT, upper respiratory tract.
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mean lung viral load in intranasally inoculated compared to intratracheally 
inoculated animals (Figure 1B). Whereas all intranasally infected animals 
tested positive for viral RNA in the lungs, two animals that had been 
intratracheally inoculated tested negative for viral RNA. This suggests that 
intratracheal inoculation is more error-prone than intranasal inoculation, 
which is likely due to the possibility of inadvertent administration of the 
inoculum into the esophagus. The two RSV-negative animals were 
excluded from all further analysis. Upon exclusion of these two animals, 
the mean viral load was approximately 2-fold higher in the intranasally 
compared to the intratracheally inoculated animals, which was a statistically 
significant difference (Figure 1C). No virus was detected in any of the mock-
inoculated animals.
To determine whether the high viral load upon intranasal inoculation 
was accompanied by more pronounced pathology in the lung, we 
subsequently quantified the albumin concentration in the bronchoalveolar 
lavage (BAL) fluid and assessed changes in body weight during the 
course of the experiment. Leakage of serum albumin from the circulation 
into the lung lumen can be used as a measure for lung damage [23]. 
Although intratracheal RSV inoculation did not result in any observable 
lung damage, with albumin concentrations comparable to those of mock 
inoculation, intranasal inoculation with RSV resulted in higher albumin 
concentrations compared to both intranasal mock inoculation and 
intratracheal RSV inoculation, although this was not statistically significant 
(Figure 1D).In addition to lung damage, animals that had received RSV 
through intranasal inoculation showed a decrease in body weight, losing 
almost 5% of body weight at day 1 (Figure 1E). In contrast, animals that 
had received an intratracheal inoculation did not show a decrease in body 
weight, but rather gained weight throughout the experiment. Intranasally 
mock-inoculated animals did not show a change in body weight.  
Virus-induced pulmonary cellular influx is more pronounced upon 
intranasal compared to intratracheal inoculation
To investigate the effect of inoculation method on inflammatory parameters, 
we assessed pulmonary cellular influx by determining (specific) immune 
cell counts in the BAL at three dpi by flow cytometry. The total leukocyte 
count in the BAL was significantly increased upon RSV infection compared 
to that of mock infection for both inoculation methods (Figure 2A). 
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FIGURE 2   Pulmonary cellular influx following intratracheal or intranasal RSV infection  ·  
Mice were (mock-) inoculated either intratracheally or intranasally with 2 x 106 pfu of live 
RSV-A2 or vehicle control. Cells were isolated from the bronchoalveolar lavage (BAL) and 
analyzed using flow cytometry. Mice from individual experiments are indicated with a distinct 
symbol (IT: white / light / dark  circles; IN: white / dark squares). Graphs depict absolute cell 
counts for A. total leukocytes (CD45+), B. NK cells (CD3-, CD56+), C. neutrophils (CD3-, Ly-6G+, 
CD11b+), D. antigen-presenting cells (CD3-, Ly-6G-, CD11b+), E. CD4 T cells (CD3+, CD4+), 
and F. CD8 T cells (CD3+, CD8+). All graphs depict geometric mean and SD. Cell count data 
were log transformed before analysis by a one-way ANOVA, followed by Tukey’s multiple 
comparisons test (*P<0.05, **P<0.01, ***P<0.001). Abbreviations: APCs, antigen-presenting >> 
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In addition, total leukocyte counts were significantly higher upon intranasal 
RSV inoculation compared to those of intratracheal RSV inoculation. Cell 
type-specific analysis revealed that natural killer (NK) cell (Figure 2B), 
neutrophil (Figure 2C), antigen-presenting cell (APC) (Figure 2D), and CD4 
and CD8 T cell (Figure 2E-F) counts were increased upon RSV infection 
compared to those of mock infection for both inoculation methods. These 
differences were statistically significant, except for neutrophils. In addition, 
NK cell, neutrophil, APC, and CD4 and CD8 T cell counts were markedly 
higher upon intranasal compared to intratracheal RSV inoculation. 
These differences were statistically significant, except for CD4 T cells. No 
increased B cell counts were detected after intratracheal or intranasal RSV 
inoculation in the BAL at three dpi. These data indicate that the observed 
pulmonary influx is composed of a variety of immune cells and does not 
appear to be linked to influx of one particular cell type. Overall, we found 
that at three dpi the pulmonary cellular influx in the BAL induced by 
intranasal RSV inoculation was much more pronounced than that induced 
by intratracheal RSV inoculation. 
Elevated virus-induced pulmonary influx upon intranasal inoculation is 
accompanied by increased cytokine and chemokine levels
The influx of immune cells in the lungs is a hallmark of inflammation and 
is often accompanied by an increase in the levels of (pro-inflammatory) 
cytokines and chemokines. To investigate whether intranasal inoculation 
results in elevated secretion of soluble pro-inflammatory mediators 
compared to intratracheal inoculation, we determined the concentration of 
various cytokines and chemokines in the BAL fluid at three dpi. We focused 
on soluble mediators that are known to be involved in the response against 
viral infection.
Compared to mock infection, RSV infection via both inoculation methods 
resulted in increased BAL concentrations of CCL2 (MCP-1), CCL5 
(RANTES), CXCL1, CXCL10 (IP10), IFN-α, IFN-γ, and TNF (Figure 3A-G). 
These differences were statistically significant, except for CCL5 and IFN-α 
in the case of intratracheal inoculation. IL-1β, IL-12, and GM-CSF showed 
no difference upon RSV infection compared to mock infection and the 
<< cells; BAL, bronchoalveolar lavage; IN, intranasal; IT, intratracheal; NK cells, natural killer 
cells; RSV, respiratory syncytial virus; SD, standard deviation.
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FIGURE 3  Cytokine and chemokine levels in the bronchoalveolar lavage following 
intratracheal or intranasal RSV infection   ·      >>
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levels of IFN-β, IL-6, and IL-10 remained below the limit of detection. 
Compared to intratracheal RSV inoculation, mice that had been intranasally 
inoculated with RSV showed 3- to 8-fold higher levels of CCL2, CCL5, 
CXCL1, CXCL10, IFN-α, IFN-γ, and TNF (Figure 3H). These differences 
were all statistically significant. Similar to the pulmonary cellular influx, we 
observed differences in some of the pro-inflammatory mediators between 
experiments performed on different days. In summary, RSV infection 
induced expression of a number of pro-inflammatory cytokines and 
chemokines. Animals that were inoculated intranasally showed markedly 
higher levels of RSV-induced pro-inflammatory mediators in BAL fluid 
than intratracheally inoculated animals at three dpi. 
DISCUSSION
Seemingly minor methodological differences can have profound effects 
on the outcome of animal studies. It is therefore of pivotal importance to 
understand beforehand the implications of choosing a particular method, 
in order to allow for proper interpretation of the results obtained at the end 
of the experiment. In the present study, we compared the pathological 
and immunological effects of RSV infection via intratracheal or intranasal 
inoculation. The latter resulted in a slightly higher viral load that was 
accompanied by more pronounced pathology compared to intratracheal 
<< Mice were (mock-) inoculated either intratracheally or intranasally with 2 x 106 pfu of live 
RSV-A2 or vehicle control. Bronchoalveolar lavage (BAL) fluid was analyzed at 3 dpi using 
a multiplex mouse anti-virus response panel immunoassay. A-G. Concentrations in pg/
ml of CCL2, CCL5, CXCL1, CXCL10, IFN-α, IFN-γ, and TNF. Mice from individual experiments 
are indicated with a distinct symbol (IT: white / light / dark circles; IN: white / dark squares). 
Cytokine concentrations were log transformed before analysis by a one-way ANOVA, followed 
by Tukey’s multiple comparisons test (**P<0.01, ***P<0.001). H. Concentration of indicated 
soluble pro-inflammatory mediators after either intratracheal or intranasal RSV infection. The 
bars represent the geometric mean and SD of all animals belonging to the indicated groups. 
Fold change between intratracheal and intranasal infection is indicated above each pair of 
bars. Abbreviations: BAL, bronchoalveolar lavage; CCL, CC chemokine ligand; CXCL, CXC 
chemokine ligand; IN, intranasal; IP10, interferon gamma-induced protein 10; IT, intratracheal; 
MCP-1, monocyte chemoattractant protein 1; RANTES, Regulated upon Activation, Normal T cell 
Expressed and presumably Secreted; RSV, respiratory syncytial virus; SD, standard deviation.
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inoculation. In addition, inflammatory parameters such as pulmonary 
cellular influx and pro-inflammatory cytokine and chemokine levels were 
significantly higher after intranasal versus intratracheal inoculation. 
A possible explanation for the observed differences in viral load, 
pathology, and host responses is the difference in (primary) infection site 
between intratracheal and intranasal inoculation. During intratracheal 
inoculation, the virus is delivered directly to the lung, presumably resulting 
in an infection that is confined to the lower respiratory tract, at least initially. In 
contrast, intranasal inoculation with the volume used in this study results in 
infection of both the upper and lower respiratory tract [24]. It is conceivable 
that viral replication in the upper airways contributes to a higher viral load 
in the lungs. In addition, it is likely that the host response to viral infection in 
the upper airways influences the immune response in the lower airways. 
Previous studies have shown that viral replication and host responses may 
vary depending on the anatomical localization of the RSV infection. For 
example, in vitro studies have shown increased viral production in human 
nasal epithelial cells compared to bronchial epithelial cells [25]. In contrast, 
ex vivo studies with primary pediatric epithelial cell cultures have shown 
lower RSV titers accompanied by slightly lower cytokine responses in nasal 
cells compared to bronchial cells [26]. Interestingly, influenza virus infection 
in ferrets resulted in higher mortality rates after intratracheal inoculation 
compared to intranasal inoculation [15]. These findings highlight that virus-
specific information on the outcomes of different inoculation routes is 
essential for the design of future studies.
Another important factor that might have contributed to the observed 
differences is the differential use of anesthetics between the two inoculation 
methods. For intratracheal inoculation, which is a more invasive procedure, 
the induction of anesthesia through ketamine/xylazine injection is common 
practice. Intranasal inoculation only requires a short duration of anesthesia 
and is therefore performed under inhaled isoflurane anesthesia. Although 
not specifically investigated for RSV infection, the use of anesthetics can 
have a major impact on the immune system [27-30]. Multiple studies 
have reported that ketamine possesses anti-inflammatory properties 
and impairs the release of pro-inflammatory cytokines [29,31,32]. In 
addition, ketamine has been shown to have antiviral properties against 
rabies virus [33]. Although isoflurane has also been shown to reduce 
inflammation, these effects were mostly seen after long-term exposure 
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[30,34,35]. Taken together, the use of ketamine/xylazine anesthesia for 
intratracheal inoculation may, at least in part, explain the observed lower 
immunopathology compared to intranasal inoculation. Considering this, 
we found it striking that a considerable number of published studies fail to 
specify the type of anesthesia that was used during RSV infection in mice.
The main limitation of our study is the fact that the intratracheal and 
intranasal inoculations were performed in separate experiments, which is 
a suboptimal experimental setup to compare the two methods. However, 
during each experiment, exactly the same virus dose was used, originating 
from the same virus batch. In addition, all animals were obtained from the 
same source, were of similar age, and were handled at the same facility. 
Nevertheless, we did observe differences between experiments performed 
on different days, especially regarding the immunological read-outs. As 
we used female mice for our study, a possible explanation for these effects 
is the ovarian cycle of the different batches of animals. Multiple studies 
have shown differences in the immune response between the different 
ovarian cycle phases [36,37]. For future experiments, the use of male mice 
might be more appropriate. However, this phenomenon also highlights 
the importance of performing experiments on multiple days to control 
for these kinds of variations. Taken together, we believe the experimental 
conditions of our study were similar enough to warrant a comparison 
between the two inoculation methods, especially considering the fact that 
the observed differences are quite striking and may have implications for 
the choice of inoculation method for future animal experiments.
Another limitation of our study is the fact that most pathological and 
immunological parameters were only assessed at one time-point post 
infection. It is possible that the observed differences are due to variations 
in the kinetics of virus replication and host response depending on the site 
of initial infection and/or anesthesia. However, the absence of a change 
in body weight upon intratracheal inoculation suggests this is not the 
main cause underlying the observed effects. Notably, we only assessed 
the short-term consequences of viral infection on pathology and host 
response. It remains a possibility that long-term immune responses, such 
as humoral and cellular memory responses, are differently affected by the 
two inoculation methods. Nevertheless, when focusing on these short-
term responses, intranasal inoculation appears to be the method of choice. 
In conclusion, we have demonstrated striking differences between 
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intratracheal and intranasal RSV inoculation with regards to pathological 
and immunological read-outs, which may be explained by differences 
in the (initial) site of infection or the differential use of anesthetics. Based 
on our findings, intranasal inoculation appears to be better suited to the 
study of RSV-induced immunopathology than intratracheal inoculation. 
Not only does intranasal inoculation more accurately mimic the natural 
route of infection, it is also a less invasive procedure, requires milder 
anesthetics, is less error-prone, and, as we have demonstrated, induces 
more pronounced pathology and immune responses than intratracheal 
inoculation. Although it remains to be investigated whether the route of 
administration or the anesthetic is the main factor underlying the observed 
differences, it is evident that the selection of inoculation method (even 
when both techniques deliver the virus to the lower respiratory tract) is 
of crucial importance to obtain the most appropriate model to mimic RSV 
disease in humans.
Supplementary Materials are available online at: 
https://www.mdpi.com/1999-4915/11/6/508#supplementary
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ABSTRACT
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory 
tract infections in infants. Hospitalization peaks below six months of age, 
when maternal antibody levels are declining. Although it is generally 
assumed that antibodies hold the key to protection against severe RSV 
disease, it has also been suggested that sub-neutralizing antibody 
titers lead to enhanced RSV infection and disease. However, in vivo data 
supporting this hypothesis of antibody-dependent enhancement (ADE) 
is lacking. 
In this in vivo study, we evaluated the viral load, pathology and 
inflammatory response in the presence of serially diluted RSV-specific 
antibodies, mimicking the waning maternal antibody titer in infants. In 
contrast to the expected reduction in viral load observed at high antibody 
concentrations at 3 days post infection, low antibody concentrations 
resulted in a significantly higher viral load compared to the absence of 
antibodies. Moreover, mice that received low antibody concentrations 
displayed slightly increased pathology compared to the absence of 
antibodies. Inflammatory markers, such as pulmonary cellular influx and 
some cytokine and chemokine concentrations, were marginally increased 
in the presence compared to the absence of antibodies. 
These data provide the first clues towards the occurrence of enhanced 
RSV infection and disease in vivo, mediated by antibodies induced by 
natural RSV infection, indicating that a sub-protective humoral response 
may have pathological consequences. Additional experiments should be 
performed to further elucidate this phenomenon, which, if substantiated, 
would be an important point of concern in view of the development of 
(maternal) RSV vaccines. 
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INTRODUCTION
Respiratory syncytial virus (RSV) infection is a major cause of severe 
respiratory illness requiring hospitalization in young infants [1]. 
Hospitalization for severe RSV-mediated disease peaks between six 
weeks and six months of life [2,3]. Maternal antibodies are present during 
these first months of life, but levels are rapidly waning over time [4-6]. 
Multiple studies show that high maternal antibody titers are associated 
with protection against RSV infection or disease [6-9]. However, others 
demonstrate that high titers do not have a protective effect [10-13] or even 
associate with an increased risk of recurrent wheezing [14]. 
Originally, the main functionality of antibodies was thought to be direct 
virus neutralization. However, in addition to reducing the infectivity of the 
virus, antibodies may influence the immune response through the formation 
of immune complexes and opsonization of virus-infected cells. There is 
increasing evidence that antibody effector functions besides neutralization 
play an important role in RSV infection and disease (reviewed in [15,16]). In 
contrast to their beneficial role in providing protection against infection and 
disease, antibodies have also been implicated in enhancement of disease. 
Interestingly, the disastrous vaccine trials in the 1960s with a formalin-
inactivated (FI) RSV vaccine induced poorly-neutralizing antibodies which 
have been suggested to be involved in vaccine-enhanced disease upon 
natural infection [17,18].
The presence of RSV-antibody complexes in the lungs during severe 
RSV infection has been demonstrated in multiple studies, but their role in 
infection and disease remains largely unknown [17,19,20]. FI-RSV vaccine-
induced antibodies contributed to enhanced disease upon subsequent 
natural infection in a mouse model [17]. However, in natural RSV infection, 
the contribution of RSV-antibody complexes in disease is debated. In 
hospitalized RSV-infected infants, immune complexes were identified in 
all groups independent of the severity of disease [20]. In an RSV infection 
mouse model, RSV-antibody complexes were shown to initiate the 
adaptive immune response [21]. In addition, immune complexes have 
been shown to lead to increased infection levels in Fc gamma receptor 
(FcγR)-expressing (primary) cells in vitro [22-26]. However, thus far no 
evidence for enhancement of infection or disease by naturally occurring 
antibodies has been shown during RSV infection in vivo. 
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In utero, every infant receives RSV-specific antibodies from the mother via 
transplacental transfer. Maternal vaccination to boost these antibodies is 
considered for the prevention of RSV disease. It is therefore essential to 
understand the implications of the presence of these maternal RSV-specific 
antibodies, and the waning thereof after birth, on the immune response 
during subsequent RSV infection in vivo. However, assessment of the 
RSV-specific immunological response is routinely performed in naïve 
animals. Although the absence of antibodies makes the interpretation of 
the results of such studies less complex, it only provides a limited view of 
the processes underlying severe disease in infants. Mimicking the situation 
present in the target population is essential, especially in the context of 
assessing therapeutic or prophylactic treatments.
In this study, we infected BALB/c mice with RSV-A2 after administration 
of serially diluted RSV-specific antibodies, mimicking the waning maternal 
antibody levels in infants. Subsequently, we evaluated the effect of different 
antibody concentrations on viral load, pathology, and inflammatory 
response. Although preliminary, our study provides the first indications 
that sub-neutralizing concentrations of naturally occurring antibodies may 
indeed enhance RSV infection and disease. Further research is necessary 
to confirm these findings and establish the underlying mechanisms. This 
knowledge will be key for the development of safe and effective (maternal) 
RSV vaccines.
METHODS
RSV-A2 production
HEp-2 cells (ATCC CCL-23) were cultured in Minimum Essential Medium 
(MEM; Gibco) supplemented with 10% heat-inactivated fetal calf serum, 
and 1% penicillin/streptomycin/glutamine (Gibco). Human RSV-A2 (ATCC, 
VR1302) was propagated in HEp-2 cells. Virus stocks were purified 
between layers of 10% and 50% sucrose by ultracentrifugation. Virus titers 
were determined by 50% tissue culture infective dose (TCID50) assay on 
HEp2 cells. TCID50/ml was calculated using the Spearman and Karber 
method [27] and converted to plaque-forming units (pfu) per ml by 
multiplication with 0.69. 
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Passive transfer experiment in mice
Female, specific-pathogen-free BALB/c mice (7-9 weeks old) were 
obtained from Charles River Laboratories and kept at the animal facilities 
of Intravacc (Netherlands). The animals were allowed to acclimatize to their 
new environment for at least one week. The study was approved by the 
Animal Ethical Committee of the Netherlands (CCD). All experiments were 
performed in accordance with the guidelines of the institutional animal 
care committee.
The study included 6 groups of 6 animals each, divided over 2 experiments 
that were performed on separate days (indicated by distinct colors in each 
graph). On day 0, mice first received an intravenous (IV) injection of 200 
µl antibodies or vehicle control (PBS). Three hours after IV injection, mice 
were anesthetized using inhaled isoflurane before intranasal inoculation 
with 2 x 106 pfu of live RSV-A2 in 50 µL PBS. Control animals received 
intranasal mock inoculation with 50 µL PBS containing 10% sucrose. One 
group was mock-infected after receiving an IV injection with the vehicle 
control. The other groups were RSV-infected after receiving an IV injection 
of vehicle control, 100, 10, or 1 mg/ml intravenous immunoglobulins (IVIg, 
Baxter), or 2 mg/ml Palivizumab (Synagis, Alliance Healthcare). 
Sample collection
At 3 days post-infection (dpi), anesthesia was induced by isoflurane and 
mice were euthanized by exsanguination. Bronchoalveolar lavage (BAL) 
specimens, lungs, and blood were collected and processed as described 
below. 
BAL specimens were obtained by infusing 0.8 mL or 0.9 mL (depending 
on weight of the animal) phosphate buffered saline (PBS) into the lungs 
via the trachea, followed by aspiration into a syringe. The BAL fluid was 
centrifuged at 500 × g for 5 min. Cell pellets were collected for flow 
cytometry analysis and the supernatant was snap-frozen and stored at 
-80°C for subsequent analysis of antibody concentrations, cytokine levels 
and albumin concentrations. 
Single-cell suspensions were prepared from mouse lungs by digestion 
with collagenase and DNase (Sigma-Aldrich). Cells were pushed through 
70 µM cell strainers and erythrocytes were lysed with ammonium-
chloride-potassium (ACK) lysis buffer (0.155 M NH4Cl, 10 mM KHCO3, and 
0.1 mM Na2EDTA). Lung cells were used for determination of the viral load.
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Blood was collected in heparin collection tubes. Collection tubes were 
centrifuged at 750 × g for 10 min after which plasma was harvested. Plasma 
was stored at -80°C until measurement of antibody concentrations. 
Viral load
Viral RNA was quantified as a proxy for viral load by quantitative reverse 
transcriptase PCR (RT-qPCR). Total RNA was extracted from lung single-cell 
suspensions using a Nucleospin RNA extraction kit (Machery Nagel), and 
quantified on a fluorimeter (Qubit). Subsequently, cDNA was synthesized 
using an iScript cDNA synthesis kit (Bio-Rad) on a thermal cycler (Applied 
Biosystems PCR system 9700). Quantification was performed on a real-
time PCR machine (Applied Biosystems StepOne Plus) using SYBR green 
reagents (Bio-Rad) and RSV-specific primers. Resulting CT values were 
converted to arbitrary units (AU) using a standard curve. Amplification with 
primers corresponding to mouse actin mRNA was performed in parallel 
and used for normalization. Primer sequences are detailed in Table 1.
 
Plasma and BAL antibody levels
To quantify the concentration of RSV-specific IgG in plasma and BAL 
samples at 3 days post infection, a multiplex immunoassay was performed 
as described before [28]. In short, plasma and BAL samples were incubated 
with RSV antigen-coupled beads and the bound antibodies were labeled 
with a secondary goat anti-human IgG antibody (Jackson Immunoresearch 
Laboratories). Measurement of the samples was performed on a Bio-Plex 
200 in combination with Bio-Plex Manager software version 6.1 (Bio-
Rad). For each analyte, median fluorescence intensity (MFI) was converted 
to arbitrary units/ml (AU/ml) by interpolation from a 5-parameter logistic 
TABLE 1   Primer sequences
Transcript Sequence
RSV N Forward: 5’-TGACAGCAGAAGAACTAGAGGC-3'
Reverse: 5'-TGGGTGATGTGAATTTGCCCT-3'
Mouse actin Forward: 5'-CGGTTCCGATGCCCTGAGGCTCTT-3'
Reverse: 5'-CGTCACACTTCATGATGGAATTGA-3'
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standard curve from an in-house reference serum pool known to have 
high RSV titers [28].
Flow cytometric analysis of BAL cell subsets
BAL cells were isolated as described above and incubated with anti-mouse 
CD16/CD32 Fc receptor block (BD Pharmingen) at 1 µg per 2 x 106 cells 
for 10 min at 4°C. Cells were subsequently incubated with the following 
antibodies: CD3-Pacific Blue (17A2, Biolegend), CD4-APC (RM4-5, 
BD Pharmingen), CD8a-PE (53-6.7, Biolegend), CD11b-BV711 (M1/70, 
Biolegend), CD19-BV510 (1D3, BD Horizon), CD41-PE-CY7 (MWReg30, 
Biolegend), CD45-BUV395 (30-F11, BD Horizon), NKp46-BV605 (29A1.4, 
Biolegend), and Ly-6G-PE/Dazzle (1AB, Biolegend). Ultimately, cells 
were fixed in 3.7% paraformaldehyde in PBS for 10 minutes before flow 
cytometric analysis using an LSR Fortessa X20 (BD Biosciences). FlowJo 
software V10 (FlowJo, LLC) was used for data analysis. Gating strategy for 
one representative BAL sample is depicted in Supplementary Figure 1.
Albumin and cytokine/chemokine determination in BAL fluid
Albumin concentrations were determined using a mouse albumin ELISA 
(Immunology Consultants Laboratory), according to the manufacturer’s 
protocol. Cytokine concentrations in BAL samples were analyzed using 
the mouse anti-virus response panel LEGENDplex (Biolegend), according 
to the manufacturer’s protocol. Only cytokines and chemokines that 
consistently had levels above the detection threshold are depicted. 
Statistical methods
All statistical analyses were performed with Prism 7 software (GraphPad). 
Viral load, cell counts, albumin concentrations and cytokine/chemokine 
concentrations were log transformed before statistical testing. Multiple 
comparisons were analyzed using a one-way ANOVA, followed by 
Dunnett’s multiple comparisons test. P values <0.05 were considered 
statistically significant. 
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RESULTS
Passive transfer of IVIg is detectable in both plasma and lungs
To mimic infants’ waning maternal antibody levels in the absence of a 
cellular memory response, we passively transferred serially diluted IVIg 
(containing naturally induced RSV-specific antibodies) to RSV-naive mice. 
As we injected 200 µL per animal, we expect the group that received 100 mg/
mL to obtain an IVIg plasma concentration similar to healthy human adults, 
which is approximately 10 mg/mL. The other two concentrations represent 
the waning (maternal) antibody titers seen in infants. Subsequently, mice 
were challenged with RSV-A2 and sacrificed at day 3 after infection. The 
presence of IgG in blood plasma and BAL was assessed with an RSV 
antigen-specific MIA. Antibodies were readily detectable at 3 days after 
injection for the different RSV antigens: the attachment (G) protein from 
both RSV-A and RSV-B strains (Figure 1A-B), the post- and pre-fusion 
conformation of the fusion (F) protein (Figure 1C-D), and the nucleoprotein 
(N) (Figure 1E). The concentration of pre-F, post-F and N specific antibodies 
was the highest, whereas G-specific antibody levels were low, as described 
in literature [9,28]. To confirm that IV injection of IVIg results in transfer of 
RSV-specific antibodies to the site of infection, BAL samples obtained 
at 3 days after administration were also assessed. RSV-specific IgG was 
detectable in the BAL fluid at 100-fold lower concentration than in plasma, 
as exemplified for RSV pre-F- and G-specific antibodies administered at 
100 mg/ml IVIg concentration (Figure 1F). 
FIGURE 1  Passive transfer of IVIg is detectable in blood & lungs   ·      >> 
Mice were intravenously injected with 200 µL of the indicated doses of IVIg or 2 mg/mL 
Palivizumab. Subsequently, mice received intranasal inoculation with 2 x 106 pfu of live 
RSV-A2 or PBS containing 10% sucrose (mock). Mice from separate experiments are indicated 
with a distinct color. A-E. Plasma IgG levels were determined by multiplex immunoassay for 
the attachment protein (G) from both RSV-A and -B strains (A-B), the post- and pre-fusion 
conformation of the fusion (F) protein (C-D), and the nucleoprotein (N) (E). (F) Comparison of 
plasma and bronchoalveolar lavage IgG levels from animals that received 100 mg/mL IVIg 
or 2 mg/mL Palivizumab. Each dot represents six animals. All graphs depict geometric mean 
and SD. Abbreviations: AU, arbitrary units; BAL, bronchoalveolar lavage; IgG, immunoglobulin 
G; IVIg, intravenous immunoglobulin; RSV, respiratory syncytial virus.
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Currently, the only available prophylactic treatment against RSV infection 
is the administration of an F-specific monoclonal antibody (Palivizumab), 
which has been shown to reduce viral load in in vivo mouse models [29,30]. 
Therefore, we included a group receiving this antibody in our experiments 
and measured antibody levels in both plasma and BAL. The plasma and 
BAL samples of these mice showed a pre- and post-F-specific signal as 
Palivizumab binds both F protein conformations (Figure 1A-F).
Sub-neutralizing antibody concentrations increase viral load and 
pathology
A reduction in viral load was observed for animals that received high 
doses of IVIg (100 mg/mL or 10 mg/mL) or Palivizumab (Figure 2A). This 
decrease was only statistically significant in mice that received the highest 
dose of IVIg or Palivizumab. In contrast, mice that received IVIg at 1 mg/mL 
showed a statistically significant increase in viral load at 3 dpi compared to 
control animals that were infected in the absence of antibodies. Although 
the viral load showed considerable variation in this group, it was consistently 
higher than the viral load detected in the RSV-infected group that had not 
received antibodies.
FIGURE 2   Sub-neutralizing antibody concentrations enhance viral load & pathology  ·   >> 
Mice were intravenously injected with 200 µL of the indicated doses of IVIg or 2 mg/mL 
Palivizumab. Subsequently, mice received intranasal inoculation with 2 x 106 pfu of live RSV-A2 
or PBS containing 10% sucrose (mock). Mice from separate experiments are indicated with a 
distinct color. A. Viral load in mouse lung cells as determined by RT-qPCR. Geometric mean and 
SD are depicted. Viral load was log transformed before analysis by a one-way ANOVA, followed 
by Dunnett’s multiple comparisons test (*P<0.05, **P<0.01, ***P<0.001). The dotted line indicates 
the geometric mean of the RSV-infected control animals that received no antibodies. B. Mouse 
body weight with the weight at day 0 set to 100%. Each dot represents the mean weight (+/- SD) 
of the mice from both experiments within one group (n = 6). C. Albumin concentration in the BAL 
fluid was measured by ELISA. Albumin concentrations were log transformed before analysis by 
a one-way ANOVA, followed by Dunnett’s multiple comparisons test. Geometric mean and SD 
are depicted. The dotted line indicates the geometric mean of the RSV-infected control animals 
that received no antibodies. Abbreviations: AU, arbitrary units; BAL, bronchoalveolar lavage; 
IgG, immunoglobulin G; IVIg, intravenous immunoglobulin; Pali, palivizumab; RSV, respiratory 
syncytial virus; RT-qPCR, quantitative reverse transcriptase polymerase chain reaction.
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To investigate whether the enhanced viral load resulted in enhanced 
pathology, we assessed body weight loss and albumin concentrations in 
the BAL as a measure for lung damage. Mock animals showed no decrease 
in weight loss, whereas all mice that were RSV-infected showed weight 
loss at 1 dpi (Figure 2B). The weight loss was moderate for animals that 
had received no antibodies, a high concentration of IVIg, or Palivizumab. 
The most pronounced decline in weight was seen for the mice that had 
received the lowest IVIg concentrations (10 mg/mL and 1 mg/mL). In 
addition, a slightly higher mean albumin concentration was measured in 
mice that had received 1 mg/mL IVIg, but this was not statistically significant 
(Figure 2C). Taken together, viral load was higher in mice that received low 
concentrations of antibodies compared to the absence of antibodies. This 
higher viral load was accompanied by a trend towards more body weight 
loss and lung damage. 
Antibodies have only minor effects on lung inflammation at 3 dpi
The immune response is considered to be an important contributor to 
RSV-induced pathology in humans. Therefore, we next investigated 
potential differences in immunological parameters between mice in the 
presence or absence of antibodies. Both the pulmonary cellular influx and 
the secretion of cytokines and chemokines in the BAL were assessed. 
The total influx of leukocytes in the BAL was significantly increased in all 
RSV-infected compared to mock-infected mice (Figure 3A). 
FIGURE 3  Antibodies have only minor effects on pulmonary cellular influx   ·      >>
Mice were intravenously injected with 200 µL of the indicated doses of IVIg or 2 mg/mL 
Palivizumab. Subsequently, mice received intranasal inoculation with 2 x 106 pfu of live RSV-A2 
or PBS containing 10% sucrose (mock). Cells were isolated from the BAL fluid and analyzed using 
flow cytometry. Mice from separate experiments are indicated with a distinct color. Graphs depict 
absolute cell counts for A. total leukocytes (CD45+),  B. NK cells (CD3-, CD56+), C. neutrophils 
(CD3-, Ly-6G+, CD11b+), D. antigen-presenting cells (CD3-, Ly-6G-, CD11b+),  E. CD4 T cells (CD3+, 
CD4+), and F. CD8 T cells (CD3+, CD8+). Cell count data were log transformed before analysis by 
a one-way ANOVA, followed by Dunnett’s multiple comparisons test. All graphs depict geometric 
mean and SD. The dotted line indicates the geometric mean of the RSV-infected control animals 
that received no antibodies. Abbreviations: APCs, antigen-presenting cells; BAL, bronchoalveolar 
lavage; NK cells, natural killer cells; RSV, respiratory syncytial virus.
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In addition, mice that had received IVIg appeared to have slightly higher 
pulmonary leukocyte influx than mice that had received no antibodies or 
Palivizumab, although this difference was not statistically significant. This 
shows that the pulmonary leukocyte influx is independent of the viral load, 
considering that the viral load was significantly reduced in animals that had 
received a high dose of IVIg. 
To specify whether there were differences in specific cell subsets, we 
investigated the composition of the pulmonary leukocyte influx. The 
numbers of natural killer (NK) cells (Figure 3B), neutrophils (Figure 3C), 
antigen-presenting cells (APCs) (Figure 3D), and CD4+ or CD8+ T cells 
(Figure 3E-F) were all significantly increased upon RSV infection compared 
to mock infection at 3 dpi. No significant increase in B cell numbers upon 
RSV infection was detected at 3 dpi (data not shown). Except for the APCs, 
which showed similar numbers in the presence or absence of antibodies, 
all RSV-induced cell types showed a similar pattern as the total leukocyte 
influx. Of note, the presence of Palivizumab did result in a slightly reduced 
influx of NK cells, neutrophils, and APCs for some of the animals compared 
to the control animals that received no antibodies. 
Besides the pulmonary leukocyte influx, the presence of soluble 
mediators is another measure of lung inflammation. We measured the 
presence of different cytokines and chemokines that are related to the 
early response against viral infection. A clear response upon RSV infection 
was measured for CCL2, CCL5, CXCL1, CXCL10, IFN-α, IFN-γ, and TNF 
FIGURE 4  Antibodies have only minor effects on lung inflammation   ·   >>
Mice were intravenously injected with 200 µL of the indicated doses of IVIg or 2 mg/mL 
Palivizumab. Subsequently, mice received intranasal inoculation with 2 x 106 pfu of live 
RSV-A2 or PBS containing 10% sucrose (mock). Fluid from the bronchoalveolar lavage was 
analyzed using a multiplex mouse anti-virus response panel. Mice from separate experiments 
are indicated with a distinct color. A-G. Only cytokines and chemokines that showed a 
response upon RSV infection are depicted. Cytokine concentrations were log transformed 
before analysis by a one-way ANOVA, followed by Dunnett’s multiple comparisons test 
(***P<0.001). Geometric mean and SD are depicted. The dotted line indicates the geometric 
mean of the RSV-infected control animals that received no antibodies. Abbreviations: BAL, 
bronchoalveolar lavage; CCL, CC chemokine ligand; CXCL, CXC chemokine ligand; IFN, 
interferon; RSV, respiratory syncytial virus; TNF, tumor necrosis factor.
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(Figure 4A-G). No significant upregulation was seen for IL-12, IL-1β, and 
GM-CSF and levels of IL-10, IFN-β, and IL-6 were below detection level 
(data not shown). The mean concentrations of CXCL1, CCL2, CXCL10, TNF, 
and IFN-α were slightly increased in the presence of IVIg compared to 
controls, but this difference was not statistically significant. Comparable to 
the cellular influx in the BAL, some of the animals that received Palivizumab 
showed decreased CCL2, CCL5 and IFN-γ levels. In summary, these 
results suggest that both the leukocyte influx and the concentrations of 
the assessed soluble mediators in the BAL at 3 dpi are independent of the 
viral load. 
DISCUSSION
In this study, we evaluated an in vivo mouse model for RSV infection in 
infants, in which we mimic the waning of transplacentally transferred 
maternal IgG through the intravenous injection of serially diluted IVIg. 
Using this in vivo model, we demonstrate that animals that received low 
concentrations of IVIg show higher RSV viral load and possibly pathology, 
as measured by a slight increase in weight loss after infection. To our 
knowledge, this provides the first in vivo indications of enhancement of 
RSV infection and disease by antibodies induced by natural RSV infection. 
It must be noted that this has only been investigated at 3 dpi and no clear 
correlation with inflammation was found. Therefore, follow-up research 
to corroborate our findings is urgently needed, as this would have major 
implications for preventive measures such as (maternal) vaccination.
ADE of infection is a well-studied phenomenon in vitro for multiple viruses 
(as extensively reviewed in [31]). For RSV, both monoclonal antibodies and 
RSV-immune serum have been shown to induce ADE of infection in vitro 
in a range of FcγR-expressing (primary) cells [22,23,25,26,32]. However, 
only for dengue virus, mouse models have demonstrated ADE of infection 
and ADE of disease in vivo [33-35]. It was shown that the presence of 
dengue-specific antibodies led to enhanced systemic virus levels and 
increased disease severity in mice [33]. In addition, enhanced dengue 
disease was found in the presence of maternally acquired dengue-specific 
antibodies, indicating a role for maternal antibodies in ADE of dengue 
virus infection in mice [35]. Recently a large long-term pediatric cohort 
in Nicaragua supported these mouse studies by demonstrating that 
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high dengue-specific antibody titers correlate with protection, whereas 
intermediate antibody titers correlate with severe dengue disease in 
humans [36]. 
In the current study, we use human IVIg in a mouse model. Previous 
studies have shown that human IgG can bind mouse FcγRs and can 
induce cellular effector functions in wild-type mice [37,38]. Additionally, it 
was shown that human IgG interacts with the mouse neonatal Fc receptor, 
resulting in a similar half-life of human IgG in mice and humans [39]. 
However, it is debated whether mouse Fc receptors mediate similar effector 
functions as human Fc receptors [40]. Besides RSV-specific antibodies, 
IVIg contains antibodies with a broad range of specificities. Although 
we expect the effect on RSV viral load and pathology to be caused by 
RSV-specific antibodies, we cannot rule out effects by other antibodies. 
Efforts to deplete IVIg of RSV-specific antibodies are ongoing. 
In accordance with previous studies [41,42], our results show that 
RSV-specific antibodies are readily transferred from the blood to the 
lung lumen and can be detected in the BAL, albeit in 100-fold lower 
concentrations than in plasma. These data highlight that the presence of 
neutralizing antibody titers in plasma does not guarantee the presence of 
neutralizing titers in the lungs, which is the primary site of infection for RSV. 
Therefore, it is essential to realize that measuring the neutralizing capacity 
of antibodies in the plasma only provides limited information about the 
local neutralizing response in the lungs. 
In our study, we observed a reduction of viral load in the presence of 
high IVIg concentrations, while pulmonary cellular influx and secretion of 
inflammatory cytokines and chemokines remained high. This indicates 
that the inflammatory parameters we measured are independent of viral 
load. Earlier studies in cotton rats have also shown decreased viral titers 
in the presence of monoclonal antibodies, accompanied by a lack of 
decrease in inflammation markers [43,44]. The mechanisms underlying 
severe RSV disease are unclear, but both heightened viral load [45-47], 
as well as a pathological excessive immune response [48] are thought to 
play a role in severe RSV disease. Although many studies exclusively look 
at decreased viral load for effectiveness of monoclonal antibodies and 
vaccines, our observations indicate that the immune response should also 
be monitored. Interestingly, the mice that received Palivizumab show lower 
pulmonary cellular influx and lower secretion of cytokines and chemokines 
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compared to the 100 mg/mL IVIg group, while both these groups 
demonstrated a reduction in viral load. This substantiates earlier findings 
that the functionality of Palivizumab is different from other RSV-specific 
(monoclonal) antibodies [49].  
Our data indicate that the viral load is enhanced in the absence of an 
apparent increase in the immune response, as judged by pulmonary 
cellular influx and a limited number of cytokines/chemokines. Potential 
limitations of our experimental set-up were the assessment of viral and 
immunological parameters at a single time point (3 dpi) and the absence 
of histopathological analysis of the lungs. Inclusion of earlier and later 
time points will elucidate the kinetics of the viral replication and immune 
response against RSV in the presence or absence of antibodies. This will 
indicate whether the higher viral load at low antibody concentrations is a 
result of enhanced infection or reduced viral clearance. In addition, it would 
be of added value to take along a group that received IVIg depleted of 
RSV-specific antibodies to prove the effect on viral load and pathology 
is caused by RSV-specific antibodies. Lastly, mainly the immunological 
parameters show considerable variation between experiments, which 
could reflect differences in the ovarian cycle phase [50,51]. Therefore, 
additional experiments should be performed in male mice.
In conclusion, we have developed a model to study ADE of RSV infection 
and disease in vivo. We demonstrate that the presence of sub-neutralizing 
levels of RSV-specific IgG in the lungs can modify the course of infection, 
resulting in higher viral load and possibly also increased pathology. 
Additional studies are needed to confirm these findings and unravel the 
mechanisms underlying these effects. To date, (pre-)clinical tests for RSV 
vaccines often only demonstrate induction of (neutralizing) antibodies in 
plasma. In light of the findings presented in the current study, it should 
be reconsidered whether such a limited assessment of the response to 
vaccination and infection is appropriate.
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GENERAL DISCUSSION  
AND  
FUTURE PERSPECTIVES
Why does a minority of infants develop severe 
disease after RSV infection, whereas the majority 
remains asymptomatic or only develops mild illness?
 
The question above is one of the most important unanswered questions 
in the RSV field. It has occupied RSV researchers since the discovery of 
the virus and forms the basis of this PhD project. Hospitalization for severe 
RSV disease peaks in the first 6 months of life [1,2]. During these months, 
infants mainly rely on both their innate immune system and maternally-
derived antibodies for protection. Maternal vaccination is considered as a 
potential strategy to prevent RSV disease in infants, therefore, it is of pivotal 
importance to obtain a thorough understanding of the mechanisms 
by which maternal antibodies can protect against severe disease, both 
directly and through their interaction with innate immune cells. It has been 
suggested that high IgA levels in the upper respiratory tract contribute 
to protection in adults [3]. In infants, a local protective effect of IgA in the 
upper respiratory tract could be achieved by passive transfer through 
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breastmilk [4-6]. However, it is debated whether IgA is the main protective 
determinant in breastmilk [7]. If antibody levels in the upper respiratory 
tract are not high enough, RSV infection can disseminate to the lower 
respiratory tract (Figure 1). Maternal IgG is present in the lower respiratory 
tract through neonatal Fc receptor (FcRn)- mediated transepithelial 
transport [8]. High pulmonary antibody levels can neutralize disseminating 
viral particles and protect against infection. However, low or intermediate 
antibody levels result in incomplete neutralization, followed by infection of 
lung epithelial cells and recruitment of immune cells. These events lead 
to the presence of virus-infected cells, antibodies and immune cells in 
the lungs, creating the perfect niche for Fc-mediated antibody effector 
functions. Whether these effector functions are protective or detrimental to 
the host depends on the degree of activation, which is partly determined 
by antibody characteristics. However, research on this topic is lacking 
in the RSV field. In this thesis, we have explored differences in maternal 
antibody functionality that potentially explain the variation in susceptibility 
to severe disease.
FIGURE 1  Interaction between RSV and (local) antibodies in infants   ·       >>
Upon infection, RSV first encounters local antibodies present in the upper respiratory tract 
(URT). The main antibody subclasses in the mucosa are IgA and IgG that infants obtain through 
breastfeeding. High mucosal antibody levels will neutralize the virus and protect the individual 
from infection. Low or intermediate antibody levels will bind the virus in a non-neutralizing 
manner, resulting in infection of the URT and dissemination to the lower respiratory tract (LRT). 
Maternal IgG is transferred from the blood to the LRT via the neonatal Fc receptor (FcRn). High 
pulmonary IgG levels will neutralize the virus and protect from infection. Low or intermediate 
pulmonary antibody levels do not neutralize the virus, which leads to the infection of airway 
epithelial cells. RSV-infected cells will secrete cytokines and chemokines, resulting in the 
recruitment of immune cells to the lungs. The presence of virus-infected cells, antibodies, and 
immune cells creates a favorable environment for Fc-mediated antibody effector functions. 
A balanced activation of these effector functions is important, as immune complexes can 
induce viral clearance leading to mild disease. However, immune complexes can also induce 
an inappropriate immune response, resulting in inflammation and severe disease.
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THE ROLE OF MATERNAL ANTIBODIES IN RSV INFECTION: 
EMPHASIS ON FUNCTIONALITY AND IMPLICATIONS IN DISEASE
For nearly all licensed vaccines, antibodies are the presumed correlate 
of protection, but the underlying mechanisms of protection often remain 
unknown [9]. Interestingly, in addition to binding and neutralization, 
antibodies induce Fc-mediated effector functions. However, this potential 
area of research has been underappreciated in the RSV field. With Chapter 
2, we aimed to encourage a paradigm shift from neutralization-based 
studies toward functional studies examining the precise role of Fc-mediated 
antibody effector functions in vaccine efficacy and RSV disease. Only 
a few studies have used FcγR-knockout mice or modified RSV-specific 
antibodies to elucidate the importance of Fc-mediated effector functions 
in protection from RSV infection and disease [10-13]. However, data on the 
effect of antibody functionality in natural RSV infection in humans is lacking 
and most studies into vaccine and monoclonal antibody efficacy only 
report antibody (neutralization) titers and disregard Fc-mediated effector 
functions.
To investigate maternal antibody characteristics that potentially play 
a role in RSV disease, we employed a case-control study, as described 
in Chapter 3. This study included RSV patients, RSV-negative infection 
controls, and uninfected controls below 7 months of age. Using a multiplex 
immunoassay, we measured plasma IgG levels specific for different RSV 
antigens. We did not detect a correlation between these antibody levels 
and RSV hospitalization. These results are in accordance with an earlier 
study that found no correlation between RSV disease severity and antibody 
levels, avidity, and neutralization using a subset of these samples [14]. To 
investigate the involvement of Fc-mediated antibody effector functions, 
we developed an assay to measure the capacity of RSV-specific maternal 
antibodies to induce natural killer (NK) cell activity. We used this assay to 
demonstrate that RSV-specific antibodies, particularly those targeting the 
G protein, induce NK cell CD107a surface expression and interferon gamma 
(IFN-γ) production. The capacity of maternal antibodies to induce IFN-γ 
production was lower in infants with severe respiratory tract infections 
compared to uninfected controls. Importantly, the capacity to induce NK 
cell activity was highly variable within the groups indicating that research 
into additional factors is required. 
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Fc-mediated antibody effector functions during viral infection do not only 
contribute to protection, but they can also facilitate infection. Antibodies 
can target viruses to Fc gamma receptor (FcγR) expressing cells, thereby 
increasing the number of infected cells. This phenomenon is called 
antibody-dependent enhancement (ADE) of infection and has been 
demonstrated in vitro to occur for multiple viruses [15]. Our studies showed 
that sub-neutralizing concentrations of RSV-specific maternal antibodies 
induce ADE of infection in vitro and have reduced neutralization capacity 
on FcγR-carrying cells (Chapter 4). Antibodies from formalin-inactivated 
(FI-) RSV-immunized cotton rats showed no neutralization, but were 
potent inducers of ADE of infection in vitro. Although the antibodies from 
all infants in our cohort had the capacity to cause ADE of infection in vitro, 
there was no correlation with disease severity. Multiple studies show the 
presence of RSV in FcγR–expressing cells in vivo [16-18], indicating that 
ADE of infection should not be ignored as a possible player in RSV disease. 
RSV infection of immune cells may have multiple effects, ranging 
from activation to shutting down cellular effector functions. Any of 
these effects could lead to the known contribution of immune cells to 
immunopathology in severe RSV-mediated disease. We were able to 
demonstrate that RSV-infected NK cells are more prone to produce IFN-γ 
than uninfected cells, whereas the cytotoxic response is not increased 
(Chapter 5). Moreover, we show that ADE of NK cell infection augments 
the effect on IFN-γ production and even inhibits the cytotoxic response. 
This detrimental combination may contribute to RSV immunopathology 
in vivo, but more research is needed to support this hypothesis. RSV is not 
the only virus known to infect NK cells (Chapter 6). The fact that multiple 
viruses can infect NK cells suggests that this feature can contribute to 
the establishment of a successful infection. It is essential to expand our 
knowledge on possible cellular targets and reservoirs of viral infections, as 
the development of specific therapeutics could benefit from studies into 
viral infection of different cell types. 
Thus far, all the assays we have used in the aforementioned chapters 
were in vitro cell-based assays. However, to investigate the in vivo relevance 
of antibody effector functions, we have set up an RSV infection mouse 
model. Initially, we compared the effect of intratracheal versus intranasal 
inoculation and demonstrated striking differences with respect to 
pathological and immunological read-outs (Chapter 7). These differences 
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FIGURE 2  Summary of the chapters in this thesis   ·
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may be explained either by differences in the (initial) site of infection or the 
differential use of anesthetics. Based on our findings, intranasal inoculation 
appears to be better suited to study RSV-induced immunopathology than 
intratracheal inoculation. Using this model to study ADE of RSV infection 
and disease in vivo, we demonstrate that the presence of sub-neutralizing 
levels of passively transferred human IgG in the lungs can modify the 
course of infection, resulting in higher viral load and possibly increased 
pathology (Chapter 8). Studies are ongoing to further substantiate these 
findings and unravel the mechanisms underlying these effects. Figure 2 
gives a summary of the different chapters in this thesis. 
RSV DISEASE IS MULTIFACTORIAL
There is much debate on the factors that contribute to severe RSV disease, 
which is characterized by an inappropriate immune response. Despite 
extensive research efforts, the underlying cause of the excessive immune 
response remains unknown. In this thesis we point out that antibodies are 
important modulators of the immune response (Chapter 2), which can 
play both a protective (Chapter 3) and enhancing role in RSV infection 
and disease (Chapter 4, 5 and 8). Nevertheless, it is most likely that the 
underlying cause for the dysregulated immune response is multifactorial 
and driven by additional factors besides antibodies.  
Multiple mouse studies have investigated the role of T cells in the 
induction or prevention of severe RSV disease. Despite the importance of T 
cells in viral clearance, they are paradoxically also suggested to contribute 
to tissue injury [19]. Early experiments in mice showed that the transfer 
of an RSV-specific T cell line enhanced lung pathology [20]. In addition, 
disease after primary infection was diminished by depletion of CD8+ T cells 
[21]. Also in reinfection studies, the pathological role of (memory) CD8+ T 
cells has been indicated [21-23]. However, it is unlikely that (memory) T cell 
responses play a major role in severe RSV disease, because hospitalization 
most frequently occurs below six months of age when the adaptive immune 
response does not yet generate an effective antiviral (memory) response 
[24]. It is possible that maternal antibodies are involved in the skewing of the 
T cell response, as RSV-antibody immune complexes have been shown to 
affect the CD4+/CD8+ T cell balance [25]. Disturbance of this balance could 
lead to an exaggerated immune response, resulting in severe disease.
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The frequent presence of co-infections may be another underlying 
cause of the dysregulated immune response during severe RSV disease. 
Invading pathogens may contribute to an inflammatory milieu that skews 
the response to an RSV infection. In our cohort, 35% of the hospitalized 
RSV patients also had other detectable viral pathogens (Chapter 3). 
Bacterial co-infections were not recorded, but are most probably present 
in a subset of infants as well. There is increasing interest in the influence 
of the (respiratory) microbiome on infections and the immune response 
during an RSV infection, as extensively reviewed by Vissers et al. [26]. A 
recent study has demonstrated that clinically significant lower respiratory 
tract infections result from the interplay between host characteristics 
and (viral and bacterial) respiratory microbiota [27]. In addition, this study 
suggested that the nasopharyngeal microbiota can serve as a valid proxy 
for the lower respiratory tract microbiota, enabling the use of less invasive 
techniques to study the local microbiota. Future studies are needed to 
unravel the role of the local respiratory (microbial) environment in causing 
severe RSV disease. 
The immunological response after RSV infection may also be affected 
by age. RSV disease is most frequently seen in the youngest infants, when 
maternal antibodies are still present. At a certain age, maternal antibodies 
will be completely gone, but this does not seem to predispose to more 
disease. Older children may be able to mount a more robust immune 
response against RSV infection and recover more quickly, even in the 
absence of any pre-existing immunity. Age may therefore be an important 
co-factor for RSV disease. Age in this respect is not just “time since birth”, 
but biological age, indicating the level of maturity of the immune system, 
the respiratory tract, and probably many other factors.
Taken together, many factors potentially influence disease outcome after 
an RSV infection. As long as we do not have conclusive knowledge on 
the underlying causes of severe RSV disease, the multifactorial nature of 
RSV disease should be taken into consideration when developing model 
systems and analyzing test results.
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THE NEED FOR AN UPDATE OF PRE-CLINICAL MODELS
The development of vaccines against RSV infection is of great importance, 
especially for developing countries where RSV-related mortality is high 
and passive immunization with monoclonal antibodies is inaccessible due 
to high costs. There is an extensive pipeline of vaccines that are being 
tested in different phases of clinical development (https://www.path.
org/resources/rsv-vaccine-and-mab-snapshot/). However, despite the 
major research efforts to develop effective vaccines, no candidates have 
gained market-approval so far. The high failure rate of vaccine candidates 
is not limited to the RSV field, as recent estimates indicate that only 33% 
of total vaccine candidates that enter phase 1 clinical trials reach market-
approval [28]. The success rate is even more dramatic when including all 
pre-clinically tested vaccine candidates, with only 6% reaching the market 
[29]. High failure rates are in part due to the use of pre-clinical models that 
do not accurately represent the in vivo situation. Therefore, improvement of 
pre-clinical tests is highly needed, especially in the RSV field. 
Antibody neutralization tests for RSV: opportunities for improvement
The golden standard for testing the neutralization capacity of RSV-specific 
antibodies, is the plaque reduction neutralization test (PRNT) [30]. This 
assay is mostly performed on Vero or HEp2 cells [31]. Both these cell lines 
do not resemble the natural target cells for RSV, which are airway epithelial 
cells. The RSV entry receptor on cell lines is heparin sulfate [32], which is not 
detected on the apical surface of human airway epithelial (HAE) cultures. 
In these physiologically relevant HAE cultures, CX3CR1 serves as entry 
receptor for RSV [32]. In addition, HAE cells have been shown to express 
FcγRs [33], suggesting that sub-neutralizing antibody concentrations can 
potentially lead to ADE of infection in the human lungs. As Vero and HEp2 
cells do not express endogenous FcγRs, assessing antibody neutralization 
capacity on these cells does not consider the effect of FcγRs, which have 
been shown to reduce neutralization when expressed on Vero cells 
(Chapter 4).
The discrepancy in the neutralization capacity between cell lines 
and primary cells is well illustrated by experiments with RSV G-specific 
antibodies. Whereas most RSV G-specific antibodies are unable to 
neutralize RSV infection in immortalized cell lines, these antibodies 
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are potent inhibitors of infection in primary HAE cultures and in in vivo 
mouse models [32,34-36]. This striking example indicates that a new 
physiologically relevant model to study antibody neutralization is highly 
needed. The use of primary HAE cultures in neutralization assays is 
impractical as these cells demand long differentiation protocols and 
batches are highly variable due to donor and differentiation differences. 
Therefore, future research should focus on identifying or constructing cell 
lines that mimic the human airway epithelium and express all relevant 
entry receptors for RSV.
In most studies, antibodies originating from the serum are used 
to measure the neutralizing capacity after infection or vaccination. In 
accordance with previous studies, we have shown in Chapter 8 that local 
IgG levels, present in the bronchoalveolar lavage of mice, are approximately 
100-fold lower than serum IgG levels. We have also shown in Chapter 4 
and 5 that sub-neutralizing concentrations of antibodies may lead to ADE 
of infection. Maximum enhancement is achieved with 1000-fold serum 
dilutions, which are concentrations with physiological relevance at the 
site of infection. Infants that have neutralizing antibody concentrations in 
their serum could therefore potentially experience ADE of infection in the 
respiratory tract. Our in vivo mouse model, described in Chapter 8, provides 
indications for enhanced viral load in the bronchoalveolar lavage (BAL) of 
mice that received a low concentration of IVIg. The concentration in the 
BAL was 100-fold lower than in the plasma, reaching sub-neutralizing, 
potentially enhancing concentrations at the site of infection. Consequently, 
high serum antibody levels are needed to achieve local protection in the 
respiratory tract. Thus, neutralizing concentrations in the blood are not 
necessarily a guarantee of neutralizing concentrations at the site of infection. 
The measurement of local antibody levels in humans is complicated by 
the lack of non-invasive techniques to sample the lung lumen. However, 
increased knowledge about antibody transfer rates to the lungs after 
RSV infection or vaccination could benefit the interpretation of serum 
neutralization titers. In addition, it should be investigated whether nasal 
samples can be used as a proxy for lung antibody levels, as this facilitates 
less invasive sampling techniques. Of note, the expression of FcRn, which 
facilitates IgG transport to the lungs [8], varies depending on the region 
in the respiratory tract and may thus lead to differences in local antibody 
levels [37]. 
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Towards a systems serology approach
Conventional neutralization tests have proven valuable for RSV research in 
the past. However, RSV-specific neutralization titers correlate poorly with 
protection for reasons described above. Moreover, additional mechanisms 
by which antibodies may confer protection against RSV need to be 
investigated. Mounting evidence suggests that antibody effector functions 
beyond neutralization can contribute to both protection and disease 
during RSV infection [10-13]. A balanced activation of different antibody 
effector functions is essential to prevent excessive inflammation and tissue 
damage (Chapter 2). It will be of importance to implement RSV-specific 
assays that determine the functionality of monoclonal and vaccine-
induced antibodies. 
The NK cell activation assay described in Chapter 3 determines the 
capacity of antibodies to induce NK cell CD107a surface expression 
and IFN-γ production. However, this assay is performed with primary 
human peripheral blood mononuclear cells (PBMCs), complicating 
standardization and high-throughput applications. This limitation can be 
overcome by the use of NK cell lines that express FcγRIIIA, which have been 
developed to study antibody-dependent NK cell responses against tumor 
cells [38]. In addition, these cell lines were also shown to be successful in 
studying influenza virus-specific NK cell activation [39]. The development 
of additional functional assays is of importance for the evaluation and 
development of future vaccines. This will potentially provide insight in the 
difference between protective and detrimental antibody profiles in RSV 
disease.
To comprehensively assess a broad range of antibody characteristics and 
functions, a systems serology approach can be used. Systems serology 
systematically surveys humoral immune responses, capturing a broad 
range of antibody characteristics and functions [40,41]. It consists of multiple 
high-throughput in vitro assays, followed by computational methods to 
examine the multiple layers of information. Antibody characteristics that are 
assessed include subclass, isotype, glycosylation, epitope specificity, and 
affinity (for the antigen as well as the Fc receptor). The functional assays 
in these approaches often measure the extent of neutralization, NK cell 
activation (IFN-γ and MIP-1β secretion, and CD107a surface expression), 
antibody-dependent cellular phagocytosis (ADCP) by both monocytes 
and neutrophils, complement deposition, and cytokine release by various 
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immune cells [40,41]. However, numerous additional factors may be taken 
into account, as up to 70 humoral features have been measured within 
one study [42]. The incorporation of all these factors together allows for 
the identification of features or patterns within the antibody response that 
distinguish protective from non-protective immunity. 
A systems serology approach has been used to identify antibody 
features that contribute to protection against Ebola virus infection [43]. In 
addition, this approach was used to distinguish between patients with 
latent tuberculosis infection and active tuberculosis disease [42]. Both 
studies demonstrate that the integration of multiple characteristics and 
functionalities is needed, as no single assay was able to predict protection. 
In addition to the unbiased evaluation of multiple factors at once, the 
requirement of only low amounts of sample is another benefit of a systems 
serology approach. This allows profound analysis of precious samples 
with only limited volume, such as those from infants. Of course, systems 
serology leads to the acquisition of enormous amounts of data, indicating 
the need for researchers that are skilled in bio-informatics and modelling. 
The demand for these skills will only grow as the generation and availability 
of big data will rapidly increase in the future.
Systems serology is still in its early developmental stages. New insights 
in antibody functionality and improved analytical methods will contribute 
to the improvement of the technique. The broader the range of antibody 
features that is included, the more comprehensive our understanding of 
desirable antibody profiles will be. This will help to guide rational design 
of future vaccine candidates. An important antibody feature that has not 
been included in systems serology approaches so far is the binding 
capacity to FcRn. FcRn extends the half-life of serum antibodies [44] and 
is essential in the transport of antibodies across the lung epithelium [8]. 
Determining the FcRn binding capacity may therefore provide important 
clues about local antibody levels in the lungs. Another antibody feature 
that should be included is specificity at an epitope level. A method recently 
developed by Xu et al. has revolutionized high throughput serological 
profiling, allowing the identification of the complete antibody response at 
epitope level [45]. This approach has recently been used to demonstrate 
that preterm and term infants receive a comparable repertoire of maternal 
RSV-specific antibodies, although preterm infants receive a lower amount 
of these maternal antibodies [46]. Incorporating this “Virscan” method in a 
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systems serology approach could provide essential information about the 
difference between a beneficial and detrimental antibody specificity profile. 
Tailor-made animal models for the investigation of antibody effector 
functions
Much of the information on the RSV immune response comes from 
animal models, due to the difficulty to study the immune response against 
RSV in infants because of both ethical and practical considerations. The 
limited information that is available originates from the most severe cases 
that require hospitalization, which may not be representative for the mild 
disease seen in most infants. Moreover, by the time of hospitalization, the 
trigger for severe disease may already be gone. In addition, investigating 
the local immune response is challenging, as sampling the response in the 
respiratory tract is invasive and challenging in infants that suffer from RSV 
disease. This makes it necessary to use animal models to investigate the 
immune response against RSV.  
The most widely used animal models are inbred mouse strains, because 
of the availability of immunological reagents as well as the possibility to 
genetically modify these animals. However, most inbred mouse strains, 
including the widely used BALB/c and C57Bl/6 mice, are only semi-
permissive hosts for RSV infection. Mice need a high viral inoculum to 
detect any lower respiratory tract disease symptoms and general measures 
of illness such as weight loss [47,48]. In addition, the innate and adaptive 
immune responses after RSV infection differ greatly between humans and 
mice. For example, mice show a limited recruitment of neutrophils to the 
lungs, whereas neutrophils are the most abundant cell type during human 
RSV infection [47,49]. Another important discrepancy between natural 
infection in humans and experimental infection in mice is the presence 
of RSV-specific antibodies. RSV infections in humans practically always 
occur in the presence of (maternal) RSV-specific antibodies, whereas 
most mouse studies are performed in RSV-naïve mice. The presence of 
antibodies can have a major influence on RSV infection, as we have shown 
in Chapter 8, and should therefore not be ignored when using RSV-naïve 
mouse models. 
There are considerable differences in FcγR expression and affinity 
between mice and humans. To assess antibody functionality in vivo, the use 
of mice with a humanized immune system (HIS) or mice with humanized 
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FcγRs may ease the translation between mouse studies and the response 
in humans. HIS mice are generated by the introduction of human HLA 
class II genes, various human cytokines, and human B cell activation factor 
into non-obese diabetic/severe combined immunodeficiency gamma 
mice, followed by engraftment of human hematopoietic stem cells [50]. 
Sharma et al. demonstrated that HIS mice mimic RSV disease in humans 
and induce human anti-RSV antibody responses [51]. However, further 
development of this mouse model is needed, as the CD8+ T cell response 
in these mice is nonfunctional. In addition, use of HIS mice in functional 
antibody studies neglects the biological functions of human FcγRs at sites 
other than immune cells. Expression of FcγRs on nasal epithelial cells has 
recently been demonstrated [33] and may be of importance in respiratory 
infections in the presence of pre-existing (maternal) antibodies. Therefore, 
the use of transgenic mice expressing human FcγRs may be superior in 
translational research into antibody effector functions [52]. However, the 
currently available transgenic mouse models do not express all human 
FcγRs [53], indicating that also for this mouse model further development 
is needed. To our knowledge, no attempts to investigate RSV antibody 
effector functions in transgenic FcγR mice have been published.
Although most widely used, mice are not the only available animal model 
in the RSV research field. Cotton rats have been instrumental in the testing 
of vaccines and monoclonal antibodies  [54]. They are approximately 
100-fold more permissive to RSV infection than BALB/c mice and show 
vaccine-enhanced disease after immunization with FI-RSV [55]. However, 
cotton rats do not develop clinical signs of disease after natural infection and 
species-specific (immunological) reagents and molecular tools are lacking, 
impeding mechanistic studies of RSV immunity in this animal model. The 
downside of the semi-permissive nature of human RSV infection in animal 
models can be solved by the use of related non-human pneumoviruses 
in their native host. Although studies with bovine RSV (BRSV) and 
pneumonia virus of mice (PVM) have increased our understanding of viral 
pathogenesis (as reviewed in [56]), the differences between the species-
specific immune responses limit the relevance to RSV disease in humans. 
Additionally, transfer of maternal antibodies to calves exclusively takes 
place via the colostrum [57], indicating that cattle are an unsuitable model 
to study the role of (vaccine-induced) maternal antibodies.
Besides the necessity to use tailor-made animal models for specific 
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research questions, also the reporting in these experimental models 
urgently needs improvement. Most animal studies on vaccine or antibody 
responses only report on inhibition of viral load, whereas an excessive 
immune response has also been suggested to contribute to severe 
disease. Measures of immunopathology such as pulmonary cellular 
influx, lung damage, local cytokine and chemokine secretion, or immune 
cell activation should be included.  In our studies, we have shown that 
viral load is lower in the presence of high dose IVIg but both pulmonary 
cellular influx and cytokine responses remain high, indicating that viral 
load and immunopathology are not always associated (Chapter 8). These 
findings are in accordance with studies in cotton rats, showing decreased 
viral load but no decrease in inflammation markers in animals that received 
Palivizumab [58,59].
As described above, animal models of RSV do not mimic all aspects 
of human disease, which may hamper investigation of the RSV immune 
response. Investigation of hospitalized infants allows the observation of 
natural disease, but does not provide insight in the immune status before 
infection and its correlation with susceptibility. Due to the mild symptoms 
of natural RSV infection in healthy adults, experimental human challenge 
models can be used to offer important insights in pre-existing immunity 
and the kinetics of the (early) immune response. Experimental RSV 
infection of healthy adults has elucidated the protective effect of mucosal 
IgA responses and indicated that a defective IgA B cell memory explains the 
recurrent RSV infections seen throughout life [3,60]. To study RSV-specific 
(protective) immune responses during natural infection, the human 
challenge model is the ultimate model. However, as challenge models only 
include well-informed adult volunteers, primary infections in presence of 
maternal antibodies, but in absence of a cellular memory response, cannot 
be mimicked. In addition, depletion and knockout studies are instrumental 
to unravel the contribution of specific factors to protection and disease. 
Therefore, animal models are still irreplaceable in this respect.
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DEVELOPMENT OF FUTURE VACCINES
Thus far, no RSV vaccine candidates have proven successful enough 
for market-approval. As described above, preclinical testing needs 
improvement to recognize promising vaccine candidates more efficiently. 
In addition, research efforts into potential correlates of protection and 
rational vaccine design are highly necessary. 
The lack of accurate correlates of protection hampers the development 
of new vaccines, as efficacy now has to be demonstrated in expensive 
large-scale clinical trials. It is important to realize that natural RSV infection 
only temporarily protects against re-infection by the induction of a short-
lived protective mucosal IgA response [3,60]. Natural infection apparently 
does not induce a long-lived protective immune response, indicating that 
we may need to look at clinical trials with various vaccine concepts to find 
potential correlates of protection. Most importantly, this demonstrates that 
future vaccines need to induce a superior immune response compared to 
natural RSV infection. Increasing knowledge on the distinction between 
protective and detrimental immune responses will help in the rational 
design of vaccines.
Lessons for vaccine design
The majority of vaccine candidates currently in clinical trials are designed 
to induce systemic (neutralizing) antibodies, mostly against the RSV F 
protein. As described earlier in this chapter, this presents multiple problems. 
First, vaccine-induced antibodies need to be tested for more functional 
characteristics than just neutralization capacity. A more polyfunctional 
antibody response may contribute to protection against infection as has been 
shown in HIV vaccine trials [61-63]. Second, systemic antibody characteristics 
are not necessarily representative for local lung antibodies. Only certain 
antibody isotypes and subclasses are readily transferred across the lung 
epithelium, and lung antibody levels are approximately 100-fold lower than 
serum antibody levels (Chapter 8). In addition, RSV-specific locally-derived 
(adenoid) antibodies have higher binding affinity and neutralizing capacity 
compared to antibodies from the blood [64]. Whether there are additional 
functional differences between serum antibodies and local antibodies in the 
lungs remains to be determined. An efficacious vaccine should induce a 
preferably long-lasting, local antibody response in the lungs and/or induce 
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antibodies that readily bind FcRn and are efficiently transported from the 
serum. Third, the recent failures of two (post-) F-specific vaccine candidates 
tested in elderly, show that a broader specificity of the immune response may 
be needed to confer protection against RSV-mediated disease [65] (press 
release Novavax, September 15, 2016). The RSV G protein has long been 
ignored as a potential vaccine antigen, but is now increasingly recognized 
as a critical target in vaccine development [66]. The G protein was shown 
to be a target for broadly neutralizing antibodies [36,67] and G-specific 
antibodies are the major contributors to NK cell activation (Chapter 3) 
[68]. Besides its involvement in the attachment of viral particles to target 
cells, the G protein is known to modulate the immune response through 
interaction with CX3CR1 [69]. The induction of G-specific antibodies may 
thus be important to reduce immunomodulation by the RSV G protein. With 
currently as many as 21 different vaccine candidates in clinical trials (https://
www.path.org/resources/rsv-vaccine-and-mab-snapshot/), the results 
of these studies will provide us with additional clues for the design of an 
effective RSV vaccine.
Infants as target population: The rationale for maternal vaccination
Most of the current RSV vaccine candidates have a pediatric target 
indication. However, vaccination at this young age has several downsides. 
The generation of T and B cell memory in infants is poor due to impaired 
antibody affinity maturation and less efficient antigen presentation, resulting 
in inappropriate adaptive immunity after early vaccination [24]. Thus, 
multiple vaccinations will be necessary to induce an adequate immune 
response. In addition, the presence of maternal antibodies may inhibit the 
vaccine response at an early age, as they may have an immunosuppressive 
effect on the (humoral) immune response against RSV [70-73]. An 
alternative strategy to protect infants at early age is the vaccination of 
pregnant women, which will boost the mother’s antibody response as 
illustrated in Figure 3. This will lead to an increased transplacental transfer 
of specific antibodies to the blood of the unborn child. Increased serum 
antibody levels result in increased lung antibody levels, which can provide 
passive immunity during the first months of life. A study investigating the 
decline of naturally acquired RSV-specific maternal antibodies suggested 
that maternal vaccination could provide protection in infants for at least 
3 – 6 months [74]. 
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FIGURE 3  Mechanism of transfer of vaccine-induced maternal antibodies   ·   
Vaccination during pregnancy will boost the maternal immune response leading to increased 
levels of vaccine-induced immune cells and antibodies in the maternal blood. The neonatal 
Fc receptor (FcRn) facilitates the transfer of IgG from maternal blood to fetal blood. Immune 
cells are not able to cross the placental barrier, therefore, the unborn child will only receive 
humoral maternal immunity.
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To date, two maternal anti-RSV vaccines have been tested in clinical 
trials. The first vaccine candidate was an adjuvanted purified F protein, 
which was reported to be safe and well tolerated [75]. However, a more 
immunogenic vaccine was desired as the functional neutralizing antibody 
response was disappointing. The other vaccine candidate is an alum-
adjuvanted F protein nanoparticle vaccine [76]. This recombinant F 
protein has a prefusion-‘like’ conformation (Smith 2012) (https://novavax.
com/download/files/presentations/NOVAVAX-WVC_RSV_2018APR3-
FINAL.pdf). The only outcome measures for the phase 2 clinical trial were 
anti-F IgG antibody titers, Palivizumab-competitive antibody levels, and 
microneutralization titers [77]. No additional antibody characteristics or 
functions were reported. The first results of the phase 3 clinical trial show 
that the primary efficacy endpoint (reduction of medically-significant 
RSV lower respiratory tract infection) was not met (https://novavax.com/
presentation.show). However, the vaccine did demonstrate a significant 
reduction in hospitalization and severe hypoxemia. An interesting finding 
that warrants further investigation is the geographic imbalance in efficacy: 
whereas vaccine efficacy appeared to reach 57% in South Africa, it was 
-32.7% in the U.S., suggesting that more infants acquired medically-
significant RSV disease in the vaccinated group compared to the placebo 
controls. Therefore, besides not meeting the primary endpoint, the 
induction of solely pre-F-‘like’ antibodies could potentially prime for 
vaccine-enhanced disease. A possible explanation for these geographical 
differences could be the frequency or duration of breastfeeding. It must 
be noted that the wide confidence intervals of the vaccine efficacy in this 
study complicate the interpretation of the results. Further analysis will have 
to provide more definitive conclusions on this trial, but these data prompt 
a thorough examination of the underlying causes of the increase in cases 
in the vaccine group.
Besides transplacental IgG transfer during pregnancy, infants can also 
acquire maternal IgA, IgG, and IgM postnatally through breastfeeding. 
Transfer of maternal antibodies through breastfeeding is known to 
increase protection against respiratory tract infections [78,79]. For RSV 
infection, decreased hospitalization rates are demonstrated in breastfed 
infants [4,5], whereas another study indicates reduced disease severity in 
breastfed infants, but no effect on hospitalization rates [6]. In addition, pre-F 
protein-specific IgG levels, but not IgA levels, were lower in breastmilk fed 
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to RSV-infected infants compared to healthy controls [7]. These studies 
indicate that maternal vaccination could also improve the protective effect 
of breastfeeding. Novavax’ recent clinical trial may provide insight in the 
protective role of vaccine-induced antibodies from breastmilk.
The goal of maternal vaccination to induce high maternal antibody levels 
in infants also has a downside: The higher the maternal antibody levels, the 
longer it takes until the child’s own humoral immune response is effective 
due to interference of the maternal antibodies [57]. Maternal vaccination 
might therefore only delay the age at which infants are vulnerable to 
infection, whereas the length of the vulnerable period will stay the same. 
However, delay of disease may already provide substantial clinical benefit, 
as older infants may cope better with RSV infection [1].
The perfect RSV vaccine to prevent disease in infants
There is no such thing as ‘the’ perfect RSV vaccine. The ideal formulation 
of the vaccine greatly depends on the target population and desired 
goal. Completely preventing RSV infection may not be feasible; therefore, 
prevention of severe RSV disease should be the major goal of RSV vaccine 
development. Currently, maternal vaccines are not specifically designed 
for the use in pregnant women. However, a design specifically catered for 
maternal vaccination should be considered. Due to the FcRn-restricted 
transplacental transfer, IgG is the main isotype that is transported to the 
unborn child [80]. Of all IgG subclasses, IgG1 is transferred most efficiently, 
whereas IgG2 is not [81]. A maternal vaccine should therefore induce a 
robust IgG1 response. This has implications for vaccine design, as the 
response to protein antigens induces class switching to IgG1 or IgG3, 
whereas polysaccharide antigens induce class switching to IgG2 [82]. 
Potent FcRn binding also facilitates recycling of the antibodies in the infant, 
resulting in a longer half-life. 
Concerning specificity, a maternal vaccine should primarily consist of the 
RSV surface proteins (pre-) F, G, SH, and N. Although the RSV N protein 
was initially recognized to be an internal protein, its expression on the 
surface of RSV virions and infected cells has recently been demonstrated 
[83] and high anti-N (maternal) antibody levels have been demonstrated 
in plasma (Chapter 3). Antibodies against the pre-fusion conformation of 
the F protein were shown to be the most potent neutralizers [84], therefore, 
the pre-F protein is indispensable in the vaccine design. Antibodies to the 
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RSV G protein also induce some neutralizing activity, and additionally block 
the immunomodulatory activity of the secreted G protein [85]. Instead of 
using the native G protein in the vaccine, inclusion of an adapted form 
of the G protein may be beneficial to prevent its contribution to disease 
pathogenesis [86]. A recent study demonstrated that only a small domain 
of the G protein is responsible for the majority of anti-RSV G antibodies 
[46], indicating that only part of the G protein may be needed to elicit an 
efficient antibody response.  
The antibody response induced by maternal vaccination should be tested 
for FcRn binding and transport, virus neutralization, cytolytic functionality, 
and complement fixation capacity before use in the target population. 
Complement fixation should be prevented, as antibody-complement 
deposition has been shown in RSV vaccine-enhanced disease [87]. T cells 
are not transplacentally transferred; therefore, an effector T cell response 
is not the major goal in maternal vaccination. However, a T (helper) 
cell response is needed to optimize the humoral response and is thus, 
indirectly, important during maternal vaccination. 
The most ideal vaccine platform for maternal vaccination may be the use 
of nanoparticles or viral-like particles (VLPs), as these have been shown 
to elicit high specific antibody responses against human papilloma virus 
in the target population [88]. Recently, an RSV pre-F-specific nanoparticle 
vaccine was developed, which demonstrated superior (neutralizing) 
responses in animal models compared to the use of soluble single antigens 
[89]. Whereas this nanoparticle vaccine is composed of pre-F proteins 
only, nanoparticle vaccines and VLPs can be generated in such a way 
that they contain multiple RSV (surface) proteins, thus eliciting a broadly 
specific antibody response. While the current maternal vaccine programs 
recommend non-adjuvanted vaccines, the use of adjuvants may be useful 
to modulate antibody characteristics that regulate transport, half-life and 
functionality. Therefore, future research should also focus on the effect of 
adjuvants on the antibody characteristics described above. 
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RECOMMENDATIONS
The findings described in this thesis, together with an extensive review 
of the current literature, lead to certain recommendations for the RSV 
field. The following points should be considered in future RSV research 
initiatives:
1  Current in vitro neutralization tests should be improved to reflect 
the physiological situation in the lungs.
2  To predict local protection, assays to measure lung antibody 
levels are needed, in addition to an increased understanding 
of the factors that determine the ratio between serum and lung 
antibody levels.
3  Antibody functionality besides neutralization should be explored 
as potential (co-)correlate of protection. Systems serology 
captures a wide array of antibody characteristics and effector 
functions and may be useful in identifying antibody features that 
contribute to protection.
4  Although antibodies are known to modulate the immune 
response, other factors are likely to be involved in RSV disease 
and should be investigated as potential correlates of disease.
5  Human challenge studies and vaccine evaluations in preclinical 
animal models need to report on immune readouts, as an 
excessive immune response is an important factor underlying 
severe RSV disease. Early elimination of vaccine candidates that 
are not effective in decreasing immunopathology will decrease 
the failure rate in clinical trials.
6  The ideal formulation of the vaccine greatly depends on the target 
population and desired goal. Designs of future vaccines should 
be specifically catered for their target population. Maternal RSV 
vaccines should induce a protective antibody response against 
the RSV surface proteins that is efficiently transferred to the 
unborn child. 
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CONCLUDING REMARKS
In conclusion, the research described in this thesis has provided novel 
insights in the role of antibody effector functions during RSV infection. We 
have developed several assays to investigate RSV-specific Fc-mediated 
antibody effector functions, some of which are thought to be protective 
in nature, whereas others potentially contribute to disease. A better 
understanding of the broad range of effector mechanisms that are induced 
by RSV-specific antibodies will greatly contribute to the much-needed 
development and testing of next generation vaccines against this virus. 
Future research should focus on integrating a broad range of antibody 
features, using a systems serology approach, to distinguish between 
protective and detrimental antibody responses. 
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Virussen zijn interessante ziekteverwekkers. Ze bestaan slechts uit 
genetisch materiaal (zoals DNA of RNA) dat goed is ingepakt in een 
beschermende eiwitmantel. Toch kunnen virussen ontzettend veel 
schade aanrichten in een individu of zelfs in hele populaties, zoals in het 
verleden is gebeurd met de uitbraak van Spaanse griep of SARS, en recent 
met de uitbraak van Ebola. Bij een virusinfectie dringen virussen de cellen 
van de gastheer binnen om daar te vermenigvuldigen. Hierbij ontstaat 
vaak schade aan deze cellen waardoor weefsel en organen minder goed 
gaan functioneren. Dit kan leiden tot ziekte of zelfs tot overlijden van de 
geïnfecteerde persoon. Hoewel er heel wat vaccins op de markt zijn tegen 
virusinfecties (denk aan mazelen, bof of polio), zijn er verschillende virussen 
waar we nog vrij weinig tegen kunnen doen, terwijl ze wel ernstige ziektes 
kunnen veroorzaken. Over één van die virussen gaat dit proefschrift: het 
respiratoir syncytieel virus.
Respiratoir syncytieel virus, ook wel RSV of RS-virus genoemd, is een 
virus dat vooral in het winterseizoen voor veel overlast zorgt. In gezonde 
kinderen of volwassenen veroorzaakt het virus slechts een verkoudheid 
met milde symptomen, maar in jonge kinderen (onder de zes maanden) kan 
een infectie leiden tot ernstige luchtweginfecties en zelfs longontsteking. 
Ondanks dat er al lange tijd onderzoek gedaan wordt naar RSV, is er nog 
steeds geen behandeling of vaccin beschikbaar. In Nederland worden 
elke winter duizenden kinderen opgenomen in het ziekenhuis met een 
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ernstige RSV infectie, maar door de goede gezondheidszorg komt sterfte 
hier niet veel voor. Helaas is dat wereldwijd gezien anders en sterven ruim 
100.000 kinderen per jaar aan de gevolgen van een RSV infectie. Vandaar 
dat het belangrijk is om onderzoek naar dit virus te doen en testen te 
ontwikkelen om de werkzaamheid van toekomstige vaccins beter te 
kunnen beoordelen.
Van alle jonge kinderen die geïnfecteerd raken met RSV in hun eerste 
levensjaar, wordt maar een klein deel ernstig ziek. We weten nog steeds 
niet precies waarom deze jonge kinderen zo ziek worden en dat maakt 
het ontwikkelen van een vaccin tegen RSV extra moeilijk. Er zijn 
aanwijzingen dat een verkeerde activatie van het immuunsysteem een 
grote rol speelt in het ontstaan van een ernstige RSV infectie. Essentieel 
in het immuunsysteem van een pasgeborene zijn de zogenaamde 
maternale antistoffen die tijdens de zwangerschap via de placenta worden 
overgedragen van moeder naar het (dan nog ongeboren) kind. 
Antistoffen zijn Y-vormige eiwitten die door het hele lichaam aanwezig 
zijn. Vooral in het bloed vinden we veel van deze antistoffen, maar 
bijvoorbeeld ook in de longen; de plek waar RSV infecties plaatsvinden. 
Antistoffen worden gemaakt door het immuunsysteem met als doel om 
aan lichaamsvreemde stoffen, zoals virussen of bacteriën, te binden (zoals 
weergegeven in Figuur 1). De binding van antistoffen aan ziekteverwekkers 
kan vervolgens op verschillende manieren bescherming bieden. Een van 
de meest bekende functies is neutralisatie: hierbij wordt het virus volledig 
omgeven door antistoffen, waardoor het geen cellen meer kan infecteren. 
Er bestaan echter nog veel meer, vaak minder bekende, functies van 
antistoffen. Welke functie door de antistoffen wordt uitgevoerd, hangt 
onder andere af van het aantal antistoffen dat bindt, de kenmerken van die 
antistoffen (welk type antistof en hoe goed ze binden) en de staat van het 
immuunsysteem. Het onderzoek dat in dit proefschrift wordt beschreven, 
focust op de rol van verschillende functies van maternale antistoffen tijdens 
een RSV infectie. We kijken of bepaalde antistoffuncties bijdragen aan 
bescherming of misschien juist bijdragen aan een ernstiger ziekteverloop.
Na een korte introductie in hoofdstuk 1, geven we in hoofdstuk 2 een 
overzicht van de verschillende antistoffuncties waarvan bekend is dat 
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FIGUUR 1   Schematische weergave van de vorming van RSV-antistof complexen  · 
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ze een rol kunnen spelen in virale infecties. In dit hoofdstuk beschrijven 
we het onderzoek dat wereldwijd is uitgevoerd op het gebied van 
antistoffuncties. Op het gebied van RSV blijkt dat er nog vrij weinig bekend 
is over antistoffuncties, en is er dus nog veel kennis te behalen. Met het 
onderzoek dat in de rest van dit proefschrift beschreven wordt, leveren wij 
een bijdrage aan het vergroten van deze kennis. De volgende hoofdstukken 
van dit proefschrift beschrijven het onderzoek dat we hebben uitgevoerd 
om te kijken we naar verschillende antistoffuncties. In hoofdstuk 3 laten 
we zien dat RSV-antistoffen bepaalde immuuncellen, genaamd natural 
killer (NK) cellen, kunnen activeren. Deze NK cellen zijn onderdeel van 
ons aangeboren immuunsysteem en belangrijk voor het opruimen van 
virusinfecties. Wanneer we antistoffen van kinderen met een ernstige 
virale infectie vergelijken met de antistoffen van gezonde kinderen, dan 
zijn de antistoffen van zieke kinderen minder goed in het activeren van NK 
cellen. Dit is een aanwijzing dat NK cel activatie door antistoffen belangrijk 
is voor de bescherming tegen ernstige infecties. Behalve hun bijdrage aan 
bescherming, kunnen antistoffen in sommige gevallen ook bijdragen aan 
ziekte. Er werd altijd gedacht dat RSV vooral longcellen infecteert, maar 
in hoofdstuk 4 laten we zien dat de aanwezigheid van antistoffen soms 
ook kan leiden tot een verhoogd aantal geïnfecteerde immuuncellen. 
Dit vindt met name plaats wanneer er wel antistoffen aanwezig zijn, 
maar te weinig om het virus volledig te neutraliseren. Om te voorkomen 
dat antistoffen de infectie bevorderen in plaats van bestrijden, is het dus 
belangrijk dat toekomstige vaccins zorgen voor de juiste antistoffen en dat 
de concentratie van deze antistoffen hoog genoeg blijft om te beschermen 
tegen ernstige ziekte
Na de ontdekking dat RSV immuuncellen kan infecteren, en dat een 
lage concentratie antistoffen kan bijdragen aan dit proces, hebben we 
voor hoofdstuk 5 uitgezocht wat het effect van deze infectie is op het 
functioneren van immuuncellen. We hebben in het laboratorium NK cellen 
geïnfecteerd met RSV en zagen dat deze cellen wel een ontstekingsreactie 
kunnen veroorzaken, maar minder goed waren in het opruimen van de 
infectie in vergelijking met niet-geïnfecteerde NK cellen. Het is dus goed 
mogelijk dat deze combinatie van niet goed opruimen én een verhoogde 
ontstekingsreactie bijdraagt aan het ontstaan van een longontsteking. 
RSV is niet het enige virus dat NK cellen kan infecteren. In hoofdstuk 6 
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belichten we 13 andere virussen waarvan bekend is dat ze NK cellen 
infecteren en beschrijven we hoe deze virussen het functioneren van NK 
cellen aantasten. 
Voor het laatste deel van dit proefschrift hebben we gekeken of onze 
eerdere bevindingen in celkweekmodellen ook in een levend organisme 
plaatsvinden. Omdat het niet goed mogelijk is om het effect van antistoffen op 
een RSV infectie in mensen te testen, hebben we een diermodel ontwikkeld. 
We maken hiervoor gebruik van muizen omdat de ontstekingsreactie 
goed bestudeerd kan worden en ze een veelgebruikt infectiemodel zijn 
voor RSV onderzoek. In hoofdstuk 7 laten we zien dat muizen het beste 
via druppels in de neus met RSV geïnfecteerd kunnen worden. Deze 
toedieningsroute leidt tot hogere infectiewaarden, meer symptomen en 
een hogere immuunrespons in vergelijking met een toediening direct 
in de longen. Dit heeft belangrijke implicaties voor alle laboratoria die het 
muismodel gebruiken voor onderzoek naar RSV infecties. In hoofdstuk 8 
beschrijven we hoe we dit muismodel hebben ingezet om het effect van 
antistoffen op het verloop van een RSV infectie te bepalen. Muizen kregen 
verschillende concentraties antistoffen toegediend, waarna ze geïnfecteerd 
werden met RSV. Zoals verwacht lieten de muizen die een hoge concentratie 
antistoffen hadden gekregen lagere infectiewaarden zien dan de dieren 
zonder antistoffen. Maar in muizen met een lage concentratie antistoffen 
zagen we juist hogere infectiewaarden, in vergelijking met muizen zonder 
antistoffen. Dit resultaat was vergelijkbaar met wat we in hoofdstuk 4 al in 
celkweekmodellen hadden gevonden. Het lijkt er dus op dat het belangrijk 
is om óf een hoge concentratie antistoffen te hebben, óf helemaal geen 
antistoffen, omdat een lage concentratie antistoffen mogelijk juist bijdraagt 
aan het ontstaan van een ernstig ziektebeloop.
Concluderend geeft ons onderzoek inzicht in de rol van antistoffuncties 
tijdens RSV infecties. We hebben verschillende methoden ontwikkeld om 
deze functies te onderzoeken en laten zien dat sommige antistoffuncties 
waarschijnlijk beschermend werken, terwijl anderen misschien juist 
bijdragen aan de ernst van ziekte. Een beter begrip van alle verschillende 
antistoffuncties die een rol spelen tijdens RSV infectie, zal bijdragen aan 
de ontwikkeling en het testen en beoordelen van nieuwe vaccins tegen 
dit virus.
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PHD PORTFOLIO
LIZ VAN ERP
Department
Department of Laboratory Medicine
Graduate School
Radboud Institute for Molecular Life 
Sciences
PhD period
01-05-2015 – 01-08-2019
Promotors
Prof. dr. R. de Groot,
Prof. dr. D. van Baarle
Co-promotors
Dr. P.B. van Kasteren
Dr. J.G. Ferwerda
TRAINING ACTIVITIES Year(s) ECTS
Courses
RIMLS Graduate course (RIMLS) 2015 2.0
Scientific writing for academic publication (UU) 2015 3.0
Scientific Integrity Course (RIMLS) 2016 1.0
“Van Kinsbergen” advanced Immunology course (UU) 2017 2.0
Radboud Summer School: Molecules, mice and math: A 
statistical toolbox for the lab (Radboud)
2017 2.0
Career guidance for PhDs (Radboud) 2017 1.0
Workshops
Creative and innovative thinking (Proneri, RIVM) 2016 0.2
Writing DEC proposals 2017 0.2
Career choices (Proneri, RIVM) 2017 0.2
Pitching (Proneri, RIVM) 2017 0.2
Networking and building relationships (Proneri, RIVM) 2017 0.2
“This is not a conflict” (ElroyCOM + Proneri, RIVM) 2017 0.2
Careers in vaccinology (ReSViNET) 2017 0.2
“Small sample, big data” (Radboudumc, Tobias Kollmann) 2018 0.2
Analytic Storytelling (Proneri, RIVM) 2018 0.2
Scientific Happiness (ElroyCOM + Proneri, RIVM) 2018 0.2
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TRAINING ACTIVITIES Year(s) ECTS
Seminars & lectures
Radboud Research Rounds (Radboud) 2015-2019 0.3
Eijkman Lectures GSLS (UU) 2015-2019 0.4
RIVM IIV monthly seminar (RIVM) 2015-2019 1.5
LTI Seminars (UMCU) 2015-2019 0.5
Clinical immunology seminars (UMCU) 2015-2019 0.1
Symposia
Radboud New Frontiers - Nijmegen (2015, 2017) 2015-2017 2.0
Vaccine symposium – Utrecht (2015) 2015 0.25
Protection and therapy of RSV and influenza early in life – 
Utrecht (2016)
2016 0.25
RSV Symposium – Utrecht (2017#) 2017 0.5
DAVS – Amsterdam (2018, 2019) 2018-2019 0.5
KNAW Vaccination symposium – Amsterdam (2018) 2018 0.25
I&I Science symposium – Utrecht (2018#) 2018 0.5
Congresses
RIMLS PhD Retreat – Veldhoven (2015, 2016*, 2017*, 2018#) 2015-2018 3.0
NVVI Winterschool – Noordwijkerhout (2015*, 2017*) 2015-2017 1.5
RSV 2016 Conference – Bariloche, Argentina (2016*) 2016 1.5
BSI-NVVI Joint meeting – Liverpool, UK (2016*) 2016 1.25
Proneri PhD Retreat – Utrecht (2017*) 2017 0.75
RSV Vaccines for the world – Malaga, Spain (2017*) 2017 1.25
KNVM Scientific Spring Meeting – Papendal (2018#, 2019*) 2018-2019 1.5
ASV Annual meeting – College Park, USA (2018#) 2018 1.5
European Congres of Immunology – Amsterdam (2018*) 2018 1.25
European Congres of Virology – Rotterdam (2019*) 2019 1.25
Other
Journalclub IIV (RIVM) 2015-2019 1.0
Peer review of scientific paper 2019 0.1
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TEACHING ACTIVITIES Year(s) ECTS
Lecturing
Onderzoeker in de klas 2017-2019 0.3
Primary school education: “Immunology & vaccination” 2018 0.1
Lecture series “From DNA – protein” (Life Science Leiden) 2017 0.5
Supervision of internships
Student supervision 2016-2018 6
Other
Career- and internship market Mebiose (Utrecht) 2016-2019 1.5
Incl. Workshop: “Research at the RIVM”
Tour + lectures for honours students UU 2019 0.5
TOTAL 45.3
# Oral presentation
* Poster presentation
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Tot slot is het tijd voor het dankwoord: Het enige deel uit een proefschrift 
dat niet gecheckt en verbeterd wordt door je begeleiders en waar ik dus 
helemaal los kan gaan! In mijn eentje had ik dit hele PhD traject nooit 
kunnen volbrengen en daarom wil ik graag iedereen bedanken die de 
afgelopen vier jaar een steentje heeft bijgedragen aan dit grote geheel. 
Beste Oliver en Puck, voor jullie een gedeelde eerste plaats. Oliver, jij 
hebt ervoor gezorgd dat ik voor dit PhD project gekozen heb; we hadden 
tijdens het sollicitatiegesprek al zoveel ideeën en nieuwe onderzoeks-
vragen bedacht, dat ik mijn idee om in de VS te promoveren liet varen. 
Onze samenwerking bleef ook tijdens mijn PhD project erg soepel en we 
hebben lange dagen in het lab gemaakt, o.a. om “tizzle-idel-fizzles” te 
doen. Helaas was het voor jou na 1,5 jaar tijd om een volgende carrièrestap 
te maken en moest je het maternale antilichamen project en je eerste PhD 
student achterlaten. Ik ben blij dat we nog steeds contact hebben en dat ik 
er een vakantieadresje in Londen bij heb! Toen Oliver wegging, was het aan 
jou, Puck, om mijn project verder te begeleiden. Het was geen makkelijke 
start, aangezien het (maternale) antilichamen onderzoeksveld nieuw voor 
je was en je ook nog niet zo lang aan RSV werkte. Maar uiteindelijk zijn we 
echt een super goed team geworden en hebben we de laatste jaren heel 
veel voor elkaar gekregen samen. We hebben mooie tripjes gemaakt, veel 
mensen leren kennen en ik heb ontzettend veel van je geleerd. Onwijs 
bedankt voor alles!
Beste Gerben, jouw ideeën raakten nooit uitgeput. We zagen elkaar niet 
vaak, maar áls we een meeting hadden, kwam ik daar met een hoofd vol 
inspiratie weer uit. Ik ben heel blij dat ik in NK cellen ben blijven geloven, 
maar om eerlijk te zijn ben ik ervan overtuigd dat dat niet de enige belang-
rijke cellen zijn. Jouw voorliefde voor monocyten en macrofagen kan 
dus best nog wel eens tot interessante bevindingen leiden: Ik ben heel 
benieuwd!
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Natuurlijk kun je niet promoveren zonder promotor(en). Ronald en 
Debbie, dankzij jullie is het eind van mijn PhD een stuk soepeler verlopen 
dan ik had durven hopen en zijn mijn “ambitieuze plannen” werkelijkheid 
geworden. Bedankt daarvoor!
Leden van de manuscriptcommissie, prof. dr. Annemiek van Spriel, prof. 
dr. Louis Bont en prof. dr. Frank van Kuppeveld, hartelijk bedankt voor de 
tijd die jullie hebben genomen voor het beoordelen van mijn proefschrift. 
Ook de rest van de promotiecommissie wil ik bedanken voor hun tijd en 
aanwezigheid bij de verdediging. Ik kijk uit naar de discussies tijdens mijn 
verdediging!
Beste Willem en Marien, bedankt voor jullie waardevolle input en 
begeleiding. Vaak waren jullie de rots in de branding wanneer het echt 
even nodig was. Willem, je was als topexpert betrokken bij mijn project, 
maar eigenlijk was je een soort (RSV-)vader. Je kende iedereen binnen 
de virologie in Nederland, wist van alle (politieke) verhoudingen binnen 
het RSV veld en had altijd mooie verhalen over “vroeger”. Ik heb veel 
van je geleerd, over veel meer dan alleen RSV! Marien, ik ken weinig 
afdelingshoofden met zoveel hart voor de afdeling als jij. Je staat werkelijk 
voor iedereen klaar en maakt altijd tijd wanneer dat nodig is, ondanks je 
drukke agenda. Ik heb veel respect voor hoe je dat doet en vond het fijn 
dat ik altijd bij je terecht kon. 
Lieve Sara en Hella, het is een fijn idee dat jullie straks naast mij staan 
tijdens de verdediging, maar ook daarna op de dansvloer! Sara, we 
zijn al buddy’s vanaf het begin van onze PhD projecten. Inhoudelijk zijn 
onze projecten erg verschillend, maar we wisten elkaar altijd te vinden 
als er dingen georganiseerd moesten worden of als we vonden dat er 
verandering nodig was op de afdeling. Ik ben nog steeds blij met ons 
vrijdagmiddagborrel-initiatief en ook al volg ik je goede raad niet altijd op 
(na 6 Leffe Blond richting Nieuwegein was écht wel een goed idee), ik vind 
het fijn dat we over alles kunnen praten samen! Hella, jouw spontane en 
attente persoonlijkheid is iets om trots op te zijn. Zonder dat je het zelf 
doorhad, heb je me door moeilijke tijden heen gesleept dankzij je positieve 
houding en lieve kaartjes. Ik hoop dat we, ondanks de afstand, wielren- en 
dansbuddy’s kunnen blijven!
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Lieve kamergenootjes, wat heb ik veel aan jullie aanwezigheid gehad. 
Daan, Elise en Sara, we begonnen met zijn vieren in A12 en dat werkte 
zo goed dat we er alles aan hebben gedaan om samen te blijven na de 
verhuizing. Gelukkig lukte dat en kregen we er een IMS-baby bij: Leon. 
We hebben met zijn vijven veel gelachen en gehuild, en zonder jullie was 
mijn PhD traject een stuk frustrerender en eenzamer geweest. Daan, 
vooral het laatste jaar hebben we veel aan elkaar gehad. Je hebt geen 
makkelijk PhD traject, en de manier waarop jij je toch staande hebt weten 
te houden is super knap. Vergeet niet om wat vaker trots op jezelf te zijn 
en (kleine) overwinningen te vieren nu ik weg ben! Elise, je bent een 
groot voorbeeld voor me. De manier waarop jij je PhD zo “soepel” (op 
sommige vlakken) wist af te ronden, heeft ervoor gezorgd dat het mij ook 
is gelukt. Ik hoop dat we nog lang met elkaar lachen, zeuren, afreageren en 
toekomstplannen maken, ongeacht de afstand! Leon, ik ben blij dat we je 
geadopteerd hebben en weet zeker dat je goed terecht gaat komen, waar 
ook ter wereld! And last but not least: Abi. Gewoon in het Nederlands, want 
dat kun je “kei goed” (Southern dialect for “super goed”). We zijn maar kort 
roomies geweest, maar ik ben blij dat Elises plek door zo’n cool persoon is 
overgenomen die ook zo van dansen houdt: Keep on “shagging”!
 
Behalve mijn kamergenootjes, wil ik ook alle andere (oud) PhD’s (Bette, 
Daantje, Elsbeth, Eric, Hella, Iris, Josien, Koen, Marieke, Marta, Michiel, 
Milou, Nora en Pauline) bij IIV bedanken voor de gezellig barbecues, 
film- en spelletjesavonden. Elsbeth, ik heb heel veel respect hoe jij je 
project draaiende hebt gehouden de afgelopen jaren. Heel veel succes 
met de laatste loodjes van je PhD en de toelating voor je specialisatie! 
Eric, fitnessmaatje! Ik zal je bemoedigende high fives bij High Five missen. 
Iris, de ontwikkeling die jij hebt doorgemaakt de afgelopen jaren is echt 
ongelofelijk knap. Niet iedereen heeft het lef om de beslissingen te maken 
die jij hebt gemaakt. Blijf geloven in jezelf! 
Ook op het lab heb ik de nodige hulp gehad; allereerst van de (master)
studenten die ik heb begeleid tijdens mijn PhD project. Maxime, je was 
mijn eerste student en al vanaf dag 1 onmisbaar. Ik had namelijk net een 
nieuwe kruisband en in het lab werken op krukken is echt een uitdaging. 
Behalve op het lab, hadden we ook persoonlijk veel aan elkaar. Laten we 
onze Tony’s traditie in stand houden, ook als je straks een (drukke) PhD 
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plek hebt gevonden! Mirjam, jouw scriptie was geen makkelijke, maar het 
heeft de basis gelegd voor de prachtige review uit hoofdstuk 6, bedankt! 
En tot slot: Anke. Wat een doorzettingsvermogen heb jij laten zien tijdens 
je stage. Die ADCC assay was geen pretje, maar het heeft tot fantastische 
resultaten geleid die te lezen zijn in hoofdstuk 3. Ik ben heel blij dat je nog 
steeds bij ons in de groep werkt als analist en wellicht in de toekomst als 
PhD student. Ik vind het vaak moeilijk om dingen aan andere mensen 
over te laten, maar bij jou had ik er altijd vertrouwen in, en ik vind het dan 
ook heel fijn dat jij de huidige projecten helpt afronden. Bedankt voor al je 
toewijding en hulp de afgelopen jaren! Behalve studenten, hebben ook 
veel andere mensen me geholpen bij proeven die te ingewikkeld of te 
uitgebreid waren om alleen te doen. Anke, Daan, Lie, Noortje, Puck en 
Teun: bedankt voor jullie hulp op de vele sectiedagen. Zonder jullie hulp 
waren hoofdstuk 7 en 8 er nooit gekomen en hadden we de belangrijkste 
in vivo ontdekking van dit proefschrift nooit gedaan. Ronald, bedankt dat je 
mij in mijn eerste jaar wegwijs hebt gemaakt in de wereld van de PBMCs, 
het FACSen en de ADCC assay. Deze technieken vormen de basis voor 
mijn proefschrift. Lie, bedankt voor de vele virussen die je hebt gemaakt 
en waar ik altijd gebruik van mocht maken. Rutger, bedankt voor alle MIA’s 
die jij voor ons hebt gedaan. Jouw aanpakmentaliteit maakt je een hele 
fijne samenwerkingspartner! Sandra, jij maakte het werk op het ML-II een 
stuk minder eenzaam, jammer dat we maar zo kort labmaatjes waren! 
Dan zijn er ook nog een hele hoop mensen met wie ik niet inhoudelijk heb 
samengewerkt, maar die mijn tijd bij IIV heel wat leuker hebben gemaakt: 
Diana (je was een voorbeeld op vele fronten. Jouw betrokkenheid heeft 
me erg geholpen), Harry (altijd een lief gebaar op het juiste moment), 
Karin (topwijf ben je! De afdeling kan niet zonder je), Rob v B (bedankt 
voor alle leuke discussies en je interesse in mijn onderzoek), Martijn, 
Rob M en Teun (zonder jullie was de vrijdagmiddagborrel nooit zo’n 
succes geworden) en Kina (bedankt voor de lekkere baksels en de 
compenserende hardlooprondjes). Het liefst zou ik iedereen van centrum 
IIV hier persoonlijk noemen en bedanken, maar daar is helaas geen 
ruimte voor: dus ook als je niet genoemd bent, bedankt voor de hulp en 
gezelligheid de afgelopen vier jaar!
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Al was ik meestal op het RIVM, ook op het Radboudumc lab was ik altijd 
welkom, iets waar ik vooral op feestjes en bij labuitjes gebruik van maakte. 
Dorien, we zijn samen begonnen en zijn nu allebei (bijna) klaar. Ik vind 
het leuk dat ons contact ook nog tot een mooie publicatie heeft geleid. 
Veel succes in Stanford! Marilen, we zijn van cord blood collega’s naar 
echte vriendinnen gegaan in korte tijd. Allebei flauwvallen op OK, onze 
gezamenlijke liefde voor bier, muziek en dansen, en allebei een vriend 
die altijd met klusprojecten bezig is: we hebben veel dingen gemeen. 
Succes met de laatste loodjes, ik geloof in je! Bryan, Esther, Evi en Lucille, 
ik kon altijd bij jullie terecht als dingen even tegenzaten en ik weer eens 
voor niks richting Nijmegen was gegaan. Ook als er iets op het lab moest 
gebeuren terwijl ik in Utrecht was, was dat geen probleem. Jullie hebben 
mijn gedeelde positie een stuk aangenamer gemaakt en waren gezellige 
congres- en retreat-buddy’s; bedankt! Christa, Elles, Fred, en Marc jullie 
hebben me wegwijs gemaakt op het lab in Nijmegen. Elles, ik vergeet nooit 
meer dat jij speciaal voor mij gedifferentieerde NHBE cellen ging maken. 
Super fijn dat jij je zo voor iedereen inzet, het heeft mij een hoop kopzorgen 
gescheeld! Fred, dankzij jou voelde ik me altijd welkom op de afdeling. 
Altijd een praatje en mooie vakantiekiekjes, en ook met mijn dierproef-
frustraties kon ik bij je terecht: bedankt! Ook wil ik graag alle andere (oud-)
LKI-ers bedanken: Dimitri, Erika, Inge A, Inge S, Jeroen, Jop, Josh, 
Kirsten, Koen, Ria en Saskia. Inge A, het cohort dat jij hebt verzameld 
vormt de basis voor twee hoofdstukken uit mijn PhD. Bedankt dat we daar 
gebruik van mochten maken! Inge S, ik vond het jammer dat je maar zo 
kort mijn RSV-maatje bent geweest, maar ik vind het ontzettend knap 
dat je je eigen pad bent gevolgd! Jop en Kirsten, onze ontmoeting op de 
dansvloer van mijn eerste PhD retreat heeft gezorgd voor een swingend 
begin van mijn PhD en zal ik nooit vergeten. Jop, ik heb veel van je geleerd 
op het lab, en vond het fijn dat ik ook altijd bij je terecht kon als ik een 
slaapplek in Nijmegen nodig had. Kirsten, ik heb altijd veel bewondering 
voor je gehad. Het is fijn om af en toe met je te kunnen sparren over de 
belangrijke dingen in het leven, let’s stay in touch! 
A big thanks to all the people that were involved in my Master’s internship 
in St. Louis. Many thanks to Dr. Curiel for letting me experience all the sides 
of science during my internship. I enjoyed my time in the lab with Lyudmila 
and Sergey so much, that I decided to give the PhD-life a try. Lyudmila and 
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Sergey, many thanks for adopting me during my time in the US, I am glad 
to have a ‘Russian-American family’ on the other end of the world. En als 
ik het over St. Louis heb, dan moet ik jou natuurlijk ook onwijs bedanken: 
Sharon. Wat een avonturen hebben wij samen meegemaakt. Je bent een 
groot voorbeeld voor me (behalve als het over je omgang met beren gaat), 
en ik denk nog vaak met een lach terug aan onze St. Louis herinneringen.
Behalve collega’s zijn er ook een hoop vrienden die me hebben bijgestaan 
de afgelopen jaren. Laura, zonder jou was deze PhD een stuk moeilijker 
geweest. Je hebt me er vaak doorheen gesleept als ik weer eens 
gefrustreerd was over de voortgang van mijn PhD. Voor de buitenwereld 
lijken we zo verschillend als water en vuur, maar we vullen elkaar perfect 
aan als vriendinnen. Bedankt voor het samen lachen en samen huilen. 
Bedankt voor alle avonturen die we samen beleefd hebben en nog gaan 
beleven. Maar bovenal: bedankt dat je er altijd voor me bent. 
Ook mijn rugbyvriendinnen van RUS verdienen een bijzonder plekje: De 
Fit old bosses, de Showpony’s, de meiden met wie ik (meerdere malen) 
het landskampioenschap heb mogen behalen en verdedigen: zonder jullie 
was ik niet wie ik nu ben. Aan rugby heb ik mijn discipline te danken, het 
heeft gezorgd dat ik tegen een stootje kan (zowel lichamelijk als mentaal), 
en daarbovenop had ik een flinke groep vriendinnen bij wie ik altijd terecht 
kon. De tijd bij RUS heeft me een van de belangrijkste motto’s uit mijn 
leven meegegeven: “Schaamte is een verspilling van je tijd” en daar hoop 
ik de rest van mijn leven in te kunnen geloven. Inmiddels heb ik er een 
tweede rugbyfamilie bijgekregen: RCN-ers, bedankt voor de liters bier en 
de gezelligheid zowel op als naast het veld!
Chantal, Erik, Guido, Joost, Manon, en Tom: Amigos! Wat bijzonder dat wij 
nog steeds zo’n goede vrienden zijn sinds het begin van onze studie. Het 
originele groepje 9 is wat uitgedund en aangevuld met groepje 10, maar 
na alles wat we overleefd hebben (vooral dingen die hier niet genoemd 
hoeven te worden), hoop ik dat we nog vaak op avontuur gaan samen! 
Chantal, jou wil ik toch nog even extra bedanken, omdat je ook op het lab 
af en toe een reddende engel was: officieel werkte je niet voor onze groep, 
maar als ik een mega proef op de planning had, kon ik altijd op je rekenen: 
bedankt! 
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Iris, we hebben eigenlijk maar één jaar samen gehandbald, maar zijn 
daarna goede vriendinnen gebleven. Skeelertochtjes tussen Rosmalen en 
Heesch, een reis door Italië (“u wilt een Bacio?”), en tegenwoordig mijn 
Nijmeegse thuis als ik in het Radboud moest zijn. Bedankt dat ik altijd 
welkom ben! Remco, begonnen als wiskunde-maatjes in 4 VWO en nu 
allebei onze PhD bij het Radboud aan het afronden. We hebben ons eerste 
PhD salaris besteed aan de Tour de Mont Blanc, wat een van mijn tofste 
vakanties ooit zal blijven. Ik vond het fijn om altijd bij je terecht te kunnen 
voor een theetje op het Radboud of een biertje in kroeg, en vond jouw 
input tijdens onze discussies over mijn onderzoek altijd erg waardevol. 
Ik wil ook heel graag de (oud-) IBB 15-IV burgerclub bedanken. Tijdens 
mijn studententijd én het begin van mijn PhD heb ik ontzettend veel aan 
jullie gehad. Na lange dagen op het lab, stond er altijd een heerlijke maaltijd 
klaar en dat maakte mijn eerste jaar als PhD een stuk aangenamer! Niks 
was te gek op 15-IV: van een jacuzzi op het balkon, tot pictionary spelen 
op de muren en het bouwen van een “man”-cave om samen Top Gear te 
kijken. Jullie zorgden altijd voor de nodige afleiding. Gelukkig wonen we 
(bijna allemaal) nog steeds binnen een straal van 3 km en kunnen we nog 
gewoon huiskamerkroegentochten doen. Marit, de serie-avondjes met 
onze vrienden Ben & Jerry zorgen altijd voor een welkom rustmomentje 
in mijn drukke schema. Ik ben blij dat we deze IBB-traditie als burgers 
hebben voortgezet! 
En dan zijn we tot slot aangekomen bij mijn lieve (schoon)familie. Lieve van 
Erpjes: papa, mama, Kim en Philip. Jullie Brabantse nuchterheid zorgde 
ervoor dat ik dingen in perspectief kon plaatsen, terwijl jullie Brabantse 
gezelligheid (vaak juist niet nuchter) me hielp om het onderzoek af en 
toe even helemaal los te laten. Bedankt dat jullie er op alle belangrijke 
momenten voor me zijn. Jullie steun en vertrouwen betekenen veel voor 
me. Ook de rest van de familie van Erp en familie van Peufflik, ooms en 
tantes, nichten en neven, bedankt voor de nodige afleiding op familiedagen 
en verjaardagen en de interesse in mijn onderzoek. Mariska, grote nicht, 
super fijn dat je altijd zo geïnteresseerd was in mijn PhD project. Ik weet 
zeker dat je er inmiddels veel meer van snapt dan je zelf wilt toegeven 
en hoop dat je bij mijn verdediging kunt zijn! Hans en Grietje, Rudy en 
Neide, Anja en Aad: bedankt dat ik als een dochter/zus in jullie familie ben 
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opgenomen. De weekendjes Ardennen gaven vaak de nodige rust en 
afleiding. Anja, behalve een schoonzus, heb ik er met jou ook een goede 
vriendin bijgekregen. Ik hoop dat we nog vaak BB-dates, escaperooms en 
festivals meemaken in de toekomst!
Lieve Erwin, jij dacht dat je niet in mijn dankwoord hoorde, want “wat 
had jij nou bijgedragen aan mijn proefschrift?”. Nou meneer, je hebt mijn 
promotietijd een stuk aangenamer gemaakt. Door jou begint iedere dag 
als een feestje, zelfs als ik daar om half 6 ‘s ochtends voor moet opstaan. 
Onze mooie reizen zorgden voor de nodige stressverlichting, al kreeg ik 
van jouw (klus)projectjes die stress soms dubbel en dwars weer terug. 
Maar dankzij al dat klussen wonen we nu wel in ons droomhuisje. Als 
experimenten weer eens mislukt waren door stomme foutjes of als ik 
gefrustreerd was over de langzame voortgang van het onderzoek, stond 
jij bij thuiskomst al met open armen (en een glaasje whisky) voor me klaar. 
Ja, jij hebt zeker bijgedragen aan dit mooie boekje als resultaat van mijn 
PhD: Dankzij jou heb ik het beste uit mezelf kunnen halen en daarvoor kan 
ik je niet genoeg bedanken. Ik hou van je!   ·  
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